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Abstract 
The goal of the research presented in this dissertation is to develop novel water soluble 
carboranylporphyrins that can deliver therapeutic dosage of boron specifically to tumors 
for application in boron neutron capture therapy. In order to accomplish this goal novel 
water soluble tetra(nido-carboranyl)porphyrin and the octa(nido-carboranyl)porphyrin 
with high boron contents are synthesized by the condensation of the carborane substituted 
benzaldehyde with the pyrrole under acidic conditions. These porphyrins are made water 
soluble by the deboronation of the closo-carboranes to afford the corresponding 
amphiphilic nido-carborane cages. The low cytotoxicity, high cellular uptake and 
intracellular localization of these carboranylporphyrins in tumor cells are accomplished. 
 The synthesis of the tetra(4-nido-carboranylphenyl)porphyrin is also accomplished and 
the comparative biological evaluation of the tetra(4-nido-carboranylphenyl)porphyrin and 
the tetra(carboranylphenyl)tetrabenzoporphyrin in the tumor cells show lower toxicity 
and better uptakes of these porphyrins in the cells. These porphyrins also show low 
toxicity in the mice. 
The syntheses of various novel neutral water soluble carboranylporphyrins is 
accomplished. These novel carboranylporphyrins synthesized are water-soluble by the 
functionalization of the carboranes with water-solubilizing groups such a polyethylene 
glycol, hydroxyl and amine groups.  
The synthesis of novel carboranylsapphyrins is attempted. Sapphyrins are penta pyrrolic 
macrocycles and various methods for the synthesis of these macro cycles are attempted 
and reported. 
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Chapter 1 
Introduction 
 
1.1 Structure of Porphyrins 
A porphyrin is an aromatic heterocyclic macrocycle made from one pyrrole subunit and 
three pyrroline subunits, and linked on opposite sides through four methine bridges 
(Figure 1-1).1 The extensive π-conjugation makes the compound chromatic, hence the 
name "porphyrin" from a Greek word for purple.2 Porphyrins and related compounds are 
the basic chromophores for a large number of biologically important natural products 
such as heme, chlorophylls and bacteriochlorophylls.3 They also exist as contracted 
structures such as corroles4 and expanded structures such as sapphyrins.5 Porphyrins are 
being studied widely because of their intriguing physical, chemical and biological 
properties.6  
 
N
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HN
 
 
Figure 1-1: Structure of the porphyrin macrocycle 
 
There are IUPAC and Fischer systems of nomenclature for porphyrins (Figure 1-2).  The 
IUPAC system assigns every carbon atom in the porphyrin with a unique number from 1-
20 and the internal nitrogen atoms are numbered from 21-24.7 The Fischer system 
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numbers the carbons at the pyrrolic β-positions as 1-8 and the four inter-pyrrolic carbons 
(or the meso-carbons) as α, β, γ, and δ.8 
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Figure 1-2: IUPAC and Fischer nomenclature 
 
Porphyrins are aromatic macrocycles containing 22 conjugated π- electrons with 18 π- 
electrons participating in the delocalization pathway at a time while the other double 
bonds are in cross conjugation. This conforms with the [4n+2] rule for aromaticity. 
Porphyrins are highly colored and they show a characteristic intense Soret9 band at 
around 400 nm with very high extinction coefficients. Porphyrins also have four satellite 
bands between 450-700 nm known as Q bands.10 The Soret band is a major characteristic 
of the optical spectra of the porphyrin macrocycle as it disappears with the disruption of 
the macrocycle.11 The intensity and wavelength of the absorption bands changes with 
variations in the peripheral positions of the porphyrin macrocycle. Protonation of two of 
the inner nitrogen atoms or insertion of a metal into the porphyrin cavity also changes the 
visible absorption spectrum. The 1H-NMR spectrum of the aromatic tetrapyrrole shows 
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anisotropic effects. 12-15 The highly shielded NH protons in the porphyrins appear at very 
high field (-2 to -4 ppm) whereas the outer meso protons which are shielded by the 
aromatic ring current appear at very low field (8 to 10 ppm).16, 17 The thermodynamically 
most favored tautomers for symmetrically substituted porphyrins are the trans NH 
tautomers. 18, 19, 20 The mechanism for N-H migration between trans- tautomers might be 
proceeding in a stepwise manner through the less favored cis-tautomers (Figure 1-3).21 
The most favored porphyrin structure is when the two inner hydrogens are bonded to 
opposite nitrogens.22 When the inner hydrogens are bonded to adjacent nitrogens there 
are Van der Waals interactions and so they are less stable.   
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Figure 1-3: Delocalization pathway in porphyrins 
 
The porphyrin macrocycle is stable to concentrated sulfuric acid and trifluoroacetic acid 
and unstable to perchloric acid, chromic acid and hydriodic acid. In the free-base 
porphyrins the central nitrogen atoms are free and the NHs can be deprotonated with 
strong bases such as alkoxides (pKa ~16) to form a dianion,23 while the two-imine 
nitrogens can be protonated with acids such as trifluoroacetic acid. The NH protons react 
with electrophilic reagents and can also be metalated. In the metalated porphyrins the 
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metal is chelated to the inner nitrogens with covalent and dative bonds and it helps in the 
transmission of the electronic information from the metal ion and its axial ligands to the 
porphyrin π-system. Two of the peripheral double bonds can undergo addition reactions 
without interfering with the aromaticity. The β-pyrrolic positions are more sterically 
favored than the meso-carbons and tend to undergo electrophilic substitution reactions 
such as nitration, halogenation, sulfonation, formylation, acylation and deuteration.24, 25 
1.2 Porphyrin Synthesis 
The porphyrin synthetic chemistry depends on the fundamentals of symmetry and 
complexity of the various substituents on the target porphyrin.26-29 The basic 
methodologies for porphyrin synthesis and their chemistry were first developed by Hans 
Fischer.30, 31, 32 Several methods for the synthesis of porphyrins using various 
intermediates have since been developed.26 Most of the synthetic methodologies that will 
be discussed in detail henceforth are important because some will be utilized throughout 
this dissertation. There are many approaches to synthesize a porphyrin but only three 
main methods will be discussed in this introduction. Firstly a simple tetramerization of 
monopyrroles in the presence of an acid catalyst will be discussed, followed by the 
MacDonald route using two dipyrromethanes, and finally the synthesis through 
cyclization of an open chain tetrapyrrole will be discussed.  
Porphyrin synthesis from monopyrroles33, 34, 35 is a simple and economical method. The 
two famous model porphyrins that can be synthesized very easily using this procedure are 
the octaethylporphyrin (OEP) 1.7 and the tetraphenylporphyrin (TPP) 1.4. The synthesis 
of TPP 1.4 reported by Rothemund36, 37 involved a high temperature reaction between 
pyrrole and benzaldehyde in pyridine, in a sealed tube. The conditions of this reaction 
were modified by Alder, Longo and their colleagues.38, 39, 40 They used hot propionic acid 
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as a solvent (at atmospheric pressure) for the condensation of pyrrole 1.1 and 
benzaldehyde 1.2 to get good yields of TPP 1.4 (20-25%). This reaction was further 
optimized by Lindsey’s group using a two step reaction where the acid catalyzed 
macrocyclization to form porphyrinogen 1.3 was followed by oxidation with 2,3-
dichloro-5,6-dicyanobenzo-1,4-quinone (DDQ) to form the tetraphenylporphyrin 1.4 in 
excellent yields (Scheme 1-1).41 
NH
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Scheme 1-1: Tetraphenylporphyrin synthesis from monopyrrole using Lindsey’s 
method41 
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A wide variety of meso-tetraarylporphyrins were synthesized successfully using 
Lindsey’s method. Lindsey’s method for the synthesis of tetraarylporphyrins was 
followed throughout this dissertation since all the carboranylporphyrins synthesized in 
this thesis are meso-substituted porphyrins.42, 43  
The naturally occurring porphyrins do not contain meso-substituents and so the synthesis 
of OEP 1.7 is the favored route for natural porphyrin synthesis. The two major routes for 
the synthesis of OEP differ in the addition of the meso carbons. The substituents on the 3- 
and 4- positions should be identical to get a unique product.44 In the first route for the 
synthesis of OEP 1.7 the tetramerization of the substituted pyrrole 1.5 is done using 
reagents such as formic acid which can provide the four meso methine carbons of the 
product (Scheme 1-2).45 
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Scheme 1-2: Octaethylporphyrin synthesis from substituted monopyrroles45 
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In the second method pyrrole 1.6 bearing a 2-CH2R substituent is used for the 
tetramerization; the methylene linkage will eventually be the source for inter pyrrolic 
carbons.46-50 Large substituents on the monopyrroles are necessary to enforce a 
polymerization of the elongating molecule into a cyclic porphyrin. 
Dipyrromethanes are key intermediates in the synthesis of porphyrins by the [2+2] 
MacDonald route. Symmetrical and unsymmetrical dipyrromethanes can be synthesized 
using straightforward approaches such as self-condensation of bromomethylpyrroles51 or 
by condensation of 2-acetoxymethylpyrroles52 with 2-unsubstituted pyrroles. MacDonald 
and coworkers reacted 1, 9-di-unsubstituted dipyrromethane 1.8 with 1, 9-
diformyldipyrromethane 1.9 in the presence of hydroiodic acid catalyst to form pure 
porphyrin 1.10 in high yields (Scheme 1-3).53 
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Scheme 1-3: Porphyrin synthesis from dipyrromethanes by the [2+2] MacDonald route53 
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The synthesis of unsymmetrically substituted porphyrins can be best achieved through 
open chain tetrapyrrolic intermediates.54-58 The scrambling of pyrrole subunits during the 
cyclization process can be avoided and the formation of only one porphyrin isomer can 
be achieved. a,c-Biladienes are the most favored open chain precursors although a 
number of open chain tetrapyrroles have been investigated and utilized in the synthesis of 
the porphyrins.  
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Scheme 1-4: Porphyrin synthesis from an open chain tetrapyrrole 
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Symmetrical a, c-biladienes can be easily synthesized by reaction of a 1, 9-diacid 
dipyrromethane 1.11 with formylpyrrole 1.12 as shown in Scheme 1-4.59 The a,c-
biladiene is than cyclized using a Cu (II) salt to yield metalated porphyrin.  The 
Cu(II)porphyrin is then demetalated to yield porphyrin 1.14 in high yields.60 Asymmetric 
porphyrins can also be synthesized using the a,c-biladiene route via a tripyrrene.61 In the 
cyclization of a,c-biladiene to porphyrin, the reaction is believed to proceed via a free 
radical pathway where one of the methyl groups is lost while the other is retained as the 
new methine carbon.62 
1.3 Carboranes  
A carborane is a cluster composed of boron and carbon atoms. Like many of the related 
borans, these clusters are polyhedra, and are similarly classified as closo-, nido-, 
arachno-, hypho-, etc. based on whether they represent a complete (closo-) polyhedron, 
or a polyhedron that is missing one (nido-), two (arachno-), or more borons (Figure 1-
4).63 
H
H
HH
-
= BH
= C
H
 
Figure 1-4: closo and nido carborane cages 
The most interesting feature of carboranes like 1, 2-C2B10H12 is the ability of the 2 carbon 
atoms and 10 boron atoms to adopt the icosahedral geometry in which the carbon and the 
boron atoms are hexa-coordinate.64, 65 Extremely stable icosahedral closo-ortho 
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carboranes have been explored for use in a wide range of applications from heat-resistant 
polymers to medical applications.66 The o-carborane cage is very stable in the presence of 
oxidizing agents, alcohols and strong acids and exhibits thermal stability to temperatures 
up to 400 0C.67 At the temperature higher than 400 0C it rearranges first to meta- 
carborane (1, 7- C2B10H12) and then to para-carborane (1, 12-C2B10H12) (Figure 1-5).68, 69, 
70 
H
H H H
H
H = BH
= C  
Figure 1-5: ortho (1, 2), meta (1, 7) and para (1, 12) carborane cages 
1, 2-C2B10H12 is synthesized from decaborane. Decaborane is attacked by a Lewis base 
complex of alkyl amines, alkyl sulfides, and acetonitrile, forming bis(ligand) derivatives 
of  B10H12L2, which in turn react with acetylene to give  o-carborane in high yields 
(Scheme 1-5). 71-74 This was the main route used for the synthesis of the o-carborane in 
the following Chapters. Various substituted acetylenes have been reacted with B10H12L2 
to form a variety of substituted carboranes. Acetylenes containing hydroxyl groups 
destroy the decaborane cage and fail to give carborane products. So the carboranes 
containing such groups are prepared by substitution reaction at the carbon. The strong 
electron withdrawing o-carborane unit facilitates the metalation of the carborane C-H 
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group (Scheme 1-6). 75, 76, 77 This can then be followed by a substitution reaction with 
alkyl or aryl halides. 
 
B10H12L2    + HH
HH
+  2L +  H2
B10H14    +    2L B10H12L2    +   H2
L = CH3CN, Alk3N, Alk2S
= BH
= C  
 
Scheme 1-5: Synthesis of ortho-carborane 
 
 
HH
+ RLi
LiH
RH+
= BH
= C  
Scheme 1-6: Reaction of ortho-carborane with n-BuLi 
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The substitution on the carbon of the o-carborane influences the reactivity of the 
unsubstituted atoms. The generation of the anion with n-BuLi was widely used in the 
following Chapters for obtaining different substituted carboranes.  
The o-carborane moieties are extremely hydrophobic. The o-carborane cage can be 
degraded by using pyridine/piperidine in 3:1 ratio.78 This mild method results in a nido-
carborane cage where a boron is missing from the o-carborane to form the nido-C2B9H12-. 
A loosely bound piperidine molecule is attached to the nido-carborane cage which can be 
exchanged with either sodium or potassium ions to form a hydrophilic nido-carborane 
cage. The attack of the base occurs on the most electropositive boron atom which is 
directly attached to the carbon atoms. The removal of the boron generates a icosahedral 
fragment with adjacent carbons on the open face. The extra hydrogen is assumed to be 
bonded to the open face of the ion by a six-center hydrogen bond.79 The nido-carborane 
cages can also be obtained by reaction of the closo-carborane cage with trialkylamines,80 
methoxides,81 hydrazine82 and ammonia.83  
The most interesting aspect of closo-carboranes and the nido-carborane compounds is 
that upon irradiation with thermal (slow) neutrons, a nuclear fission reaction results, 
breaking boron-10 atoms (which have 20% natural abundance) into an alpha particle, a 
lithium atom, and some gamma radiation for application in boron neutron capture therapy 
(BNCT). Carboranes, with their high boron content have been the molecules of choice for 
boron delivery to tumors but are by themselves inadequate due to their hydrophobicity. 
The carboranes are very stable in nature and so they can be incorporated into various 
organic and biochemical substrates and can be used as vehicles for delivery of boron to 
disease tissues which is critical to the success of BNCT. So a suitable balance between 
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the hydrophilicity of the nido-carborane cages and the hydrophobicity of the porphyrin 
macrocycle will be essential to achieve specificity to tumors. 
1.4 Boron Neutron Capture Therapy 
BNCT84 has been experimentally tested primarily as an alternative treatment for 
malignant brain tumors called glioblastomas. BNCT is a form of radio therapy that 
utilizes a neutron beam that interacts with boron injected into a patient. BNCT depends 
on the interaction of slow neutrons with boron-10 to produce highly cytotoxic particles 
(4He+2 and 7Li+3) and the release of 2.4 meV of kinetic energy, according to Scheme 1-7.  
 
10
5B + 10n 115B
4
2He + 73Li + 2.79 MeV (6%)
4
2He + 73Li + γ0.48 MeV + 2.31 MeV (94%)  
 
Scheme 1-7: Nuclear reaction initiated by collision of a neutron with boron-10 
 
Patients are first given an intravenous injection of a boron-10 tagged chemical that 
preferentially binds to tumor cells. The neutrons are created either in a nuclear reactor or 
by colliding high-energy protons into a Lithium target. The neutrons pass through a 
moderator, which shapes the neutron energy spectrum suitable for BNCT treatment. 
Before entering the patient the neutron beam is shaped by a beam collimator. While 
passing through the tissue of the patient, the neutrons are slowed by collisions and 
become low energy thermal neutrons. The thermal neutrons undergo reaction with the 
boron-10 nuclei, forming an unstable boron-11 nucleus which then undergoes 
spontaneous decay to lithium-7 and an alpha particle (Figure 1-6).  
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Figure 1-6: BNCT in cancer cells 85 
 15
Both the alpha particle and the lithium ion produce closely spaced ionizations in the 
immediate vicinity of the reaction, with a range of approximately 5-9 µM, or one cell 
diameter. This technique is advantageous since the radiation damage occurs over a short 
range and thus normal tissues can be spared. Malignant brain tumors86 are usually highly 
infiltrative of normal brain and the selective destruction of tumor cells and recurrence of 
metastatic tumors can potentially be controlled or eliminated using such a therapeutic 
modality. BNCT could dramatically increase patient life quality and expectancy.  
BNCT relies on initial targeting of tumor cells by an appropriate compound attached with 
10B which preferentially concentrates in tumor cells. BNCT is a binary system of therapy 
since the boron compound is made to target tumor cells and the neutron beam is aimed at 
the location of the tumor. The advantage of such a therapy is that each component can be 
manipulated independently of the other.  
Thermal neutrons are not effective against deep seated tumors as they dissipate while 
traversing the tissue and also thermal neutrons produce recoil protons capable of ionizing 
tissue components.87 So the more energetic epithermal neutrons which become energized 
when passing through the tissue are appropriate for BNCT.88 The source for the 
epithermal neutrons is limited to nuclear reactors. The amount of neutrons that reach the 
target area should not exceed the tolerance levels of the normal tissues. With BNCT we 
can adjust the exact time when there is the highest differential amount of 10B 
concentrations in tumor than the normal tissues and then irradiation with a non 
radioactive neutron beam for an optimum time will be highly toxic to the tumor cells.  
Furthermore, the neutron beam itself can be directed in such a way that the normal tissues 
with high 10B concentration can be excluded from the treatment zones.89, 90, 91 
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Protection of normal tissues near and within the treatment areas is achieved by selective 
targeting of 10B to the tumor. The alpha particles along with the high LET particles which 
are produced after the splitting of boron-10 also have biological advantages. X-rays and 
alpha particles do not require oxygen to enhance their biological effectiveness which is 
not the case with other forms of ionizing radiation. A rapidly growing tumor tissue 
frequently outgrows its own blood supply and so there are some regions within the tumor 
tissue which receive far less oxygen than normal tissues. As a result of this oxygen 
depletion, the tumor can become more resistant to the effects of conventional photon or 
electron (i.e. low LET) radiation therapy. Even when the tumor has limited oxygen 
supply the tumors will be sensitive towards the alpha particles. The alpha particles and 
lithium ions can also kill dividing and non dividing tumor cells. This is greatly 
advantageous since tumors are known to have a large number of viable but inactive cells. 
Other forms of radiation therapy and also chemotherapy tend to work very well only on 
cells that are dividing.92 
The 10B which has a high cross section for capture of neutrons is also the favored nuclide 
for the synthesis of BNCT agents with hydrolytically stable linkages between the boron 
and other elements such as carbon, oxygen and nitrogen.  10B nuclide93, 94, 95 produces 
high LET particles and its small atomic size permits it to be replaced instead of carbon in 
many of biologically active compounds. The use of 157Gd as a nuclide96, 97 in GdNCT 
(gadolinium neutron capture therapy) was also proposed since 157Gd has a larger cross 
section for the capture of neutrons than the 10B.98 157Gd on collision with neutron 
produces γ rays and Auger and Coster-Kronig electrons.99 The γ rays are not confined to 
the tumor cell from which they are produced and also the Auger and Coster-Kronig 
electrons have low energy which makes them less effective away from the cell nucleus. 
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The other nuclides that occur abundantly in tissue like 12C, 1H, 14N and 16O do not exhibit 
a high nuclear cross-section for neutron capture.100 The high tissue concentrations of 1H 
and 14N can contribute to secondary fission products. In order to minimize this secondary 
effect it is essential that the 10B concentration is approximately 15-30 µg of 10B/gram of 
tumor or 109 of 10B/cell so that 85% of the radiation dosage arises from 10B capture 
reaction.101, 102 The cellular concentration of 10B should be adequate and also highly 
specific to tumors so that radiation dosage to the surrounding normal tissues can be 
minimized. 
The major challenge in BNCT has been the development of a 10B delivery agent that can 
selectively destroy the glioblastoma multiforme (GSM) cells in the presence of normal 
cells. An ideal BNCT agent which is tagged with 10B should be able to deliver therapeutic 
and predictable concentrations of ~30 µg of 10B per gram of tumor. The localization of 
the 10B atoms within tumors in close proximity to the tumor cell nucleus compared to the 
cell surface increases the therapeutic effect of the BNCT agent while decreasing the 
required dosage amount. The ideal BNCT agent should have low toxicity towards the 
normal tissue surrounding the tumor. It should also have low retention times in the tumor 
and should be rapidly cleared from the blood and normal tissues. The 10B agent should 
have the propensity to cross the blood-brain barrier (BBB)103 which can be achieved with 
good lipophilicity of the drug. The 10B agent should be readily synthesized and should 
have the ability to be easily monitored in the tissue for evaluation and quantification of 
10B-localization sites.  
The quest for these ideal 10B agents started in 1950s and early 1960s when boric acid and 
sodium borate were used with no success. These compounds were non selective and had 
low tumor/brain ratios.104–107 In a search for a low toxic compound with a greater 
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persistence in tumor lead to the synthesis and biologically evaluation of 4-
dihydroxyborylphenylalanine (BPA) by Snyder et al.108, 109  Later disodium mercapto-
closo-dodecarborate (BSH) was synthesized and analyzed because of its higher 
percentage of boron and a significantly lower toxicity based on its boron content.110  Both 
BSH and BPA were chosen for clinical studies and are currently undergoing Phase I/ II 
clinical trials in the US, Europe and Japan, for the treatment of patients with melanomas 
and glioblastomas.111  However both BSH and BPA showed low selectivity for tumor 
cells and low retention times in tumors. 
 
SH
(HO)2B CO2
NH3H
Na2
BSH
BPA
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= B
 
 
Figure 1-7: Structures of BSH (disodium-mercapto-closo-dodecarborate) and BPA (4-
dihydroxyborylphenylalanine) 
 
Furthermore BSH is chemically unstable which increases its toxicity and BPA has only a 
low percentage of boron by weight so a large dose is necessary for effective BNCT.112 
For BNCT to be effective, there must be ~15-30 µg of 10B/g of tumor and a low 
concentration (<5 µg of 10B/g of normal tissue) in the surrounding normal cells and 
blood.113, 114, 115 Since BSH and BPA are not ideal BNCT agents several other BPA 
derivatives and boron containing amino acids as well as non amino acids were 
 19
synthesized and evaluated.116-120  Highly water soluble carbohydrate derivatives of BSH 
and other boron containing sugars were synthesized and evaluated both in vivo and in 
vitro studies.121-127 These compounds showed low toxicity and uptake in tumor cells. 
Various other boron-containing analogues of biologically active compounds such as 
amino acids,128 peptides,129 nucleosides/nucleotides,130 phospholipids,131 liposomes,132 
and monoclonal and bispecific antibodies have been synthesized and studied.133, 134 
Of all the novel boron-delivery agents, carboranylporhyrins appear to be the most 
promising tumor-selective compounds because of their ability to effectively accumulate 
within neoplastic cells and to be retained there for long periods of time135 in addition to 
exhibiting most of the desired characteristics of an effective BNCT agent.136 The primary 
source of boron in the new BNCT agents is usually the hydrophobic o-carborane (o-
C2B10H11) or the amphiphilic nido-carborane (o-C2B9H11-). These carborane cages have 
high boron content and display extraordinary thermal, kinetic and photochemical 
stabilities relative to other boron clusters.137, 138 The carboranylporphyrins are porphyrin 
macrocycles linked to carborane clusters via ester, amide, ether, methylene or aromatic 
linkages. The nature of these linkages affects the stability of the compound and also its 
toxicity. The carboranylporphyrins are fluorescent and so they can be easily detected and 
quantified using fluorescence microscopy. The carboranylporphyrins usually have planar 
aromatic structures and have demonstrated their ability to interact with the DNA.139 In the 
following Chapters the synthesis and biological evaluation of highly stable 
carboranylporphyrins with very high boron content will be further discussed. The novel 
carboranylporphyrins synthesized are water soluble so that they can be administered 
systemically and they are also amphiphilic compounds (suitable balance between the 
hydrophilicity and lipophilicity) which make them highly promising compounds for 
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BNCT. The carboranylporphyrins discussed in later Chapters have the potential to 
provide most favorable differential boron concentrations between the tumor and normal 
brain. The synthesis of novel stable carboranylporphyrins and their in vivo and in vitro 
toxicity and uptake studies will be discussed.  
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Chapter 2 
Synthesis and Invitro Biological Evaluation of a Tetra(nido-carboranyl)porphyrin 
and an Octa(nido-carboranyl)porphyrin  
 
2.1 Introduction  
Boronated carboranylporphyrins are a novel variety of 10B delivery agents currently 
under investigation for Boron neutron capture therapy (BNCT).1-4 A tetra(nido-
carboranyl)porphyrin and an octa(nido-carboranyl)porphyrin are the target meso-
substituted carboranylporphyrins of the present study described in this chapter. The major 
challenge in the development of 10B-delivery agents has been the delivery of therapeutic 
doses of boron to the target tumors with minimal normal tissue toxicity.  The 10B delivery 
agents have to be very selective towards the tumors, particularly towards high-grade 
gliomas which are highly infiltrative of normal brain. The ability of carboranylporphyrins 
to accumulate within tumors and their synthesis with high boron content has been 
investigated.5 Water solubility is an important factor for a 10B-delivery agent so that it can 
be administered easily into the blood stream. The lipophilicity is necessary for them to 
cross the blood-brain barrier (BBB) and diffuse within the brain and the tumor.6 
Therefore, amphiphilic compounds such as the target compounds tetra(nido-
carboranyl)porphyrin and octa(nido-carboranyl)porphyrin will have a suitable balance 
between hydrophilicity and lipophilicity. This will be of primary interest because they 
should provide the most favorable differential boron concentrations between tumor and 
normal brain, thereby enhancing tumor specificity. This critical feature of the 
carboranylporphyrins along with easy synthesis and high boron content forms the basis of 
their use as boron delivery vehicles for the BNCT of tumors. 
Only two boron containing drugs are currently clinically approved for use in BNCT: 
disodium mercapto–closo-dodecaborate (BSH)7 and L-4-dihydroxyborylphenylalanine 
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(BPA).8 However both BSH and BPA have low selectivity for tumor cells and low 
retention times in tumors.9 Furthermore BSH is chemically unstable and BPA has only 
low percentage of boron by weight so a large dose is necessary for effective BNCT. 
Among all the investigated 10B delivery agents, carboranylporphyrins appear to be 
particularly promising because of their demonstrated ability for targeting and selectively 
accumulating in tumor cells.10, 11 The first series of the carboranylporphyrins synthesized 
by Haushalter and Rudolph had the porphyrin macrocycle linked directly to carborane 
moiety via carborane-carbon atom by a methylene or phenyl linkage for example 2.1.12, 13 
These compounds were used as catalysts for reversible multi-electron reduction of small 
molecules such as O2 and N2. Later several groups of researchers synthesized 
carboranylporphyrins on the basis of natural porphyrins.14-17 Some of them showed high 
solubility in water and accumulated in the tumor cells but their toxicity levels towards the 
normal cells were too high.18 Kahl et al.19 reported a novel type of boronated porphyrin 
2.2 in which four closo-carboranes were linked to the porphyrin macrocycle by ester 
linkages. This carboranylporphyrin showed a better localization in the murine intracranial 
glioma when compared to intact brain tissue. Morgan et al20 used hematoporphyrin as 
starting compound in which carboranes were bonded to the carboxylic groups of 
hematoporphyrin to give 2.3 making the porphyrin more hydrophilic. Miura et al21 
synthesized carborane-containing metal porphyrins, for example 2.4, which showed 
lower toxicity and a better accumulation in tumor as compared to blood. A number of 
carboranyporhyrins have been synthesized by the Vicente et al.22 Some of the 
carboranylporphyrins synthesized by Vicente et al have been shown to interact with DNA 
and thereby produce in vitro DNA damage following light activation.23,  24 
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Figure 2-1: Examples of carboranylporphyrins reported in literature 
 
Porphyrin macrocyles containing up to 8 boron clusters (43 % boron by weight) attached 
to the porphyrin macrocycle via ester, amide, ether, amine and carbon-carbon bonds have 
been synthesized and evaluated in cellular and animal studies. Several of these have 
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tumor-localizing abilities coupled with high boron content that enable them to cause 
selective cell kill after irradiation with a very low intensity neutron beam. 25-29 Identifying 
the mechanism of the localization of the carboranylporphyrins in tumors will allow the 
subsequent design of new carboranylporphyrins with higher tumor to normal tissue ratio. 
The carboranylporphyrins with the ester and amide linkages have questionable in vivo 
hydrolytic stability. The tetra(nido-carboranyl)porphyrin30 synthesized in this study has 
36 boron atoms/ molecule and 30% boron /by weight. It also has stable carbon-carbon 
linkages between the porphyrin macrocycle and the carborane residues which will ensure 
that in vivo cleavage, leading to release of free carborane, is highly improbable with these 
compounds.31 Although the synthesis of one porphyrin derivative bearing eight boron 
cages linked to the porphyrin ring via ester bonds has been reported,32 studies of its 
biological properties were never undertaken. I synthesized a boron-containing porphyrin 
with eight carborane cages (44% boron by weight) linked to the porphyrin macrocycle 
via chemically stable carbon-carbon bonds and studied its biological properties. The 
cellular and animal studies done on similar carboranylporphyrins by our group have 
shown that these types of macrocycles are an excellent platform for the selective delivery 
of boron to tumor cells.30 Both porphyrins H2TMCP and H2OCP show promise of 
considerable higher therapeutic efficacy in BNCT because of their ability to deliver 
therapeutic amounts of boron to tumors with low levels of toxicity. The tetra(nido-
carboranyl)porphyrin and octa(nido-carboranyl)porphyrin are highly fluorescent and this 
enables the detection of tumor cells using fluorescence microscopy,33, 34 and the 
determination of 10B-localization in tumors and surrounding tissues. Intracellular boron 
distribution and quantification play an important role in determining the dose and length 
of neutron radiation, as well as the success of the BNCT treatment.35 In this chapter the 
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syntheses of a stable tetra(nido-carboranyl)porphyrin (H2TMCP) and an octa(nido-
carboranyl)porphyrin (H2OCP) are described. Their dark toxicity, cellular uptake and 
intracellular localization studies are reported and discussed. 
2.2 Results and Discussion 
2.2.1 Synthesis of a Tetra(nido-carboranyl)porphyrin 
Tetra(nido-carboranyl)porphyrin 2.9 containing four carborane cages linked via carbon-
carbon bonds to the meso-phenyl on the porphyrin macrocycle was prepared according to 
Scheme 2-1.22, 30 Porphyrin 2.9 was prepared in four steps from commercially-available 
4-(bromomethyl)bromobenzene 2.5, as previously described.22, 30 Reaction of the lithium 
anion36 of 1-methyl–o-carborane with 4-(bromomethyl)bromobenzene 2.5 by an SN2 -
substitution reaction produced 4-(1-methyl-o-carboranyl)methyl]bromobenzene 2.6 in 
75% yield. 4-(1-Methyl-o-carboranyl)methyl]benzaldehyde 2.7 was prepared from 4-(1-
methyl-o-carboranyl)methyl]bromobenzene 2.6, by lithium-bromide exchange at -780C, 
followed by addition of DMF and acidic hydrolysis to form the product in 60% yield.37 
Condensation of 4-(1-methyl-o-carboranyl)methyl]benzaldehyde 2.7 with pyrrole under 
Lindsey-type conditions38 (using 0.01 M of  pyrrole  and 0.005 M TFA ) afforded 
tetra(closo-carboranyl)porphyrin  2.8 in 30 % yield. The resulting porphyrin 2.8 has high 
hydrophobic character and so is soluble in non polar organic solvents like carbon 
tetrachloride. The conversion of the closo-carborane cages into nido-carborane cages was 
done by a mild procedure using 3:1 mixture of pyridine and piperidine,39 at room 
temperature for 36 hours. The tetra-sodium salts were obtained by piperidinium/Na+ 
cation exchange on a Dowex 50WX2-100 resin in the sodium form. Pure tetra(nido-
carboranyl)porphyrin 2.9 was obtained in 90% yield and was highly soluble in polar 
solvents such as acetone, methanol, DMSO and water. 
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Scheme 2-1: Synthesis of tetra(nido-carboranyl)porphyrin 2.9 
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The highly pure tetra(nido-carboranyl)porphyrin 2.9 was synthesized in good yields in 
order to study and compare the biological properties with octa(nido-
carboranyl)porphyrin. Porphyrin 2.9 has chemically stable carbon-carbon methylene 
linkages between the meso-phenyl substituents and the carborane moieties. The H2TMCP 
has 36 atoms of boron per molecule which makes it 30 % boron by weight of the 
molecule and so has the potential to deliver therapeutic concentrations of boron to tumor 
cells for the BNCT. The water soluble H2TMCP is tetra anionic and was found to have 
the highest hydrophobic character compared to other carboranylporphyrins previously 
studied.  The negatively charged nido-carborane cages make the H2TMCP water-soluble 
while the phenyl rings enhance the hydrophobicity.40 The amphiphilic character is very 
desirable in promising BNCT agents since it helps with the solubility of the drug in the 
blood and also with crossing of lipophilic membranes.41 The distribution of the carborane 
cages at the porphyrin periphery might influence the cytotoxicity, cellular uptake and the 
retention in the sub-cellular organelle. The UV-visible of the porphyrin 2.8 is similar to 
that of typical meso-substituted porphyrins42 with a soret band at 419 nm and four Q 
bands showing etio-type absorption spectrum. The H2TMCP 2.9 shows an intense Soret 
band in acetone and less intense broader bands in water and human serum. The carborane 
cages do not quench the fluorescence of porphyrin 2.9 as it shows fluorescence at 667 nm  
upon excitation at 543 nm. The high fluorescence emission helps in the detection of the 
H2TMCP 2.9 in tumor cells using fluorescence microscopy.  The pure H2TMCP was 
characterized by 1H-NMR and MALDI-MS. The 1H-NMR of the tetra(nido-
carboranyl)porphyrin shows the BH protons of the open face of the nido-carborane cages 
as broad singlet between -2.45 to -1.9 ppm and the remaining BH protons at 0.9-2.4 ppm 
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whereas in the closo-carborane cages of the porphyrin 2.8 the BH protons appear between  
1.5-3.4 ppm. The porphyrin macrocycle 2.8 exhibits a non-planar waved conformation.43 
 
 
 
Figure 2-2: Crystal structure of H2TMCP 
 
In order to study the interaction of the porphyrins with human serum an experiment with 
H2TMCP 2.9 in mixture of human serum and PBS solution at pH = 7.2 was performed. 
Equal concentrations of the porphyrin was added to increasing concentrations of human 
serum (from 0-2%) in PBS solution at pH = 7.2. The measured visible (Figure 2-3) shows 
the characteristic sharp (red) peak of porphyrin in DMSO and the short broad peak 
(black) of the porphyrin in 0% human serum which is a characteristic of an aggregated 
 37
porphyrin. As the human serum concentration increases the Soret band becomes sharper 
and resembles that of the H2TMCP in DMSO which shows that the porphyrin is de-
aggregating and probably binding to proteins within human serum. 
 
 
 
Figure 2-3: H2TMCP in DMSO (red) and 0-2% human serum (HS) in PBS (other 
colors). 
 
2.2.2 Synthesis of a Octa(nido-carboranyl)porphyrin 
Porphyrin 2.17 was obtained in seven steps using the same synthetic methodology as 
described for porphyrin 2.9 (Scheme 2-2).22 The carborane cages are linked by a 
methylene linkage at the meta-positions of the meso-phenyl rings on the porphyrin 
macrocycle. Di(bromomethyl)bromobenzene 2.11 was obtained from commercially 
available 3,5-dimethylbromobenzene 2.10 via a free radical substitution reaction in the 
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presence of NBS and benzoyl peroxide.44 The yield of this reaction was 33%. 
Di(bromomethyl)bromobenzene 2.11 reacted with two equivalence of  1-lithium-2-
methyl-o-carborane in THF via an SN2 reaction to form bis[3,5-(1-methyl-o-
carboranyl)methyl]bromobenzene 2.12 in 63% yield.  
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Scheme2-2: Synthesis of Octa(closo-carboranyl)porphyrin 2.14. 
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A lithium-bromide exchange was then performed on the bromobenzene 2.12, followed by 
reaction with DMF and acidic hydrolysis, to afford bis[3,5-(1-methyl-o-
carboranyl)methyl]benzaldehyde 2.13 in 70% yield. This aldehyde 2.13 was condensed 
with pyrrole using Lindsey-type conditions (using 0.01 M of  pyrrole  and 0.005 M TFA ) 
followed by oxidation of the porphyrinogen intermediate with p-chloranil to give the 
octa(closo-carboranyl)porphyrin 2.14 in 10% yield. Porphyrin 2.14 has high hydrophobic 
character and it is soluble in non polar organic solvents, such as carbon tetrachloride and 
toluene. Addition of one drop of acid such as TFA, increases solubility of 2.14 in 
chloroform and dichloromethane, via formation of the porphyrin dication. The porphyrin 
2.14 is found to protonate readily, possibly due to the inductive effect of the carborane 
cages.23 The porphyrin 2.14 was characterized by 1H-NMR, MS, UV-Vis and X-ray 
crystallography. Crystals of porphyrin 2.14 were grown from slow diffusion of 
cyclohexane into a concentrated solution of 2.14 in dichloromethane. Figure 2-4 shows 
the crystal structure of the free base porphyrin 2.14. The porphyrin macrocycle 2.14 
exhibits a planar conformation with the meso-phenyl rings orthogonal to each other and 
to the porphyrin plane. The closo H2OCP 14 was made into a nido H2OCP 17 by the de-
boronation of the eight carborane cages using pyridine/piperidine mixture in 3:1 ratio for 
72 hours.45 This resulted in very low yields of porphyrin 2.17 so an alternate route was 
employed. In this new route the water-insoluble porphyrin 2.14 was first metalated46 with 
Zn2+ to protect the inner NHs. The UV-visible data clearly showed the disappearance of 
the absorption bands at 513nm, 591nm and 651nm indicating the Zn insertion. The 
metallation was followed by the deboronation of the carborane cage using 
pyridine/piperdine mixture in 3:1 ratio. This was then made into a sodium salt by the 
piperdinium/Na+ exchange on a Dowex 50WX2-100 resin, to form water-soluble  
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Scheme 2-3: Synthesis of octa(nido-carboranyl)porphyrin 2.17 
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Figure 2-4: The molecular structure of porphyrin 2.14 as determined by X-ray 
crystallography. (a) top view; (b) side view. Solvent molecules and H atoms, 
except for N-H, are not shown 
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porphyrin 2.16. Porphyrin 2.16 was de-metallated using TFA to give the octa(nido-
carboranyl)porphyrin 2.17 in 90% yield.47 H2OCP 2.17 was further purified by passing it 
through a sephadex column to remove low molecular weight impurities. The base 
induced deboronation reaction gave a good yield of the corresponding octa(nido-
carboranyl)porphyrin when performed on the zinc(II)complex 2.16, rather than on the 
free base 2.14. The demetalation also occurred smoothly under acidic conditions. 
Most of the carboranylporphyrins synthesized before had 2 or 4 carborane cages attached 
to the porphyrin macrocycle by weak linkages which affected their stability in the in vivo 
environment. The charge, amphilicity and the structural features also affect the uptake in 
the tumor cells and their toxicity. The H2OCP has eight carborane cages attached by 
hydrolytically stable methylene linkages to the phenyl positions on the porphyrin 
macrocycle. The H2OCP 2.17 has a total of 72 borons which makes it an effective BNCT 
agent since it can potentially deliver 15-30 µg of Boron-10/gram of tumor. The H2OCP 
2.17 is octa-anionic and shows good solubility in polar solvents whereas the closo 
carborane analog 2.14 is soluble in non polar solvents. The perfect balance of the 
hydrophobicity and the hydrophilicity48 found in both the H2TMCP and the H2OCP helps 
in the easy uptake of these carboranylporphyrins by tumor cells. Porphyrin 2.17 had to be 
very pure for in vitro and in vivo studies as free nido carborane impurity in the compound 
is known to be toxic to cells or animals and this can totally alter the toxicity studies.  The 
UV-visible showed a characteristic porphyrin Soret band at 420 nm and the four Q bands 
in etio-type absorption spectra (Figure 2-5).42 The H2OCP is fluorescent and it has the 
excitation wavelength at 557 nm and the emission wavelength at 607 nm. The 
fluorescence emission helps in the detection of the intracellular localization of H2OCP in 
tumor cells using fluorescence microscopy.  
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Figure 2-5: UV-visible of the H2TMCP (in blue) and H2OCP (in green) in Acetone 
 
The 1H-NMR of the octa(nido-carboranyl)porphyrin 2.17 shows a broad singlet at -2.4 
ppm indicating the BH protons on the open faces of the eight carborane cages. The 
remaining 72 protons are between 1.6-2.9 ppm.  The 24 methyl protons on the carborane 
cages form a singlet at 2.0 ppm. The aromatic protons on the benzene ring are between 
7.86-8.06 ppm and the β-H on the pyrrole are at 9.91 ppm.  
2.2.3 Dark Cytotoxicity 
The biological properties of nido-carboranylporphyrins H2TMCP 2.9 and H2OCP 2.17 
were investigated and compared. Cell toxicity studies were conducted to evaluate the 
toxicity levels of these porphyrins towards V79 hamster fibroblast cells using a 
clonogenic assay.49, 50 The cells were exposed to different concentrations of porphyrins 
(0-250 µM) and incubated for 24 hours and then their toxicity levels were determined by 
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counting the survival cell colonies as shown in Figure 2-6. Concentrations of H2OCP up 
to 200 µM did not show any significant effect on cell colony proliferation, but after 200 
µM there was a decrease in the cell proliferation. H2TMCP showed more toxicity towards 
the V79 fibroblast cells than H2OCP. H2TMCP concentrations up to 150 µM had no 
significant effect on the rate of the cell colony proliferations but there was a decrease in 
the number of colonies at the higher concentrations. The CS50 value which shows the 
50% inhibition of the cell colony proliferation compared to the controls is above 250 µM 
for both porphyrins. The determined survival rates above 100% are within the experiment 
error range, which mainly derives from the heterogeneous nature of cell suspensions and 
cell counting.  
 
 
Figure 2-6: Cytotoxicity of (in green) H2OCP 2.17 and (in blue) H2TMCP 2.9 towards 
V79 cells using a clonogenic assay. 
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V79 hamster fibroblast cell mimic the normal cells surrounding the tumor cells so less 
toxicity against these cells will be advantageous in the development of an ideal 10B agent. 
The death of normal cells around the tumor is an important drawback of chemotherapy, 
however it can be avoided in BNCT by using a non toxic 10B agent which can localize 
preferentially in the tumor cells. Carboranylporphyrins H2TMCP and H2OCP have CS50 ≥ 
250 µM showing very low dark toxicity towards V79 hamster fibroblast cells using a 
clonogenic assay. The dark toxicity of H2TMCP is in agreement with the tetra 
carboranylporphyrins previously studied. 24, 51 But the low level of toxicity of octa(nido-
carboranyl)porphyrin compared to tetra(nido-carboranyl)porphyrin is very promising as it 
has more boron content and still shows similar low dark toxicity found in tetra 
carboranylporphyrins. 
2.2.4 Cellular Uptake 
The concentration-dependent uptake was investigated in human T98G cells exposed to 
concentrations up to 200 µM of H2OCP for 3 hours. The results obtained are shown in 
Figure 2-7. The concentration of the intracellular bound porphyrin was determined by the 
chemical extraction of the cells followed by the fluorescence detection using the 
excitation filter of 570-580 nm and emission filter of 650 nm. The H2OCP accumulation 
consistently increased with the increasing exogenous drug concentration. The uptake of 
the porphyrin H2OCP into T98G human glioblastoma cells was found to be concentration 
dependent. For H2OCP the amount of porphyrin accumulated in the tumor cells increased 
continuously until the exogenous porphyrin concentration increased to 50 µM. For higher 
concentrations of 50 µM - 200 µM the porphyrin accumulated in the cells did not show a 
linear increase with the exogenous concentration. 
 46
 
Figure 2-7: Concentration-dependent uptake of H2OCP 2.17 by T98G cells, after a 3 
hour time period 
 
 
This deviation might be because of the saturation of the H2OCP in the cells leading to 
egression of excess porphyrin into the surrounding medium. The H2OCP with its -8 
charge showed high aggregation in PBS solution and so H2OCP might be taken up by 
phagocytosis. Residual toxicity affects of the H2OCP also might have affected the 
concentration dependent uptake. 
The concentration dependent uptake of H2TMCP in human HEp2 cells was also 
investigated by exposing the cells to concentrations from 0-200 µM for 3 hours. The 
fluorescence filters used for H2TMCP were the excitation filter of 540 nm and the 
emission filter of 660 nm. The H2TMCP also showed a systematic increase in the 
accumulation of the porphyrin in the T98G cells with an increase of exogenous drug 
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concentration. The H2TMCP was tested for uptake in human HEp2 cells under the same 
conditions used for the uptake of H2OCP in T98G cells. 
 
 
 
Figure 2-8: Concentration-dependent uptake of H2TMCP 2.9 by Hep2 cells, after a 3 
hour time period. 
 
 
The H2TMCP showed a similar concentration dependent accumulation in HEp2 cells. 
The Figure 2-8 shows a consistent increase in the uptake of the H2TMCP with external 
concentration of the porphyrin. 
The time dependent uptake of H2OCP, ZnOCP and the H2TMCP were investigated in 
human T98G cells at the concentration of 10 µM. All the porphyrins were evaluated 
under the same conditions for a period of 24 hours and the results are shown in Figure 2-
9. At each time point the concentration of H2TMCP in the T98G cells was more than 
either that of H2OCP and ZnOCP 2.16.  
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Figure 2-9: Time-dependent uptake of H2OCP 2.17 (green), ZnOCP 2.16 (black) and 
H2TMCP 2.9 (blue) at 10 µM by T98G cells 
 
In the first four hours the amounts of all the three porphyrins accumulated in the cells 
increased briskly. Both the H2TMCP and H2OCP concentrations in the T98G cells 
reached a plateau after four hours whereas the ZnOCP 2.16 showed a consistent increase 
in concentration over the 24 hour uptake time period. The H2TMCP is taken up to a 
significantly higher extent by the T98G cells compared with the octa(nido-
carboranyl)porphyrins 2.16 and 2.17. The accumulation of the octa(nido-
carboranyl)porphyrins 2.16 and 2.17 was found to be time dependent.52 The tetra(nido-
carboranyl)porphyrin is also found to be time dependent and accumulated to a much 
higher extent than porphyrins 2.16 and 2.17. This might be due to the higher hydrophobic 
character of the H2TMCP compared with the H2OCP and the ZnOCP 2.16. The uptake 
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kinetics of the H2TMCP and the H2OCP appear to be similar as they both are taken up 
rapidly in the first four hours and then reach a plateau.  There is also difference in the 
accumulation rates of the H2OCP and ZnOCP. The ZnOCP was taken up at a slower rate 
than the metal free porphyrins H2OCP and H2TMCP but at the end of the 24 hour uptake 
period the amounts of the Zn(II)complex 2.16 and the H2OCP found in the T98G cells 
was very similar. The octa(nido-carboranyl)porphyrins 2.16 and 2.17 might have 
different biological mechanism of uptake into the tumor cells and this may be the result 
of their aggregation behavior and also isomer composition.53 The aggregated porphyrins 
are presumed to be taken up easily than the non-aggregated porphyrins.23 Though the 
octa-carboranylporphyrins 2.16 and 2.17 are taken up only half of that of the H2TMCP, 
the octa-carboranylporphyrins 2.16 and 2.17 have higher boron content and can 
potentially deliver therapeutic amounts of boron to tumors with low toxicity to the 
normal cells. The more hydrophilic octa-anionic porphyrins could induce more damage to 
the tumor tissue than the tetra-anionic porphyrins. 
2.2.5 Intracellular Localization 
The preferential sites of the localization of H2OCP 2.17 in T98G cells were investigated 
using a Zeiss axiovert fluorescence microscope. Initially the T98G cells were observed 
using the 63X/1.4 na plan-apochromatic oil immersion lens in the phase-contrast mode 
and then the cells were exposed to UV-visible light using a texas-red filter, DAPI filter 
and FITC filter to check for auto- fluorescence. The cells were exposed to 50 µM 
concentration of porphyrin 2.17 for 4 hours and then observed under fluorescence 
microscope using the texas red filter. They were also checked for fluorescence using the 
DAPI and FITC filters since the organelle trackers emit fluorescence signal in these filter 
sets. 
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Figure 2-10: Intracellular localization of H2OCP 2.17 in human T98G cells. A: Phase   
contrast; B: Porphyrin fluorescence; C: LysoSensor Green fluorescence; D: Overlay. 
Scale bar: 20 µm 
 
 
As seen in the Figure 2-10B the intracellular localization of the H2OCP 2.17 under the 
texas red filter showed a pattern similar to that of localization in the lysosomes. 
Lysosomes are small granule like organelles that are spread throughout the cytoplasm of 
the cells.  When cell cultures with H2OCP 2.17 were incubated with lysosome-specific 
dye LysoSensor, a co-localization experiment was performed, as shown in Figure 2-10 C 
and D. The signals from the Lysosensor were imaged using the FITC filter set (Figure 2-
10 C). The overlay of Figure 2-10 B and C, as shown in Figure 2-10 D, shows that both 
the porphyrin fluorescence and that of LysoSensor are localized in the same organelle.  
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The H2OCP was found to localize preferentially in the cell lysosomes of the T98G 
cells.54, 55 Negatively charged porphyrins are often known to localize subcellularly in the 
lysosomes because of the low internal pH of the lysosomes.56 One of the proposed 
mechanisms of porphyrin uptake into the tumor cells in humans involves their transport 
by the plasma lipoprotein, human low-density lipoprotein (LDL), for which the 
amphiphilic carboranylporphyrins have a high affinity. Since it has been known that the 
tumor cells have increased number of LDL receptors, the process of receptor-mediated 
endocytosis was suggested. This is thought to be followed by the maturation of the 
endolysosome into a lysosome.57 The presence of the carboranylporphyrins in the acidic 
environment of the lysosomes has been reported before. The proposed lowering of the 
tumor pH in vivo due to the conversion of the glucose to lactic acid through the glycolytic 
pathway under anaerobic conditions may also facilitate the process of porphyrin 
localization.58 
Using the same techniques and instrumentation as used for the microscopy of the H2OCP 
the intracellular localization of the H2TMCP was also performed. The H2TMCP showed 
similar localization to that of the H2OCP in the lysosomes. When Lysosensor was added 
to the T98G cells with H2TMCP, under the FITC filter the Lysosensor in the lysosomes 
was observed (Figure 2-11). When excited under the texas red filter the fluorescence 
emitted by the H2TMCP was observed (Figure 2-11 B).  The overlapped image (Figure 2-
11 D) shows the coloration formed by the overlap of the green from the Lysosensor and 
the red from the H2TMCP, indicating that H2TMCP is localizing in the lysosomes of the 
T98G cells. These results are in accordance with the studies on anionic compounds which 
preferentially target cell lysosomes, which are characterized by low internal pH.  
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Figure 2-11: Intracellular localization of H2TMCP 2.9 in human T98G cells. A: Phase                                
contrast; B: Porphyrin fluorescence; C: LysoSensor Green fluorescence; D: Overlay. 
Scale bar: 20 µm 
 
 
The prefential sites of sub-cellular localization of tetra(nido-carboranyl)porphyrin 2.9 are 
in the cell lysosomes. If the same situation occurs in the humans, an effective tumor cell 
destruction can be achieved by release of the high LET particles intracellularly in the 
lysosomes. 
2.3 Conclusions 
The total syntheses of highly promising BNCT agents tetra(nido-carboranyl)porphyrin 
2.9 and octa(nido-carboranyl)porphyrin 2.17 in reasonable yields were accomplished. 
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The nido carborane cages of H2TMCP and H2OCP make them water-soluble and 
amphiphilic. The amphiphilic character is directly responsible for the ready uptake of 
these porphyrins, H2TMCP and H2OCP, into cells in vitro. But both the porphyrins 
H2TMCP and H2OCP display low dark toxicity towards V79 hamster fibroblast cells 
(CS50 > 250 µM) using a clonogenic assay. The water-soluble tetra(nido-
carboranyl)porphyrin shows more dark toxicity than the octa(nido-carboranyl)porphyrin. 
Lower toxicity of the H2TMCP and H2OCP is an important parameter since it allows the 
administration of a higher drug dose for a therapeutic effect. The cellular uptake of 
H2TMCP and H2OCP is both concentration- and time-dependent. The tetra-anionic 
porphyrin 2.9 accumulated to a higher extent in human glioblastoma T98G cells when 
compared to the octa-anionic porphyrins 2.16 and 2.17, probably as a result of their 
higher hydrophilicity. In the time-dependent cellular uptake studies, the Zn(II)OCP 
complex 2.16 accumulated at a slower rate over 24 h than the metal free porphyrins 
H2TMCP and H2OCP . H2TMCP showed higher uptake into T98G cells over 24 h than 
the H2OCP. Both H2TMCP and H2OCP showed similar pathway of rapid accumulation in 
the cells in the first four hours and then reached a plateau. The metal free H2OCP 2.17 
accumulated at a  faster rate and to higher extent in T98G cells than its Zn(II) derivative 
2.16 at short time periods (up to 8 h), although similar amounts of 2.16 and 2.17 were 
found after 24 hours, demonstrating different uptake kinetics for these two porphyrins.  
The high cellular uptake of H2TMCP and H2OCP at lower concentrations is necessary to 
deliver therapeutic amounts of boron to the tumor cells at low toxic levels. The 
preferential sites of subcellular localization of H2TMCP and H2OCP in human 
glioblastoma T98G cells are the cell lysosomes, possibly as a result of their anionic 
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nature and/or endocytic uptake. A similar situation in vivo will result in tumor cell 
destruction with the intracellular release of the LET particles.  
2.4. Experimentals 
Chemistry: All experiments were performed under argon atmosphere in oven dried 
glassware. Commercially available starting materials were purchased from Sigma-Aldrich 
and used without further purification. Methyl carborane was purchased from Dexsil. 
Solvents used as reaction media were distilled immediately before use; THF and toluene 
were distilled from Na/ benzophenone. Methylene chloride was distilled from calcium 
hydride. 1H-NMR spectra were recorded on a Brucker AC-250 (250 MHz 1H) spectrometer 
in deuterated chloroform (CDCl3: 7.26 ppm) and deuterated acetone (CD3OCD3 : 2.05 ppm). 
Chemical shifts (δ) are given in parts per million relative to tetramethylsilane (TMS, 0 ppm); 
multiplicities are indicated as br (broad), s (singlet), d (doublet), t (triplet), q (quartet) and m 
(multiplet). 
  Analytical TLC was performed on Scientific Adsorbent Company Inc. silica gel plate. 
Flash column chromatography was performed using silica gel (Scientific Adsorbent 
Company Inc. 40-63 µm particle size, 60 A0 pore size). Electronic absorption spectra 
were measured using a Perkin-Elmer Lambda 35 UV-vis spectrophotometer. Mass 
spectra were obtained at LSU Mass Spectrometry Facility. 
[4-(1-methyl-o-carboranyl)methyl]bromobenzene (2.6): A two necked round bottom 
flask containing 1-methyl-o-carborane (5.00 g ,31.65 mmol) in dry DME(150 ml) was 
cooled down to  0oC under argon. n-BuLi (20 ml, 1.6 M in hexane) was added dropwise 
and the resulting mixture was stirred as 0oC for 30 min. A solution of 4-
(bromomethyl)bromobenzene ( 7.91 g, 31.65 mmol) in dry DME(15 ml) was added drop 
wise. After stirring at 0oC for 10 min the final reaction mixture was warmed to room 
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temperature and subsequently refluxed for 10 h under argon. The solvent was then 
removed under vacuum and the crude solid obtained was purified by recrystallization 
from dichloromethane/methanol to give the title compound (7.80 g, 75% yield) as white 
crystals, mp127-128 oC. MS (EI) m/e 327.1 (M+), 1H-NMR (CDCl3) δ 1.3-3.0 (br, 10 H, 
BH), 2.15 (s, 3H, CH3), 3.41 (s, 2H, CH2), 7.06 (d, 2H, Ar-H), 7.48 (d, 2H, Ar-H). 
[4-(1-methyl-o-carboranyl)methyl]benzaldehyde (2.7): A solution of compound 2.6 
(4.00 g ,12.23 mmol) in THF ( 150 ml) under argon was cooled to –78o C. n-BuLi (7.6 
ml, 1.6 M in hexane )was added drop wise while maintaining the temperature at -78 oC. 
The reaction mixture was stirred at -78 oC for 30 min before dry DMF (5.0 ml, 64.6 
mmol) was slowly added. The final reaction mixture was stirred at -78oC for 15 min and 
then warmed slowly to room temperature. A 2N HCl solution (150 ml) was added and the 
reaction mixture was for 2h at room temperature. The solution was then reduced to 200 
ml and extracted into CH2Cl2 (4*50 ml). The organic extracts were washed once with 
aqueous saturated NaHCO3, once with water and dried over anhydrous Na2SO4. After 
removal of the solvent under vacuum, the oily residue was purified by column 
chromatography on silica gel (CH2Cl2/petroleum ether,1:1), yielding the title compound 
(2.00 g, 62% yield ) as a white solid , mp 96-98 o C, MS (EI) m/e 276.1 (M+) . 1H-NMR 
(CDCl3) δ 1.5-3.0 (br, 10 H, BH), 2.19 (s, 3H, CH3), 3.54 (s, 2H, CH2), 7.38 (d, 2H, Ar-
H), 7.89 (d, 2H, Ar-H), 10.04 (s, 1H, CHO). 
Meso-tetra[4-(1-methyl-o-carboranyl)methylphenyl]porphyrin(2.8): A solution of the 
aldehyde 2.7 (1.16 g, 4.19 mmol) and freshly distilled pyrrole (0.30 ml, 4.32 mmol) in 
dry CH2Cl2 (420 ml) was purged with argon for 15 min. TFA (0.25 ml, 3.15 mmol) was 
added to the solution and the mixture was stirred at the room temperature under argon for 
20 h (complete disappearance of starting  compound monitored by TLC ). After addition 
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of p-chloranil (0.788 g, 3.14 mmol) the reaction mixture was stirred at room temperature 
for 2 h. The solution was concentrated under vacuum to 200 ml, and then washed once 
with aqueous saturated NaHCO3, and once with water before being dried over anhydrous 
Na2SO4. The residue obtained after removal of the solvent under vacuum was purified by 
the column chromatography on the silica gel (CH2Cl2/petroleum ether 1:1) and the fastest 
running porphyrin fraction was collected and recrystallized from CH2Cl2/methanol, 
yielding  0.375 g (32.1% yield )of the title compound as purple crystals , mp >300 0C . 
MS (MALDI) m/e 1296.0 (M+). 1H-NMR (CDCl3) δ -2.80 (br, 2H, NH), 1.6-3.1(br, 40 
H, BH), 2.34 (s, 12H, CH3), 3.81 (s, 8H, CH2), 7.59 (d, 8H, Ar-H), 8.20 (d, 8H, Ar-H), 
8.85 (s, 8H, β-H). UV-Vis (CHCl3) λmax 419 nm (ε 444,700), 514 (15,400), 548 (7200), 
588 (5100), 644 (3800). 
Meso-tetra[4-(1-methyl-nido-carboranyl)methylphenyl]porphyrin tetrasodium salt   
(2.9): Porphyrin 2.8 (0.050 g,0.0386 mmol) was dissolved in a 3:1 mixture of pyridine 
and piperdine (4.0 ml), and stirred at room temperature in the dark for 36 h, under argon. 
The solvent was completely removed under vacuum, the residue redissolved in 40% 
aqueous acetone and passed slowly through a Dowex 50WX2-100 resin in the sodium 
form. The porphyrin fraction was collected, dried under vacuum, redissolved in 70% 
aqueous acetone and again passed through the ion-exchange resin. After removal of the 
solvent under vacuum, the tetraanionic porphyrin was got as pure crystalline solid. 
Mp>300 oC MS m/e 1408.60, 1H-NMR (CD3OCD3) δ : -2.70(s , 2H, NH) ,-2.45 to –1.90 
(br, 4H, BH), 0.9–2.40 (br, 32H, BH) 1.59 (s, 12H, CH3), 3.50 (s, 8H, CH2), 7.81 (d, 4H, 
Ar-H), 8.08 (d, 8H, Ar-H), 8.90 (s, 8H, β-H). UV-Vis (CH3OCH3) λmax: 419 nm (ε 
349,700), 514 (13,600), 548 (12,400), 594 (4100), 650(6000). 
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Bis-(3,5-bromomethyl)bromobenzene (2.11): To a refluxing solution of 3,5-
dimethylbromobenzene  2.10 (4.63 g, 25.0 mmol) in dry CCl4 (300 ml) under Argon, 
were added NBS (9.79 g, 55.0 mmol) and benzoyl peroxide (0.80 g, 3.30 mmol) in 
portions, over a one hour period. The final reaction mixture was refluxed with stirring 
and under Argon for 16 hours. After cooling to room temperature, the reaction mixture 
was filtered and the filtrate washed once with an aqueous saturated solution of NaHCO3 
and once with water. The organic solution was dried over anhydrous Na2SO4 and the 
solvent evaporated under vacuum. The resulting residue was purified by column 
chromatography using dichloromethane/petroleum ether 1:9 for elution, and the main 
product collected and recrystallized from n-hexane, yielding 2.83 g (33% yield) of the 
title and literature known compound, m.p. 98-101o C. MS m/e 342.8. 1H-NMR (CDCl3) δ 
: 4.40 (s, 2H, CH2), 7.34 (s, 1H, Ar-H), 7.47 (s, 2H, Ar-H). 
Bis[3,5-(1-methyl-o-carboranyl)methyl]bromobenzene (2.12): n-BuLi (5.2 ml, 1.6 M 
in hexane) was added dropwise to a solution of methyl-o-carborane (1.39 g, 8.80 mmol) 
in dry THF (80 ml), at a temperature between -5o and 0o C, under Argon. The mixture 
was stirred at this temperature range for one and a half hours, then cooled to -15o - -20o C 
(ice/salt bath). A solution of LiI (0.166 g, 1.27 mmol) in dry THF (15 ml) and compound 
2.11 (1.372 g, 4.00 mmol) in THF (20 ml) was added and the final reaction mixture 
allowed to warm up to room temperature and stirred for 16 hours. After quenching the 
reaction with water the resulting mixture was extracted four times with diethyl ether. The 
organic extracts were washed once with water, once with brine, dried over anhydrous 
Na2SO4 and the solvent removed under vacuum. The crude product was purified by 
column chromatography using dichloromethane/petroleum ether 2:8 for elution, and the 
main product collected and recrystallized from n-hexane to give 1.26 g (63% yield) of the 
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title compound, m.p. 239-241o C. MS m/e 497.3; 1H-NMR (CDCl3) δ : 1.4-3.0 (br, 20H, 
BH), 2.17 (s, 6H, CH3), 3.43 (s, 4H, CH2), 6.96 (s, 1H, Ar-H), 7.31 (s, 2H, Ar-H). 
Bis[3,5-(1-methyl-o-carboranyl)methyl]benzaldehyde (2.13): A solution of compound 
2.12 (0.994 g, 2.00 mmol) in THF (20 ml) under Argon was cooled to –78oC. n-BuLi (1.4 
ml, 1.6 M in hexane) was added dropwise via syringe. After stirring the reaction mixture 
for 30 minutes at –78o C, dry DMF (0.77 ml, 10.0 mmol) was slowly added. The 
resulting yellow mixture was stirred at –78o C for 30 minutes and then warmed to 0o C 
and stirred at this temperature for one hour. A 5% aqueous HCl solution was added until 
the pH of the reaction mixture was between 2 and 3, and the final mixture stirred at room 
temperature for 2 h. The aqueous layer was extracted 4 times with diethyl ether, the 
organic fraction dried over anhydrous MgSO4 and the solvent evaporated under vacuum. 
Purification by column chromatography (dichloromethane/petroleum ether 2:3), afforded 
the title compound (0.632 g) in 70.9% yield, m.p. 205-207o C. MS m/e 446.4; 1H-NMR 
(CDCl3) δ: 1.5-3.0 (br, 20H, BH), 2.20 (s, 6H, CH3), 3.55 (s, 4H, CH2), 7.30 (d, 1H, Ar-
H), 7.67 (d, 2H, Ar-H), 10.03 (s, 1H, CHO). 
Meso-tetra[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin (2.14): A 
solution of aldehyde 2.13 (0.243 g, 0.54 mmol) and freshly distilled pyrrole (0.050 ml, 
0.72 mmol) in dry dichloromethane (55 ml) was purged with Argon for 15 minutes. TFA 
(0.03 ml, 0.377 mmol) was added and the final solution was stirred at room temperature 
overnight (until complete disappearance of the starting aldehyde and formation of 2 new 
spots by TLC). After oxidation with p-chloranil (0.102 g, 0.41 mmol) for 6 hours at room 
temperature, the final reaction mixture was washed once with an aqueous saturated 
solution of NaHCO3 and once with water, before being dried over anhydrous Na2SO4. 
The residue obtained after removal of the solvent was purified by column 
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chromatography using dichloromethane/petroleum ether 1:2 for elution. The porphyrin 
fraction obtained was recrystallized from dichloromethane/methanol, to give 0.10 g (10% 
yield) of the title compound, m.p. >300o C; MS m/e 1977.3 1H-NMR (d-TFA/CDCl3) δ 
ppm: -0.80 (br, NH), 1.5-3.1 (br, 80H, BH), 2.31 (s, 24H, CH3), 3.91 (s, 16H, CH2), 7.72 
(s, 4H, Ar-H), 8.33 (s, 8H, Ar-H), 8.74 (s, 8H, β-H). UV-Vis (CHCl3) λmax: 419 nm 
(497,300), 509 (20,250), 543 (8,300), 588 (6,150), 642 (4,300).  
Zn(II)-meso-tetra[bis-3,5-(1-methyl-o-carboranyl)methylphenyl]porphyrin (2.15): A 
solution of porphyrin 2.14 (0.089 g, 0.20 mmol) , ZnCl2 (0.400 g) ,THF (10 ml)  in 
dichloromethane (100 ml) was stirred at room temperature for 3hrs.The solvent was 
removed under vacuum and the reaction mixture was purified on a short silica column, 
using dichloromethane/petether in 2:3 ratio for elution. Obtained 0.30g (14.7%) of the 
title compound. HRMS m/e 2040.1766; 1H-NMR (CDCl3) δ ppm: 1.6-2.9 (br, 80H, BH), 
2.20 (s, 24H, CH3), 3.75 (s, 16H, CH2), 7.43 (s, 4H, Ar-H), 8.01 (s, 8H, Ar-H), 8.85 (s, 
8H, β-H). UV-Vis (CH2Cl2) λmax: 419nm (417,000), 547 (17,200), 582 (3,200). 
Zn(II)-meso-tetra[bis-3,5-(1-methyl-nido-carboranyl)methylphenyl]porphyrin 
tetrasodium salt   (2.16):  Porphyrin 2.15 (0.050 g,0.0245 mmol) was dissolved in a 3:1 
mixture of pyridine and piperdine (4.0 ml), and stirred at room temperature in the dark 
for 72 h, under argon . The solvent was completely removed under vacuum, the residue 
redissolved in 40% aqueous acetone and passed slowly through a Dowex 50WX2-100 
resin in the sodium form. The porphyrin fraction was collected, dried under vacuum, 
redissolved in 70% aqueous acetone and again passed through the ion-exchange resin 
.After removal of the solvent under vaccum , the octaanionic porphyrin was obtained as 
pure crystalline solid.  MS m/e 1953.66, 1H-NMR (CD3OCD3) δ ppm:-2.4(br, 8H, BH) 
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1.6-2.9 (br, 72H, BH), 2.00 (s, 24H, CH3), 3.46 (s, 16H, CH2), 7.86 (s, 4H, Ar-H), 8.06 
(s, 8H, Ar-H), 9.91 (s, 8H, β-H). UV-Vis (CH3OCH3) λmax: 425 nm (345,800), 556 
(12,519), 595 (6,180). 
Meso-tetra[bis-3,5-(1-methyl-nido-carboranyl)methylphenyl]porphyrin tetrasodium 
salt   (2.17): To the solution of Porphyrin 2.16  (0.016 g , 0.007 mmol) dissolved in 1ml 
of methanol , 2ml of TFA was added and it was stirred for 30 min. Then add a drop of 
H2SO4. The reaction mixture was dried under vacuum ,redissolved in methanol and TEA 
was added until it was basic .The solvent was  completely removed under vacuum , the 
residue redissolved in 40 % aqueous acetone and slowly passed through a Dowex 
50WX2-100 resin in the sodium form. The porphyrin fraction was collected, concentrated 
under vacuum, redissolved in 70% aqueous acetone and again passed through the ion-
exchange resin. The solvent was removed under vaccum. MS m/e 1886.14 1H-NMR 
(CD3OCD3) δ ppm:-2.4(br, 8H, BH) 1.6-2.9 (br, 72H, BH), 2.00 (s, 24H, CH3), 3.46 (s, 
16H, CH2), 7.86 (s, 4H, Ar-H), 8.06 (s, 8H, Ar-H), 9.91 (s, 8H, β-H). UV-Vis 
(CH3OCH3) λmax: 425 nm (327,700), 556 (12,519), 595 (6,180).  
Cell Culture: Human glioblastoma T98G cells and cervical carcinoma HEp2 cells were 
obtained from ATCC. The T98G cells and HEp2 cells were maintained in 50% of α-
MEM/advanced MEM supplemented with 5% FBS. Phosphate buffered saline (PBS), 
Foetal Bovine Serum (FBS) and trypsin were purchased from Gibco, Cyquant reagent 
from Molecular Probes, Triton X-100 from Calbiochem and lysosensor from Molecular 
Probes. The microscopy was performed on a Zeiss Axiovert 200M inverted fluorescent 
microscope fitted with a standard Texas Red and FITC filter sets (Chroma Technology 
Corp.). The images were pseudo-colored with Adobe Photoshop® CS version 8.0. 
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Compounds 2.9, 2.16 and 2.17 were diluted in DMSO prior to being diluted into medium; 
the final DMSO concentration never exceeded 1%. All medium solutions were filter 
sterilized (22 µm pore size) prior to use. All the data from FLUOstar was analyzed using 
Prism 3.0 graphing software. 
Stock solutions of carboranylporphyrins H2TMCP and H2OCP were prepared by 
weighing an exact amount of porphyrin in crystalline from and dissolving in 100% 
DMSO; subsequent dilutions were done directly into the culture medium, just prior to 
administration to cells. The porphyrin stocks were stored in 100% DMSO at 5 0C and 
protected from exposure to light.  
Cell Toxicity studies: Chinese hamster fibroblast cells V79 cells were sub cultured on 10 
cm Petri dishes for 48 h in DMEM supplemented with 10% FBS and 1% penicillin –
streptococci solution. To prepare the incubation solution the appropriate amount of 
porphyrin was dissolved in 250 µl of dimethylsulfoxide (DMSO) and diluted with 
medium to obtain a 500 µM stock solution, which was then filtered through a sterile filter 
(acetyl cellulose membrane, 22 µm pore size ). The cells were incubated for 24 h with 0 
µM (standards) and 100-300 µM (total volume 2.5 ml) porphyrin concentrations. After 
incubation, the cells were washed once with 5 ml sterile PBS and then harvested by 
adding 200 µl of a 0.25% trypsine solution for 10 min at 37 C. DMEM (1.8 ml) was 
added and the cells were gently aspirated, before  1 ml of the suspension was transferred 
to a sterile centrifuge tube. After dilution to a total volume of 4 ml with DMEM the cells 
were counted .Final dilutions were prepared allowing volumes of at at least 20 µl to 
transfer 100 cells. For each incubation 100, 300 or 1000 cells were transferred to a 10 cm 
petridish containing 10 ml DMEM to grow the clones for 6 to 7 days. After this period 
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the adherent colonies were washed once with 5 ml PBS and fixed with 5 ml methanol for 
10 min. Giemsa solution (5 ml) was then added to stain the clones for 40 min. The 
Giemsa solution was removed, the clones washed with 3 ml of ethanol-water (7:3) and 
finally, the colonies were counted and the percentage of survival determined by the 
comparison to the standards. Each determination was performed in triplicate for each 
porphyrin concentration. 
Concentration-dependent cellular uptake: Human glioma T98G cells were cultured in 
a costar 96 well plate at the concentration of 20000 cells/100 µL in each well. A 400 µM 
solution of H2OCP 2.17 in DMSO diluted with α-MEM/advance medium, which was 
filter sterilized. A two-fold dilution series was then prepared on the plate to give final 
porphyrin concentrations of200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM,. 6.25 µM, 3.125 
µM and 0 µM. After 3 h incubation time the cells were washed with PBS and 100 µl of 
0.25% Triton X-100 in PBS was added to each of the wells. To obtain the standard graph 
for H2OCP 2.17 a 20 µM solution of H2OCP 2.17  in 0.25% Triton X-100 was prepared 
and used to make the dilution series of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0 µM. The 
porphyrin fluorescence was measured on a FLUOstar plate reader using 570 nm 
excitation and 650 nm emission filters. The standard curve for different cell numbers was 
prepared by having 100000, 80000, 60000, 40000, 20000, 10000 and 0 number of cells in 
the wells and incubated for 3 hours. The cell numbers were determined by adding 100 
µl/well of a 2X stock solution of Cyquant reagent in PBS. The plate was read on the 
FLUOstar plate reader using 480 nm excitation and 520 nm emission filters. The same 
procedure as above was also followed for the concentration dependent uptake of the 
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H2TCP. The fluorescence of the H2TMCP was read using the FLUOstar plate reader 
using 540 nm excitation and 660 nm emission filters. 
Time-dependent cellular uptake: Human T98G cells were subcultured as described 
above. A stock solution of porphyrin 2.17 in DMSO was diluted with α-MEM/advance 
medium to make a 10 µM stock solution, which was filter sterilized. After incubation of 
the cells for 48 hrs the 10 µM stock solution was added and the cells incubated for 24, 8, 
4, 2, 1 and 0 h periods. The cells were washed with PBS and 100 µl of 0.25% triton X-
100 in PBS was added to each of the wells. To obtain the standard graph for H2OCP 2.17 
a 20 µM solution of H2OCP 2.17 in 0.25% triton X-100 was prepared and used to make 
the dilution series of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0 µM. The porphyrin 
fluorescence was measured on a FLUOstar plate reader using 570 nm excitation and 650 
nm emission filters. The standard curve for different cell numbers was prepared by 
having 100000, 80000, 60000, 40000, 20000, 10000 and 0 number of cells in the wells 
and incubated for 3 hours. The cell numbers were determined by adding 100 µl/well of a 
2X stock solution of Cyquant reagent in PBS. The same procedure was followed for the 
time dependent uptake of H2TMCP and Zn-OCP. The fluorescence of H2TMCP 
measured using on FLUOstar plate reader using 540 nm excitation and 660 nm emission 
filters. The fluorescence of ZnOCP was also measured using 570 nm excitation and 650 
nm emission filters. 
Intracellular localization: T98G cells were seeded in a Lab-Tek II two chamber 
coverglass system and incubated for 48 h. H2OCP 2.17 was added from a 25 mM stock 
solution in DMSO to reach a final concentration of 10 µM. The cells were incubated in 
the dark for 24 h, and then washed with drug-free medium three times to remove 
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unbound porphyrin. The cells were then fed medium containing 50 mM HEPES pH 7.2 
and examined using a Zeiss Axiovert 200M inverted fluorescence microscope fitted with 
standard FITC and Texas Red filter sets. For co-localization experiments the tracer 
compounds LysoSensor Green DND-189 and LysoTracker were used. The tracer 
compounds were diluted into medium to reach a final concentration of 100 nM. This was 
added to the H2OCP and incubated for 30 min. This was then washed with fresh hepes 
medium and then viewed by microscopy. Fluorescence microscopy was also done for the 
H2TMCP using the same equipment and the procedures as used for the H2OCP.  
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Chapter 3 
Synthesis of Tetra(4-nido-carboranylphenyl)porphyrin and Biological Evaluation of 
the Tetra(4-nido-carboranylphenyl)porphyrin and 
Tetra(carboranylphenyl)tetrabenzoporphyrin 
 
3.1 Introduction 
Boron containing porphyrins have been proposed for dual application in BNCT and PDT 
treatment of malignant brain tumors because of their ability to be activated by both light 
and low-energy neutrons.1 This has a significant enhancement of local control of the 
disease by targeting different mechanisms of tumor cell destruction thus improving the 
patient survival time. The low-energy neutron beam in BNCT can penetrate deep to reach 
deep seated tumors whereas the short light penetration through the tissue to reach only 
the superficial tumors is the disadvantage with PDT. The carboranylporphyrins with their 
carborane cages can effectively deliver the required dosage of 15-20 µg of 10B/ gram of 
tumor for BNCT. 2, 3 The tetrabenzoporphyrin with its carborane cages and the absorption 
in the infrared region can act as a dual sensitizer both for PDT and BNCT. 4-7 The tetra(4-
nido-carboranylphenyl)porphyrin was synthesized using Lindsey’ conditions for the 
synthesis of the meso-substituted carboranylporphyrins.  The 10B-enriched version of 
tetra(4-nido-carboranylphenyl)porphyrin was also synthesized using 10B enriched 
decaborane. Boron in its elemental form has only 20% of 10B but a 10B-enriched have 
nearly 100% of 10B.8 The derivatives of tetra(nido-carboranyl)porphyrins have also been 
reported to interact with DNA, despite their negative charge and the bulkiness of the 
carborane substituents.9 The formation of a complex between these anionic porphyrins 
and DNA is either by the porphyrin inner core protonation or by noncovalent interactions. 
They efficiently induced DNA damage when shined with light via photo-oxidation by 
singlet oxygen.6 
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Figure 3-1: Structures of the tetra(4-nido-carboranylphenyl)porphyrin 3.1 and the 
tetra(carboranylphenyl)-tetrabenzoporphyrin 3.2 
 
 
Tetrabenzoporhyrins(TBPs) belong to a family of π-extended porphyrins which contain 
four β, β- fused benzene rings onto a porphyrin macrocycle. Consequently 
tetrabenzoporphyrins have stronger absorptions in the red region of the optical spectrum, 
where light penetration is considerably deeper, compared with porphyrins.10-13 Due to this 
extension of conjugation TBPs displays unique optical, redox, chemical and physical 
properties.14, 15, 16 They have numerous applications in non-linear optical materials, near-
infrared dyes, gas sensors, photosynthetic model compounds and as photosensitizers for 
PDT of tumors.17-20   The tetrabenzoporphyrin 3.2 used for comparative biological 
evaluation in this Chapter was synthesized from 4-carboranylbenzaldehyde and 
butanopyrrole by Dr. Owendi Ongayi.13 This tetrabenzoporphyrin 3.2 and the tetra(4-
nido-carboranylphenyl)porphyrin 3.1 (synthesized by me) were evaluated for toxicity and 
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uptake in tumor cells and also the intracellular localization of these porphyrins in the 
tumor cells was also studied.21 The animal toxicity of these porphyrins was studied in 
BALB/c mice. The animal toxicity studies were done in collaboration with Dr. David 
Baker and Dr. Larry Lomax from the LSU School of Veterinary Medicine.  
3.2 Photodynamic Therapy  
Photodynamic therapy (PDT) is a binary method for the treatment of tumors that employs 
light and a photosensitizer.22 A photosensitizer that specifically accumulates in the tumor 
tissue in the presence of normal tissue is administered to the patient. Then the tumor and 
the surrounding tissue are irradiated with visible light of a certain wavelength. The 
excitation of the photosensitizer leads to the excitation energy being transferred to the 
oxygen present in the cells. Thus, the triplet state oxygen is then transformed to the 
highly reactive singlet oxygen, super oxide anion and hydroxyl radicals that cause 
irreversible damage to the tumor cells. 
A modified Jablonski diagram (without the vibrational levels) is shown in Figure 3-3, and 
it outlines the mechanism of PDT.23 Photosensitizers with a stable electronic 
configuration are in a singlet state at their ground state (S0). When irradiated with light of 
appropriate wavelength it causes excitation of the photosensitizer to its singlet excited 
state (S1). The singlet excited photosensitizer can either decay back to the ground state 
with release of energy in form of fluorescence enabling identification of tumor tissue24 or 
it can undergo a non-radiative process of inter-system crossing (ISC) thereby converting 
the photosensitizer to a triplet excited state (T1). A good photosensitizer can go through a 
spin-forbidden ISC pathway with very high efficiency and can then relax either 
radiatively by phosphorence or non-radiatively by transferring its energy to another 
molecule with a triplet ground state. 
 71
 
 
Figure 3-2: Treatment of a cancer patient with PDT.25 
 
 
Figure 3-3: Modified Jablonski diagram with the mechanism of PDT.26 
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This allows interaction with molecular oxygen in its triplet ground state thus generating 
highly cytotoxic species.27, 28 
Photofrin and Visudyne are porphyrin derivative drugs approved by the FDA for the PDT 
treatment of cancers (lung, digestive tract and genitourinary tract).29, 30 Porphyrins exhibit 
many properties needed for an ideal PDT agent such as low dark toxicity, selective 
accumulation in tumor tissue,31, 32, 33 high chemical stability, high affinity for serum 
proteins, good pharmacokinetic properties, formation of stable complexes with metal 
ions, fluorescent and strong absorbance in the visible region of the optical spectrum.1 
Tetrabenzoporphyrins have an advantage over the porphyrins as PDT sensitizers as they 
absorb strongly in the red region of the optical spectrum where the light penetration 
through the tissue is higher. 
In this Chapter I report the total synthesis of tetra(4-nido-carboranylphenyl)porphyrin 
(H2TCP) which can be used as a BNCT agent.6, 34 The first total synthesis of the boron-10 
enriched tetra(4-nido-carboranylphenyl)porphyrin was also performed. The 10B-enriched 
tetra(4-nido-carboranylphenyl)porphyrin is showing promising results in the BNCT 
treatment of the mice being conducted at Ohio State University by Dr. Rolf Barth.35 It is 
being further studied for applications in both PDT and BNCT by Dr. Giulio Jori at 
University of Padova in Italy.  
3.3 Results and Discussion 
3.3.1 Synthesis of Tetra(4-nido-carboranylphenyl)porphyrin  
The tetra(4-nido-carboranylphenyl)porphyrin 3.1 was synthesized in five steps from a 
commercially available 4-ethnylbenzaldehyde 3.3 as shown in Scheme 3-1.6, 34 In the first 
step the aldehyde functional group of the 4-ethnylbenzaldehyde 3.3 is protected using 
ethanedithiol and BF3.OEt2 to produce 4-ethnylbenzyl(1,3-dithiane) 3.4.36  
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Scheme 3-1: Synthesis of tetra(4-nido-carboranylphenyl)porphyrin 3.1 
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The reaction was done in dry DCM followed by separation with 1:4 DCM: hexanes to 
yield pure product 3.4 in 80% yield. The terminal alkyne of the 4-ethnylbenzyl(1,3-
dithiane) 3.4 is attacked with the Lewis base complex of decaborane37 to give the 4-(o-
carboranyl)benzyl(1,3-dithiane) 3.5. The reaction was followed by acid-base workup to 
remove the hydrogen formed during the reaction. This was then followed by separation 
with 1:4 DCM: hexanes to yield pure product 3.5 in 67% yield. The de-protection of 4-
(o-carboranyl)benzyl(1,3-dithiane) 3.5 to get the 4-(o-carboranyl)benzaldehyde 3.6 was 
done using Hg(ClO4)2 attack of the dithiane complex. 36 The precipitate formed at the end 
of the reaction was washed with ethyl-ether and then passed through a silica gel column 
with 1:4 DCM: petroleum ether to get pure product (without any starting material) in 
86% yield. The 4-(o-carboranyl)benzaldehyde 3.6 was then condensed  with freshly 
distilled pyrrole using Lindsey’s conditions to yield the tetracarboranylporphyrinogen. 
This was then oxidized with p-chloranil to yield crude meso-tetra(4-(o- 
carboranyl)phenyl)porphyrin 3.7 in 33% yield.38 The crude product was passed through 
silica gel column using dichloromethane-petroleum ether 1:2 for elution of the pure 
H2TCP. The fastest running fraction was collected and crystallized from methanol. Since 
the closo carborane cages are hydrophobic the tetracarboranylporphyrin 3.7 was made 
hydrophilic by the deboronation of a single boron atom from each of the four carborane 
cages using a 3:1 mixture of pyridine and piperidine.39 This was then passed through a 
DOWEX 50WX2-100 resin in the sodium form to exchange the piperidine on the nido-
carboranylporphyrin with sodium cations, to yield meso-tetra[4-(nido-
carboranyl)phenyl]porphyrin tetra sodium salt 3.1 in 90% yield. This porphyrin 3.1 is 
soluble in polar solvents such as methanol and water.  
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The tetra(4-nido-carboranylphenyl)porphyrin was synthesized in order to do a 
comparative biological study with the tetra(carboranylphenyl)tetrabenzoporphyrin 3.2 . 
The novel 10B enriched version of the tetracarboranylporphyrin 3.1 was also synthesized 
for BNCT analysis in mice. It is being studied in animals by the collaborative research 
group. 
The 10B-enriched tetra(4-nido-carboranylphenyl)porphyrin since it is structurally similar 
to the tetra(4-nido-carboranylphenyl)porphyrin was prepared using the same synthetic 
methodology. The only difference in these porphyrins is the existence of enriched 10B in 
the porphyrin which has 100% of 10B when compared to only 20 % of 10B in the tetra(4-
nido-carboranylphenyl)porphyrin 3.1. The only step that differs in the whole route is the 
attack of the Lewis base of 10B-enriched decaborane instead of decaborane in the tetra(4-
nido-carboranylphenyl)porphyrin. The Lewis base of 10B-enriched decaborane attacks the 
terminal alkyne of the 4-ethynlbenzyl(1,3-dithiane) to form the 10B-enriched 4-(o-
carboranyl)benzaldehyde. This aldehyde in condensed with pyrrole under Lindsey’s 
conditions to form the 10B-enriched tetra(4-closo-carboranylphenyl)porphyrin. This water 
insoluble porphyrin was converted into the water soluble porphyrin by base degradation 
of the carborane cages as described above followed by the exchange of the cations on an 
ion exchange resin to yield the 10B-enriched tetra(4-nido-carboranylphenyl)porphyrin in 
35% overall yield.  
The tetra(4-nido-carboranylphenyl)porphyrin 3.1 has four carborane cages attached 
directly to the para positions of meso phenyl groups on the porphyrin macrocycle. The 
closo-carboranylporphyrin 3.7 is non-polar and is soluble in organic solvents such as 
DCM. This porphyrin 3.7 when converted into a tetra-anionic nido-carboranylporphyrin 
3.1 becomes highly soluble in polar organic solvents, such as acetone, methanol, DMSO 
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and in water.  Porphyrin 3.1 has 36 boron atoms which make up 32% boron by weight, 
making it a promising BNCT agent. The tetracarboranylporphyrin 3.1 was characterized 
by MS-MALDI, 1H-NMR and UV-Vis spectroscopy.  
 
 
 
Figure 3-4: MALDI-MS of the 10B-closo-H2TCP  
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The 1H-NMR spectrum of 3.1 shows characteristic meso-phenyl protons as two doublets 
at 7.66 and 7.97 ppm and the CH protons of the nido-carborane cages at 2.57 ppm. The 
β-H on the pyrroles are present at 8.87 ppm. The BH protons on the open face of the 
carborane cage form a broad singlet from -2.45 to -1.90 ppm whereas the remaining 
protons on the carborane cages form a broad band from -0.8 to 2.40 ppm. The 1H-NMR 
spectrum of the 10B-enriched tetra(4-nido-carboranylphenyl)porphyrin showed similar 
spectrum with slight downfield shifts.  The UV-Vis spectra of tetracarboranylporphyrin 
3.1 shows the characteristic Soret band at 420 nm and the four Q-bands forming an etio-
type of spectrum (Figure 3-5).40 The compound 3.1 shows fluorescence emission at 670 
nm with an excitation at 511 nm (Figure 3-6). As previously observed,7, 41 the presence of 
the nido-carborane cages at the macrocycle periphery does not quench the fluorescence 
characteristic of porphyrin-type compounds, The molecular structure of the Zn-complex 
of porphyrin 3.7 exhibits a non-planar saddle conformation of the porphyrin macrocycle. 
 
 
 
 
Figure 3-5: UV-Visible of tetrabenzoporphyrin 3.2 (full line) and  
tetracarboranylporphyrin 3.1 (dashed line) at 5 µM concentration in methanol 
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Figure 3-6: Fluorescence emission spectra of of tetrabenzoporphyrin 3.2 (full line) and     
porphyrin 3.1 (dashed line) at 1 µM concentration in methanol (excitation at 532 and 511 
nm, respectively) 
 
 
3.3.2 Dark Toxicity of Tetra(4-nido-carboranylphenyl)porphyrin and 
Tetra(carboranylphenyl)tetrabenzoporphyrin 
 
The dark toxicity of the tetracarboranylporphyrin 3.1 and the tetrabezoporphyrin 3.2 
towards V79 hampster fibroblast cells was evaluated using a MTT-based cell viability 
assay.42 The results obtained are shown in Figure 3-8. The V79 fibroblast cells were 
exposed to both porphyrins 3.1 and 3.2 up to concentrations of 300 µM and incubated for 
24 hours at 370C. This was followed for chemical treatment of the viable V79 cells and 
measurement of the absorbance at 570 nm. A similar experiment with varying 
concentrations of DMSO which acts as a control for the cell growth, cell death and the 
assay reagents was also done (Figure 3-7). 
Figure 3-7 shows the dark toxicity of 0-10% concentrations of DMSO in the medium 
clearly indicates that the DMSO is toxic to the V79 cells at concentrations above 1%.  
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Figure 3-7:  Darktoxicity of DMSO in the medium 
 
 
 
Figure 3-8: Darktoxicity of tetrabenzoporphyrin 3.2 (full line) and porphyrin 3.1 (dashed    
line) towards V79 cells using an MTT-based assay 
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There is 50% cell viability (IC50=2.5% DMSO) at 2.5% DMSO in medium and above 5% 
concentration it is almost 100% toxic. 
Using the data from the DMSO toxicity the % DMSO in all cellular experiments never 
exceeded 1%. The results obtained, as shown in Figure 3-8 indicate that both porphyrins 
3.1 and 3.2 had no significant effect on the cell viability at concentrations up to 300 µM.  
The tetrabenzoporphyrin 3.2 showed less toxicity towards V79 cells when compared with 
tetracarboranylporphyrin 3.1.13 The dark toxicity of the tetrabenzoporphyrins has been 
reported and these indicate that the benzene rings on the β-pyrrolic positions do not effect 
the toxicity of the compound and that the porphyrin 3.2 is less toxic than the tetra-
carboranylporphyrin 3.1. In both the porphyrins 3.1 and 3.2 there is a consistent decrease 
in the % cell viability with the concentration of the exogenous porphyrin until the 
concentration reaches 37.5 µM. After concentration of 37.5 µM the % cell viability 
reaches a plateau. The results are in agreement with previous studies, 7, 16, 43 that nido-
carboranylporphyrins and their derivatives have low dark cytotoxicity. 
3.3.3 Cellular Uptake of Tetra(4-nido-carboranylphenyl)porphyrin and 
Tetra(carboranylphenyl)tetrabenzoporphyrin 
 
The concentration-dependent uptake of H2TBP 3.2 and of the H2TCP 3.1 by human 
glioblastoma T98 G cells were studied for a period of 3 hours and up to concentrations of 
200 µM. This was followed by the solubulization of the T98G cells and the 
measurements of the fluorescence intensity of the porphyrins 3.1 and 3.2. The 
fluorescence of the H2TBP 3.2 was measured using 570 nm excitation and 720 nm 
emission filters and the fluorescence of the H2TCP 3.1 was measured using 570 nm 
excitation and 650 nm emission filters. The unknown cell numbers from the experiment 
were measured for fluorescence using 480 nm excitation and 520 emission filters. 
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Figure 3-9: Concentration-dependent uptake of H2TBP 3.2 (full line) and H2TCP 3.1 
(dotted line) by human glioma T98G cells, after a 3 h time period. 
 
 
 
The standards with the known cell numbers and the porphyrin concentrations of 3.1 and 
3.2 were also calculated. The results obtained are shown in Figure 3-9. Figure 3-9 shows 
consistent increases in the uptake of porphyrins 3.1 and 3.2 with the increase in the 
concentration of the exogenous porphyrins. 
The cellular uptake studies of the H2TBP 3.2 and the H2TCP 3.1 showed that both the 
porphyrins are concentration dependent. The uptake of both the porphyrins 3.1 and 3.2 in 
the T98G human glioblastoma cells increased with exogenous porphyrin concentration in 
an almost linear fashion. At each corresponding concentration the H2TBP 3.2 
accumulated within the T98G cells at significantly higher extent than porphyrin 3.1. The 
 82
H2TBP 3.2 showed higher uptake (~ 30% more) in the cells than that of the H2TCP 3.1, 
which may be the result of higher hydrophobicity of the H2TBP 3.2 compared with 
H2TCP 3.1. The increased hydrophobic character of the H2TBP 3.2 is because of the four 
β, β’-fused hydrophobic benzene rings. The nido-carboranylporphyrins are known to 
accumulate more with the increasing hydrophobic character.44, 45  
The time-dependent uptake of the 10 µM concentration of H2TBP 3.2 and H2TCP 3.1 by 
T98G human glioblastoma cells was evaluated over different intervals of time up to 24 
hours.  
 
 
 
 
Figure 3-10: Time-dependent uptake of H2TBP 3.2 (full line) and H2TCP 3.1 (dashed 
line) at 10   µM by human glioblastoma T98G cells. 
 
 
The fluorescence intensities of both porphyrins and the cell numbers were measured 
using the same filters as described before. The standards of the cell numbers and the 
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porphyrins 3.1 and 3.2 were also evaluated.  The results obtained are shown in Figure 3-
10. The amounts of both the porphyins accumulated in T98G cells consistently increased 
with time although the amount of tetrabenzoporphyrin 3.2 taken up by the T98G cells 
was significantly more than the porphyrin 3.1 at each time point. 
The cellular uptake of the porphyrins 3.1 and 3.2 into T98G cells was also found to be 
time dependent. The H2TBP 3.2 and the H2TCP 3.1 accumulated in T98G cells over the 
period of 24 hours. The H2TBP 3.2 was taken up faster and to a significantly higher 
extent than the H2TCP 3.1 at all the time points studied. After 24 hours, the amount of 
tetrabenzoporphyrin 3.2 accumulated was three times more than that of the 
tetracarboranylporphyrin 3.1.  The higher efficiency of uptake of H2TBP 3.2 might be 
because of the higher hydrophobicity of this porphyrin.44, 45 
3.3.4 Intracellular Localization of Tetra(4-nido-carboranylphenyl)porphyrin and 
Tetra(carboranylphenyl)tetrabenzoporphyrin 
 
The preferential sites of the localization of H2TBP 3.2 in human HEp 2 cells were 
investigated using a Zeiss axiovert fluorescence microscope. First the HEp2 cells were 
observed using the 63X/1.4 na plan-apochromatic oil immersion lens in the phase-
contrast mode and then the cells were exposed to UV-visible light using a Texas-red 
filter, DAPI filter and FITC filter to check for the background fluorescence of the HEp2 
cells. The cells were then exposed to 50 µM concentration of H2TBP 3.2 for 24 hours and 
then observed under fluorescence microscope using the Texas red filter. The fluorescence 
emissions of the H2TBP 3.2 could be seen under the Texas red filter set. The HEp2 cells 
were also checked for fluorescence using the DAPI and FITC filters since the organelle 
trackers emit fluorescence signals under these filter sets. No fluorescence was seen when 
observed under the DAPI filter and FITC filters. The localization pattern of the H2TBP 
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3.2 in HEp2 cells was similar to the analyzed carboranylporphyrins that localized in the 
cell lysosomes. 
 
 
 
 
Figure 3-11: Intracellular localization of H2TBP 3.2 in HEp2 cells. A: Phase contrast; B: 
H2TBP fluorescence; C: LysoSensor Green fluorescence; D: Overlay. Scale-20 µm. 
 
So a co-localization experiment using lysosensor which preferentially localizes in the 
lysosomes was used. After the incubation with the lysosensor for 30 min the HEp2 cells 
were observed first under the Texas red filter for the fluorescence of the H2TBP 3.2 and 
then using the same field of view the filter set was switched to the FITC under which the 
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fluorescence from the lysosensor was observed. The images obtained were processed 
using the Adobe Photoshop software. 
Figure 3-11 A shows the HEp2 cells under phase contrast mode and Figure 3-11 B shows 
the fluorescence of the H2TBP 3.2 under the Texas red filter, and it indicates a pattern 
similar to that of localization in the cell lysosomes. This hypothesis was confirmed when 
a co-localization experiment with lysosome specific probe lysosensor was done. Figures 
3-11 C shows the fluorescence of the lysosensor in the lysosomes under the FITC filter. 
When the figures showing the fluorescence of the lysosensor and the H2TBP fluorescence 
were overlaid Figures 3-11 D was obtained which confirms that the two compounds 
localize in the same organelle. The H2TBP 3.2 preferential localization in the cell 
lysosomes of the HEp2 cells is the common pattern seen in negatively-charged 
porphyrins which have affinity for the lysosomes   because of their low internal pH.46, 47 
The intracellular localization of the H2TCP 3.1 was also studied using the same methods 
and instrumentation used for the H2TBP 3.2. The HEp2 cells were checked for 
background fluorescence and then incubated with tetra(4-nido-
carboranylphenyl)porphyrin 3.1 for 4 hours at  a concentration of 10 µM. After the 
incubation the fluorescence of the H2TCP 3.1 through the Texas red filter was imaged and 
the fluorescence in the DAPI and FITC filters was also checked. Since the pattern was 
similar to that of the H2TBP 3.2 and other similar carboranylporphyrins, a co-localization 
experiment to confirm the localization of the H2TCP 3.1 in the lysosomes was performed 
using the lysosome specific biomarker lysosensor. The lysosensor in the lysosomes of the 
HEp2 cells was imaged through the FITC filter. The same field of view was also used to 
image the H2TCP 3.1 using the Texas red filter.  
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Figure 3-12: Intracellular localization of H2TCP 3.1 in human HEp2 cells. A: Phase 
contrast; B: Porphyrin fluorescence; C: LysoSensor Green fluorescence; D: Overlay. 
Scale: 20 µm. 
 
 
 
The H2TCP 3.1 was found to localize preferentially in the cell lysosomes of HEp2 cells. 
Figure 3-12 A shows the phase contrast images of the HEp2 cells with the porphyrin 3.1 
and the lysosensor. When imaged under the Texas red filter the fluorescence of porphyrin 
3.1 can be clearly seen as the red dotted pattern in Figure 3-12 B. The filter set was 
switched keeping the field of view constant and Figure 3-12 C under the FITC filter 
shows the fluorescence of the lysosomes. Figures 3-12 B and 3-12 C were overlapped 
using a imaging software to get Figure 3-12 D which clearly shows the yellow color 
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formation indicating the exact overlap of the fluorescence from both porphyrin 3.1 and 
the lysosensor, which are both localized in the lysosomes. These results are also in 
accordance with the studies on anionic compounds such as H2TBP 3.2 which tend to 
preferentially localize in the cell lysosomes because of their low internal pH. In contrast 
cationic porphyrins often localize in the mitochondria because of the high 
electrochemical potential of the inner mitochondrial membrane.48 The hydrophobicity 
and the charge of the compounds play a vital role in the mode of entry into the cells and 
their localization within the cell. 
3.3.5 Animal Toxicity 
The experiments were conducted in collaboration with Dr. David Baker and Dr. Larry 
Lomax in the School of Veterinary Medicine. The animal toxicity experiments were 
performed with the different concentrations of tetracarboranylporphyrin 3.1 and the 
tetrabenzoporphyrin 3.2 on the BALB/c mice (4-6 weeks of age and weighing 12-24 g). 
The experiments were started from a dosage of 20 mg / Kg and several different dosages 
of 40 mg/kg, 80 mg/kg and 120 mg/kg were administered to the mice. The highest dosage 
was 160 mg/kg.  Tables 3-1 and 3-2 summarize the clinical data obtained for mice 
receiving H2TBP 3.2 while Tables 3-3 and 3-4 summarize the results obtained with 
tetracarboranylporphyrin 3.1. All mice received intra-peritoneal (i.p.) injections ranging 
from volumes of 0.16 - 0.72 ml. The maximum dosage administered to groups 9 (mice 
received H2TBP) and group 10 (mice received H2TCP) was 160 mg/kg, and represented 
maximum saturation of 4 mg/ml. The highest dosage of 160 mg/kg was not toxic to mice 
and also no serum chemistry changes occurred which were attributable to either 
compound or vehicle administration, as suggested by the clinical and histologic values 
shown in Tables 3-1 to 3-4.  
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Both the porphyrins H2TCP 3.1 and H2TBP 3.2 did not show any signs of the toxicity in 
the BALB/c mice. In the mice with H2TBP 3.2 (Tables 3-1 and 3-2) the glucose levels 
were increased probably due to excitement and increased corticosteroid release. The 
serum aspartate transaminase (AST) levels for some mice generally higher than normal 
for some mice but were similar for most of the mice. They are not considered elevated 
due to either H2TBP 3.2 or vehicle administration, because the increases were 
inconsistent and the values found for mice in group 7 (receiving 120 mg/kg and 6% 
Cremophore) had the lowest of the group means. This result suggests that muscle injury 
or exertion may have contributed to increased AST levels in several of the mice. The 
serum Alanine transaminase (ALT) levels were also similar and although higher than 
normal in some mice. The elevations were not consistent among mice in the same 
treatment groups so ALT levels are not considered elevated due to either H2TBP 3.2 or 
vehicle administration and also the serum ALT is not specific for hepatocellular injury in 
mice. The serum Alkaline Phosphatase (AP) levels although differed with each group but 
were all within the normal range. The serum bilirubin levels also showed the same trend 
and were all within the normal range. The serum Total Protein (TP) levels differed by 
group, but were generally within the normal range. The TP levels for mice in group 9 
were low probably because of the decrease in the albumin and globulin levels. The serum 
albumin levels for mice in group 9 were lower than for other mice which might be 
because of the decrease in the synthesis of the albumin as a result of hepatocellular 
injury. However, tissue injury was not evident histopathologically. The low levels of 
serum albumin can also result from the increased loss through renal or intestinal disease. 
Likewise, the serum globulin levels were lower than expected, or lower than for control 
mice in groups 1, 3, and 9. 
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Table 3-1: Serum chemistry values for six BALB/c mice administered H2TBP 3.2 
(groups 1, 3, 5) or 4% Cremophore (vehicle: group 11), by i.p. injection. The values 
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows 
with superscripts in common are not different from one another (p >0.05). 
 
Group 1 3 5 11 
Glucose 
(mg/dl) 
153.5a 
(0.5) 
219.5c 
(5.5) 
229.5c 
(6.5) 
188.0b 
(10.0) 
AST 
(U/L) 
177.5 
(121.5) 
455.5 
(406.5) 
454.5 
(411.5) 
83.0 
(33.0) 
ALT 
(U/L) 
151.5 
(131.5) 
96.5 
(73.5) 
120.0 
(101.0) 
31.0 
(6.0) 
AP 
(U/L) 
189.5a,c 
(0.5) 
201.0b,c 
(31.0) 
138.0a 
(8.0) 
128.5a 
(1.5) 
Bilirubin 
(mg/dl) 
0.15 
(0.05) 
0.20 
(0.10) 
0.20 
(0) 
0.15 
(0.05) 
Total Prot. 
(g/dl) 
4.65 
(0.15) 
4.7 
(0) 
5.1 
(0) 
4.5 
(0.20) 
Albumin 
(g/dl) 
2.85 
(0.05) 
2.8 
(0) 
2.75 
(0.05) 
2.75 
(0.15) 
Globulin 
(g/dl) 
1.8a 
(0.1) 
1.9a 
(0) 
2.35b 
(0.05) 
2.3b 
(0.1) 
BUN 
(mg/dl) 
28.0 
(0) 
27.0 
(3.0) 
25.5 
(2.5) 
29.0 
(1.0) 
 
 
 90
Table 3-2: Serum chemistry values for four BALB/c mice administered H2TBP 3.2 
(groups 7, 9) or 6% Cremophore (vehicle: group 12), by i.p. injection. The values 
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows 
with superscripts in common are not different from one another (p >0.05). 
 
 
 
Group 7 9 12 
Glucose 
(mg/dl) 
224.5 
(12.5) 
172.0 
(19.0) 
206.5 
(12.5) 
AST 
(U/L) 
73.0 
(16.0) 
498.0 
(410.0) 
774.0 
(149.0) 
ALT 
(U/L) 
29.0 
(3.0) 
206.0 
(176.0) 
411.5 
(123.5) 
AP 
(U/L) 
161.0a 
(3.0) 
223.5b 
(0.5) 
169.0c 
(0) 
Bilirubin 
(mg/dl) 
0.2 
(0) 
0.25 
(0.05) 
0.2 
(0) 
Total Prot. 
(g/dl) 
5.1a 
(0.10) 
4.35b 
(0.05) 
4.65b 
(0.05) 
Albumin 
(g/dl) 
2.75a 
(0.05) 
2.4b 
(0) 
2.6c 
(0) 
Globulin 
(g/dl) 
2.35a 
(0.05) 
1.95b 
(0.05) 
2.05b 
(0.05) 
BUN 
(mg/dl) 
15.5a,b 
(1.5) 
22.5b,c 
(2.5) 
33.0c 
(3.0) 
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The serum Blood Urine Nitrogen (BUN) levels differed among groups, but were also 
within normal limits. All the above finding for the mice administered with H2TBP 3.2 
likely represented a stress response in the mice due to the injections and not due to the 
compound 3.2 or vehicle effects.  
For the tetracarboranylporphyrin 3.1 (Tables 3-3 and 3-4) the glucose levels showed a 
increased probably due to excitement and increased corticosteroid release. The serum 
AST levels were all similar and although slightly higher than normal, they were not 
considered elevated due to either H2TCP 3.1 or vehicle administration; muscle injury or 
exertion could also contributed to increased AST levels in several mice. The serum ALT 
levels were all similar in most of the mice but some mice exhibited higher than normal 
levels. These elevations in the ALT levels were not attributed to either 3.1 or vehicle 
administration since they were not consistent among mice in the same treatment groups. 
The serum AP and bilirubin levels were within the normal range. The serum TP levels 
were also within the normal range, and only differed from controls for group 2, which 
received the lowest dose (20 mg/kg) of H2TCP 3.1. The serum albumin levels were all 
similar and within normal limits. Likewise, serum globulin levels were only lower than 
vehicle controls for mice in group 2, which received the lowest porphyrin dose. The 
serum BUN levels differed among groups but were also within normal limits. These 
results were likely due to stress-related increases in serum corticosteroid levels. The 
histopathologic examination revealed no lesions attributable to compound administration. 
Extramedullary hematopoiesis was observed in all mice, and may represent mild levels of 
stress, typical of mice under manipulative experimental conditions.   
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Table 3-3: Serum chemistry values for six BALB/c mice administered porphyrin 3.1 
(groups 2, 4, 6) or 4% Cremophore (vehicle: group 11), by i.p. injection. The values 
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows 
with superscripts in common are not different from one another (p >0.05). 
 
Group 2 4 6 11 
Glucose 
(mg/dl) 
159.5a 
(1.5) 
188.0b 
(3.0) 
153.5a 
(9.5) 
188.0b 
(10.0) 
AST 
(U/L) 
146.0 
(36.0) 
202.0 
(144.0) 
258.0 
(181.0) 
83.0 
(33.0) 
ALT 
(U/L) 
98.5 
(25.5) 
94.0 
(71.0) 
340.0 
(296.0) 
31.0 
(6.0) 
AP 
(U/L) 
167.5a 
(11.5) 
132.0a,c 
(4.0) 
148.0a,c 
(12.0) 
128.5b,c 
(1.5) 
Bilirubin 
(mg/dl) 
0.2 
(0.10) 
0.25 
(0.05) 
0.25 
(0.05) 
0.15 
(0.05) 
Total Prot. 
(g/dl) 
4.3a 
(0.10) 
4.6a,b 
(0) 
5.0b 
(0.10) 
4.5b 
(0.20) 
Albumin 
(g/dl) 
2.7 
(0) 
2.6 
(0) 
2.8 
(0) 
2.75 
(0.15) 
Globulin 
(g/dl) 
1.6a 
(0.1) 
2.0b 
(0) 
2.35c 
(0.05) 
2.3c 
(0.1) 
BUN 
(mg/dl) 
26.5 
(2.5) 
24.0 
(2.0) 
27.5 
(1.5) 
29.0 
(1.0) 
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Table 3-4: Serum chemistry values for four BALB/c mice administered porphyrin 3.1 
(groups 8, 10) or 6% Cremophore (vehicle: group 12), by i.p. injection. The values 
represent mean (SEM) serum chemistry levels. For individual analytes measured, rows 
with superscripts in common are not different from one another (p >0.05). 
 
 
Group 8 10 12 
Glucose 
(mg/dl) 
239.5 
(8.5) 
214.5 
(29.5) 
206.5 
(12.5) 
AST 
(U/L) 
774.0 
(690.0) 
981.0 
(837.0) 
774.0 
(149.0) 
ALT 
(U/L) 
968.0 
(918.0) 
1096.0 
(1041.0) 
411.5 
(123.5) 
AP 
(U/L) 
160.5a 
(7.5) 
223.0b 
(7.0) 
169.0a 
(0) 
Bilirubin 
(mg/dl) 
0.25 
(0.05) 
0.25 
(0.05) 
0.2 
(0) 
Total Prot. 
(g/dl) 
4.9 
(0.20) 
4.5 
(0.20) 
4.65 
(0.05) 
Albumin 
(g/dl) 
2.5 
(0.1) 
2.5 
(0.1) 
2.6 
(0) 
Globulin 
(g/dl) 
2.4a 
(0.1) 
2.0b 
(0.1) 
2.05a,b 
(0.05) 
BUN 
(mg/dl) 
16.0a 
(3.0) 
25.5a,b 
(2.5) 
33.0b 
(3.0) 
 
 94
The non-toxicity of H2TBP 3.2 and porphyrin 3.1 up to a dose of 160 mg/kg is in 
agreement with the low toxicity reported for hydrophobic carboranylporphyrins.49, 50 
However, compounds 3.2 and 3.1 are significantly less toxic than other negatively 
charged carboranyl-containing porphyrins, such as BOPP, MnBOPP, BTPP, NiNTCP-H, 
ZnDPE and NiDPE.50-53 Our results show, as previously observed, that nido-
carboranylporphyrins can have low mice toxicities, even at high compound doses often 
required to achieve therapeutic levels of boron in tumors.50, 54, 55 
3.4 Conclusions 
The synthesis of promising BNCT agents tetra(4-nido-carboranylphenyl)porphyrin and 
the novel 10B enriched tetra(4-nido-carboranylphenyl)porphyrin were achieved in good 
overall yields. The biological properties of tetra(4-nido-carboranylphenyl)porphyrin 3.1 
was compared with tetra(carboranylphenyl)-tetrabenzoporphyrin 3.2 using various 
techniques. Both porphyrins 3.1 and 3.2 have 36 boron atoms and 32% boron by weight 
for tetra(4-nido-carboranylphenyl)porphyrin 3.1 and 27% boron by weight for 
tetra(carboranylphenyl)-tetrabenzoporphyrin 3.2. The tetra(carboranylphenyl)-
tetrabenzoporphyrin 3.2 showed less toxicity towards V79 cells than the tetra(4-nido-
carboranylphenyl)porphyrin 3.1 though both porphyrins showed CS50 > 300 µM. The 
tetra(carboranylphenyl)-tetrabenzoporphyrin showed higher uptake in T98G cells  than 
the tetra(4-nido-carboranylphenyl)porphyrin because of the better hydrophobicity 
resulting from its four β,β’-porphyrin fused benzene rings. Both porphyrins 3.1 and 3.2 
localized in the lysosomes of HEp2 cells when observed under a fluorescence 
microscope. The porphyrins 3.1 and 3.2 also showed very low levels of toxicity in 
BALB/c mice. Both porphyrins 3.1 and 3.2 were not toxic even at the high dose of 160 
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mg/kg administered in a single intra peritoneal injection. Since no clinical, biochemical, 
or histo-pathological effects were observed in the BALB/c mice it cannot be attributed to 
the administration of H2TBP 3.2, porphyrin 3.1 or the vehicle used. The results suggest 
that the H2TCP 3.1 is a good BNCT agent and the H2TBP 3.2 is an excellent dual 
sensitizer for BNCT and PDT. 
 3.5 Experimentals 
Chemistry: Commercially available starting materials were purchased from Sigma-
Aldrich and used without further purification. 10B-decaborane and decaborane were 
purchased from Katchem. All solvents were purchased from Fisher Scientific (HPLC 
grade) and either directly used or dried and distilled according to literature procedures. 
Silica gel 60 (70-230 mesh, Merck) and alumina grade III (70-230 mesh ASTM) were 
used for column chromatography. Analytical thin-layer chromatography (TLC) was 
performed on Merck 60 F254 silica gel (precoated sheets, 0.2 mm thick). 1H-NMR 
spectra were obtained using a Bruker DPX 250 MHz or 300 MHz spectrometer; chemical 
shifts are expressed in ppm relative to TMS (0 ppm). Electronic absorption spectra were 
measured on a Perkin Elmer Lambda 35 UV-Vis spectrophotometer and fluorescence 
spectra on a Perkin Elmer LS55 instrument. Low resolution MS analyses were conducted 
at the LSU Mass Spectrometry Facility on a Bruker Prolix III MALDI-TOF mass 
spectrometer, and the HRMS were conducted at the Ohio State University Mass 
Spectrometry and Proteomics Facility. Melting points were measured on an 
Electrothermal MEL-TEMP instrument.  
p-Ethynylbenzyl(1,3-dithiane) (3.4): To a solution of 4-ethynylbenzaldehyde (3.3) (6.0 
g, 46.15 mmol) and 1,2-ethanedithiol (5.0 g, 53.09 mmol) was added BF3·OEt2 (0.654 g, 
4.62 mmol) at 0 oC under argon. The mixture was stirred at 25 oC for 15 m then washed 
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once with a 10% aqueous NaOH solution, and once with aqueous saturated solution of 
NaCl. The organic layer was dried over anhydrous Na2SO4 and the solvent removed 
under vacuum. The resulting residue was purified by column chromatography 
(dichloromethane-hexane, 1:4) to give 7. 0 g (80%) of p-ethynylbenzyl(1,3 – dithiane). 
M.p: 68-69 oC; MS (EI) m/z 206.0 (M+); 1H-NMR (CDCl3) δ ppm: 3.09 (s, 1H, CH), 
3.38 and 3.52 (m, 2H each, CH2CH2), 5.62 (s, 1H, SCH), 7.42 (d, 2H, Ar-H), 7.48(d, 2H, 
Ar-H).   
p-(o-Carboranyl)benzyl(1,3-dithiane) (3.5): A solution of decacarborane (3.0 g, 24.59 
m mol) and ethyl sulfide (5.0 g, 55.44 mmol) in dry toluene (50 ml) were combined in a 
schlenk tube and was heated at 40 oC for 3 h and then at 60 oC for 2 h. The solution was 
allowed to cool to 25 oC and to this mixture p-ethynylbenzyl(1,3-dithiane) (3.4) (5.0g, 
24.26 mmol) in dry toluene (10 ml) was added and the final mixture was stirred at 80 oC 
for 3 days. After cooling to room temperature, the mixture was concentrated under 
vacuum and the oily residue was dissolved in methanol (250 ml) and heated to reflux for 
1 h (until no hydrogen was liberated). At room temperature, 2.5 mL of HCl (50% 
aqueous) was added dropwise and the mixture was again refluxed for another 30 m until 
the evolution of hydrogen was complete. After cooling to 25 oC, the mixture was diluted 
with ethanol and excess ethylsulfide was removed by ethanol-ethylsulfide co-distillation. 
The resulting residue was reduced in volume under vacuum and dissolved in 100 mL of 
benzene (CAUTION) at 5 oC. This was followed by addition of 100 mL of cold 10% 
aqueous NaOH solution, and the mixture was allowed to stir vigorously for 15 m. The 
organic layer was separated and washed twice with water and dried over anhydrous 
Na2SO4. After removing the solvent under vacuum, the residue was purified by column 
chromatography (eluting with dichloromethane-hexane, 1:4) to give 5.2 g (67%) of the 
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title compound. M.p: 118-119 oC; MS (EI) m/z 324.1 (M+); 1H-NMR (CDCl3) δ ppm: 1.6 
- 3.3 (br, 10H, BH), 3.36 and 3.47 (m, 2H each, CH2CH2), 3.94 (br s, 1H, o-carborane-
CH), 5.59 (s, 1H, SCH), 7.40 (d, 2H, Ar-H), 7.46 (d, 2H, Ar-H).  
10B-enriched p-(o-Carboranyl)benzyl(1,3-dithiane): MS (EI) m/z 316.2 (M+), 1H-NMR 
(CDCl3) δ ppm: 1.6 - 3.3 (br, 10H, BH), 3.41 and 3.53 (m, 2H each, CH2CH2), 3.97 (br s, 
1H, o-carborane-CH), 5.62 (s, 1H, SCH), 7.44(d, 2H, Ar-H), 7.50 (d, 2H, Ar-H). 
4-(o-Carboranyl)benzaldehyde (3.6): p-(o-Carboranyl)benzyl(1,3-dithiane) (3.5) (2.5 g, 
1.28 mmol) was dissolved in 5% aqueous THF (15 ml) and a solution of Hg(ClO4)2 (6.25 
g , 15.65 mmol) in 5 % aqueous THF (10 ml) under argon was added dropwise. The final 
mixture was stirred at room temperature for 15 m, before being filtered and the 
precipitate was washed three times with 25 ml diethyl ether. The filtrate was washed once 
with an aqueous saturated solution of Na2CO3 and with water before being dried over 
anhydrous Na2SO4. The solvent was removed under vacuum and purified by column 
chromatography (elution with dichloromethane-petroleum ether 1:4) to give the title 
compound (1.6 g, 85%) and recovering the rest of the starting material. M.p: 172-173 oC; 
MS (EI) m/z 248.2 (M+); 1H-NMR (CDCl3) δ ppm: 1.5 - 3.3 (br, 10H), 4.08 (br, 1H, o-
carborane-CH), 7.69 (d, 2H, Ar-H), 7.90 (d, 2H, Ar-H), 10.07 (s, 1H, CHO).  
10B-enriched 4-(o-Carboranyl)benzaldehyde: MS (EI) m/z 240.5 (M+); 1H-NMR 
(CDCl3) δ ppm: 1.5 - 3.3 (br, 10H), 4.07 (br, 1H, o-carborane-CH), 7.68 (d, 2H, Ar-H), 
7.88 (d, 2H, Ar-H), 10.07 (s, 1H, CHO). 
Meso-Tetra[4-(closo-carboranyl)phenyl]porphyrin (3.7): A solution of aldehyde (3.6) 
(1.05 g, 4.23 mmol) and freshly distilled pyrrole (0.03 ml, 4.32 mmol) in dry 
dichloromethane (430 ml) was purged with argon for 30 m. TFA (0.2 ml, 2.52 mmol) 
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was added to the solution and the mixture was stirred at room temperature under argon 
for 24 h. After addition of p-chloranil (0.780 g, 3.14 mmol) the final mixture was stirred 
at room temperature for 3 h. The solution was concentrated under vacuum to 300 ml, and 
then washed once with aqueous saturated NaHCO3 and once with water before being 
dried over anhydrous Na2SO4. After evaporation of the solvent under vacuum the 
resulting residue was purified by column chromatography (elution with dichloromethane-
petroleum ether 1:2) and the fastest running fraction was collected and recrystallized 
from methanol, yielding 0.407 g (33% yield) of the title compound. M.p: > 300oC; MS 
(MALDI) m/z 1183.02 (M+); 1H-NMR (CDCl3) δ ppm: -2.89 (br, 2H, NH), 1.7 - 3.4 (br, 
40H, BH), 4.28 (br s, 4H, o-carborane-CH ), 7.90 (d, 8H, Ar-H), 8.18 (d 8H, Ar-H), 8.78 
(s, 8H, β-H ). UV-Vis (CHCl3) λmax: 418 nm (ε 469,000), 514 (18,200), 550 (8,600), 590 
(6,200) and 646 (4,900). 
10B-enriched meso-Tetra[4-(closo-carboranyl)phenyl]porphyrin: MS (MALDI) m/z 
1151.07 (M+); 1H-NMR (CDCl3) δ ppm: -2.84 (br, 2H, NH), 1.7 - 3.4 (br, 40H, BH), 4.32 
(br s, 4H, o-carborane-CH ), 7.92(d, 8H, Ar-H), 8.20 (d 8H, Ar-H), 8.82 (s, 8H, β-H ). 
Meso-Tetra[4-(nido-carboranyl)phenyl]porphyrin tetra sodium salt (3.1):Porphyrin 
3.7 (0.050 g, 0.0423mmol) was dissolved in a 3:1 mixture of pyridine and piperdine (4.0 
ml), and stirred at room temperature in the dark for 36 h, under argon. The solvent was 
completely removed under vaccum, the residue redissolved in 40% aqueous acetone and 
passed slowly through a Dowex 50WX2-100 resin in the sodium form. The porphyrin 
fraction was collected, dried under vaccum, redissolved in 70% aqueous acetone and 
again passed through the ion-exchange resin. After removal of the solvent under vaccum, 
the tetraanionic porphyrin was recrystallized from methanol-diethyl ether yielding pure 
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crystalline solid. Mp>300 oC MS m/e 1229.84, 1H-NMR (CD3OCD3) δ ppm: -2.78 (s , 
2H, NH) , -2.45 to –1.90 (br, 4H, BH), 0.8–2.40 (br, 32H, BH), 2.57 ( br s, 4H, nido-
carborane-CH), 7.66 (d, 8H, ArH), 7.97 (d, 8H, ArH), 8.87 (s, 8H, β-H). UV-Vis 
(CH3OCH3) λmax: 420 nm (ε 302,900), 516 (11,600), 554 (10,600), 594 (3,300), 
650(4,900). 
10B-enriched meso-Tetra[4-(nido-carboranyl)phenyl]porphyrin tetra sodium salt: 
MS m/e 1201.56, 1H-NMR (CD3OCD3) δ ppm: -2.70 (s , 2H, NH) , -2.45 to –1.90 (br, 
4H, BH), 0.8–2.40 (br, 32H, BH), 2.61 ( br s, 4H, nido-carborane-CH), 7.72 (d, 8H, 
ArH), 8.02 (d, 8H, ArH), 8.93 (s, 8H, β-H). 
Cell Culture: Cervical carcinoma HEp2 cells, human glioblastoma T98G cells and V79 
hampster fibroblast cells were obtained from ATCC. All the cells were maintained in 
50% of α-MEM/advanced MEM supplemented with 5% fetal bovine serum (FBS). 
Phosphate buffered saline (PBS), FBS and trypsin were purchased from Gibco, Cyquant 
reagent and Lysosensor from Molecular Probes, and Triton X-100 from Calbiochem. 
Microscopy was performed on a Zeiss Axiovert 200M inverted fluorescent microscope 
fitted with a standard Texas Red and FITC filter sets (Chroma Technology Corp.). The 
images were aquired with a Zeiss Axiocam MRM CCD camera fitted to the microscope 
and pseudo-colored with Adobe Photoshop® CS version 8.0. Compounds 3.1 and 3.2 
were dissolved in DMSO (Sigma-Aldrich) prior to being diluted into cell medium; the 
final DMSO concentration never exceeded 1%. All medium solutions were filter 
sterilized (22 µm pore size) prior to use. All data obtained from the FLUOstar plate 
reader was analyzed using Prism 3.0 graphing software.  
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Dark toxicity: V79 hampster fibroblast cells were sub-cultured on 96-well plates at the 
concentration of 2,000 cells/100 µl α-MEM/advance medium per well, and incubated for 
48 h. A stock solution of 300 µm of H2TBP 3.2 was prepared. The overall DMSO 
concentration never exceeded the 1% limit. Serial dilutions were done starting with the 
300 µm and achieving different concentrations of 150 µM, 75 µM, 37.5 µM, 18.75 µM, 
9.375 µM and 0 µM. Various concentrations of DMSO in medium ( 10%, 5%, 2.5%, 
1.25%, 0.625%, 0.3125% and 0%) were also done as a control for cell growth, cell death 
and the assay reagents. 0.4% of saponin in PBS was also added to some wells to mimic 
the 100% cell death. The plate was incubated for 24 h. After incubation the porphyrin 
compound was removed and the cells were washed twice with fresh medium and a 100 µl 
of fresh medium was added to each of the wells. To each of the wells a 15 µl of the pierce 
cell titer 96 MTT substrate was added and then incubated for 4 h. After the 4 h a stop 
solution was added and incubated for a hour at 37 0C or at room temperature overnight. 
This solubilizes the insoluble colored precipitate that forms when MTT is reduced by 
living cells. The absorbance was read on FLUOstar plate reader at 570 nm. The 
calculation and normalization of the data was done using prism 3.0 graphing software. 
The same procedure was also used for the dark toxicity of the H2TCP 3.1. Both the 
experiments were done simultaneously under the same conditions.    
Concentration-dependent cellular uptake: Human T98G cells were sub-cultured on 
96-well plates at the concentration of 10,000 cells/100 µl α-MEM/advance medium per 
well, and incubated for 48 h. A 200 µM stock solution of H2TBP 3.2 in DMSO was 
diluted with α-MEM/advance medium and added to the cells to achieve H2TBP final 
concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.125 and 0 µM. After incubation for 3 h, 
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the medium was removed, the cells washed with PBS, and 100 µl of 0.25% Triton X-100 
in PBS added to each well. A H2TBP 3.2 standard graph was obtained by diluting a 10 
µM stock solution in 0.25% Triton X-100 in PBS to achieve 10, 5, 2.5, 1.25, 0.625, 
0.3125 and 0 µM H2TBP concentrations. The H2TBP fluorescence of the known and the 
unknown concentrations was measured on a FLUOstar plate reader using 570 nm 
excitation and 720 nm emission filters. The standard curve for different cell numbers was 
obtained by placing 100000, 80000, 60000, 40000, 20000, 10000 and 0 cells in the wells 
followed by incubation for 3 h. The known cell numbers for the standard graph and the 
unknown cell numbers from the experiment were determined by first adding 100 µl/well 
of 5 µM stock solution of Cyquant reagent in PBS and then reading the plate on the 
FLUOstar plate reader using 480 nm excitation and 520 emission filters. The data 
obtained from the FLUOstar plate reader were analyzed and interpreted using Prism 3.0 
software. The same procedure was followed for determination of the concentration-
dependent cellular uptake of porphyrin 3.1, using 570 nm excitation and 650 nm emission 
filters. 
Time-dependent cellular uptake: Human T98G cells were sub-cultured on 96-well 
plates at the concentration of 10,000 cells/100 µl of α-MEM/advance medium per well, 
and incubated for 48 h. A filter sterilized 10 µM stock solution of H2TBP 3.2 in 1% 
DMSO/medium was added and the cells incubated for 24, 16, 8, 4, 2, 1, 0.5 and 0 h. The 
medium was removed, the cells washed with PBS and 100 µL of 0.25% Triton X-100 in 
PBS was added to each well. A H2TBP 3.2 standard graph was obtained by diluting a 10 
µM stock solution in 0.25% Triton X-100 in PBS to achieve 10, 5, 2.5, 1.25, 0.625, 
0.3125 and 0 µM H2TBP concentrations. The fluorescence of the known and unknown 
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concentrations of H2TBP 3.2 was measured on a FLUOstar plate reader using 570 nm 
excitation and 720 nm emission filters. The standard curve for different cell numbers was 
obtained by placing 100000, 80000, 60000, 40000, 20000, 10000 and 0 cells in the wells 
followed by incubation for 3 h. The known cell numbers for the standard graph and the 
unknown cell numbers from the experiment were determined by first adding 100 µl/well 
of 5 µM stock solution of Cyquant reagent in PBS and then reading the plate on the 
FLUOstar plate reader using 480 nm excitation and 520 emission filters. The data 
obtained from the FLUOstar plate reader were analyzed and interpreted using Prism 3.0 
software.  The same procedure was followed for determination of the time dependent 
cellular uptake of porphyrin 3.1, using 570 nm excitation and 650 nm emission filters. 
Intracellular localization: Human HEp2 cells were sub-cultured on Lab-Tek II chamber 
cover slips with α-MEM/advance medium for 48 h. H2TBP 3.2 was added to each 
chamber to reach a final concentration of 50 µM. The cells were incubated for 24 h, 
washed twice with 50 mM HEPES to remove unbound H2TBP 3.2, new medium 
containing 50 mM HEPES pH 7.4 was added and the cells examined immediately by 
fluorescence microscopy. For the co-localization experiments 100 nM of Lysosensor was 
added to the TBP-containing cells 30 minutes before the completion of the incubation 
time. The same techniques and instrumentation were used for the evaluation of the intra-
cellular localization of the tetra(4-nido-carboranylphenyl)porphyrin. The human HEp2 
cells were incubated with tetra(4-nido-carboranylphenyl)porphyrin for period of 4 hours 
at a concentration of 10 µM. 
Animal Toxicity: The mice were obtained from the breeding colony operated by the 
Division of Laboratory Animal Medicine, School of Veterinary Medicine, Louisiana 
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State University. The animal studies were conducted under an animal use protocol 
approved by the LSU Institutional Animal Care and Use Committee, fully accredited by 
the Association for the Assessment and Accreditation of Laboratory Animal Care, 
International. Twelve groups of two BALB/c mice, 4-6 weeks of age and weighing 12-24 
g (mean = 19 g), were used; among these 8 were female and 16 were male. Mice in 
groups 1, 3, 5, 7, and 9 were administered H2TBP 3.2 once via i.p. injection, at increasing 
dosages: group 1 (20 mg/kg of a 2 mg/ml solution), group 3 (40 mg/kg of a 2 mg/ml 
solution), group 5 (80 mg/kg of a 4 mg/ml solution), group 7 (120 mg/kg of a 4 mg/ml 
solution), and group 9 (160 mg/kg of a 4 mg/ml solution). Mice in groups 2, 4, 6, 8, and 
10 were administered porphyrin 3.1 once via i.p. injection at increasing dosages: group 2 
(20 mg/kg of a 2 mg/ml solution), group 4 (40 mg/kg of a 2 mg/ml solution), group 6 (80 
mg/kg of a 4 mg/ml solution), group 8 (120 mg/kg of a 4 mg/ml solution), and group 10 
(160 mg/kg of a 4 mg/ml solution). Two groups of mice served as vehicle controls. Mice 
in group 11 received sterile 4% Cremophor EL (Fluka) in PBS and served as controls for 
mice receiving 20, 40, and 80 mg/kg compound while mice in group 12 received 6% 
Cremophor EL and served as controls for mice receiving 120 and 160 mg/kg compound.  
For each compound, groups were dosed sequentially and each group evaluated daily 
for signs of toxicity, including hunched posture, rough hair coat, and decreased 
responsiveness. Mice were anesthetized with CO2 48 h after compound administration, 
and blood collected by cardiocentesis for clinical chemistry evaluation. The serum 
chemistry performed included glucose, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (AP), bilirubin, total protein (TP), 
albumin, globulin, and blood urea nitrogen (BUN). The mice were exsanguinated and a 
necropsy performed. Tissues, including lung, kidney, thymus, heart, harderian gland, 
 104
spleen, stomach, small intestine and colon were fixed in 10% neutral buffered formalin. 
The fixed tissues were processed and examined by a board-certified pathologist. 
Statistical Analyses: The clinical chemistry values were compared using the Number 
Cruncher Statistical System software (NCSS, Kaysville, UT). Variables of interest were 
statistically evaluated for group effect, using One-Way ANOVA. When the overall F 
statistic was significant (p < 0.05), the Fisher’s Least Significant Differences test was 
performed to compare the groups. Significant differences existed when p > 0.05. 
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Chapter 4  
Syntheses of Tetra[4-(1-hydroxyethyl-carboranyl)methylphenyl]porphyrin, Tetra[4-
(1-triethyleneglycol-carboranyl)methylphenyl]porphyrin and Tetra[4-(1-
aminomethyl-carboranyl)phenyl]porphyrin 
 
4.1 Introduction 
 
In BNCT, the boron-containing compound must be non-toxic and selectively accumulate 
in cancerous tissue while delivering therapeutic amounts of boron, ~15-30 µg of 10B/g of 
boron to tumors.1 Hydrophilicity is one of the most important properties in the 
development of an ideal BNCT agent. Both disodium mercapto-closo-dodecarborate 
(BSH) and 4-dihydroxyborylphenylalanine (BPA), the only two drugs currently 
undergoing BNCT clinical trails show low selectivity for tumor cells and low retention 
times in tumors. Furthermore BSH is chemically unstable which increases its toxicity and 
BPA has only low percentage of boron by weight so a large dose is necessary for 
effective BNCT.2 Since BSH and BPA are not ideal BNCT agent several other BPA 
derivatives and boron containing amino acids as well as non amino acids were 
synthesized and evaluated.3-7 Highly water soluble carbohydrate derivatives of BSH and 
other boron containing sugars were synthesized and evaluated both in vivo and in vitro.8-
14 These compounds showed low toxicity and uptake in tumor cells. Various other boron-
containing analogues of biologically active compounds such as amino acids,15 peptides,16 
nucleosides/nucleotides,17 phospholipids,18 liposomes,19 and monoclonal and bispecific 
antibodies20, 21 have been synthesized and studied. 
Of all the compounds analysed porphyrins and their analogues are of great interest in the 
field of development of the ideal BNCT agent.22 The tetraphenylporphyrins (TPPs) 
contain four phenyl groups, typically on the meso positions of the porphyrin ring.23 The 
tetraphenylporphyrins can be made water soluble by the functionalization of its phenyl 
 109
rings with sulfonates,24 carboxylates25 and caboranes.26 Porphyrins have been synthesized 
with the carborane groups attached to the phenyl ring of tetraphenylporphyrin.27 The 
porphyrin macrocycle and the closo-carborane cages are hydrophobic. Amide, ester, or 
urea bonds which are more hydrophilic than carbon-carbon likages have been used to link 
the carboranes to the porphyrins.28-31 The disadvantage with using such hydrophilic 
groups is that they have a propensity to hydrolyze while being transported in vivo 
resulting in the release of the hydrophobic carboranes. This causes failure in delivering 
therapeutic amounts of boron to the tumor tissue.  Therefore there has been significant 
effort to increase the water solubility of carboranylporphyrins while not compromising 
their chemical stability. Vicente and coworkers solved this problem of stability by 
synthesizing a series of carboranylporphyrins with a water-soluble carborane linked to 
the meso phenyl groups on the porphyrin macrocycle with hydrophobic carbon-carbon 
linkages.32 These stable methylene linkages are not prone to hydrolysis or any other 
chemical attack in the in vivo environment. The series of carboranylporphyrins 
synthesized by Vicente and coworkers are water soluble by the degradation of the 
carborane cages in to a nido-carborane cage.33 The closo carborane cage can be degraded 
with the use of base to remove one boron and form a negative charge on the carborane 
cage. These anionic carboranylporphyrins localize in the tumor cells and they also have 
low in vivo and in vitro toxicity.34 Water-soluble compounds can be directly dissolved in 
saline and administered to patients whereas the hydrophobic compounds have to be 
solubilized using liposomes or Chremophor EL which can alter the pharmacokinetics of 
these compounds.35-40 A suitable balance between the hydrophilicity of the nido-
carborane cages and the hydrophobicity of the porphyrin macrocycle is essential to 
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achieve high specificity towards tumors and high tumor to blood and to normal tissue 
boron ratios.  
The target carboranylporphyrins synthesized and discussed in this Chapter are water-
soluble not by degradation of the carborane cages but by the functionalization of the 
carboranes with water-solubilizing groups such as amine, hydroxy and 
polyethyleneglycol groups (see Figure 4-1). 
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Figure 4-1: Structures of the target porphyrins 4.1, 4.2 and 4.3 
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In the preceding Chapters I have synthesized water-soluble carboranylporphyrins which 
were negatively charged and localized selectively in the lysosomes of tumor cells 
because.41, 42 It has been reported that cationic porphyrins localize in the mitochondria 
because of the high electrochemical potential of the inner mitochondrial membrane.43 
Neutral, anionic and cationic porphyrins display multiple localization sites within the 
cells which can effectively result in the tumor cell destruction. The uptake of the 
carboranylporphyrins is dependent on the nature of the peripheral side chains, 
hydrophobic character, charge, molecular weight, acid-base properties, aggregation state, 
charge/mass ratio and also the charge distribution. All the neutral carboranylporphyrins 
synthesized have 40 boron atoms each and 28%-32% of boron by weight. So they can 
potentially deliver therapeutic amounts of boron-10 to the tumors. The target porphyrins 
have stable methylene linkages between the meso phenyl group of the porphyrin 
macrocycle and the carborane. The carboranes are functionalized only on the ortho 
position of the carborane and so these functional groups will not be hydrolyzed nor 
attacked by other chemicals inducing loss of the carboranes before they reach the tumor. 
Another advantage of these functionalized carboranylporphyrins is that they are highly 
fluorescent and this enables the detection of tumor cells using fluorescence microscopy,44 
and the determination of 10B localization in tumors and surrounding tissues. Intracellular 
boron distribution and quantification play an important role in determining the dose and 
length of neutron radiation, as well as the success of the BNCT treatment. 
4.2 Synthesis of Tetra[4-(1-hydroxyethyl-carboranyl)methylphenyl]porphyrin 
Porphyrin 4.1 is prepared from commercially available 4-butyn-1-ol 4.4 as indicated in 
Scheme 4-1. The terminal alcohol of 4.4 was protected with t-butyldimethylsilylchloride 
(TBDMSCl) 45 to produce protected alkyne 4.5. The 4-butyn-1-ol was dissolved in DMF 
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with imidazole and to this mixture t-butyldimethylsilylchloride was added and the final 
solution heated at 500C. The mixture was neutralized and purified on a silica gel column 
using 1:9 ratio of ethyl acetate/hexane to give an oily clear liquid in 60% yield. The 4-
butyne-1-ol 4.4 was first protected with t-butyldimethylsilylchloride before it was reacted 
with decaborane since acetylenes containing hydroxyl groups fail to give the carborane 
products. Since the hydroxyl groups on the acetylenes can degrade the carborane cages, 
the protected alkyne 4.5 was reacted with a Lewis base complex of ethylsulfide and 
decaborane46 in dry toluene to give the substituted protected siloxy carborane 4.6. The 
reaction was done in a schlenk tube for three days and after the reaction was finished it 
was worked up first with methanol, followed by 50% aqueous HCl and 10% aqueous 
NaOH. The product formed was purified by filtration through a silica column with 1:9 
ethyl acetate and hexane. The ratio of ethyl acetate was slowly increased until it finally 
reached 6:4 (ethyl acetate: hexane) and a pure product was obtained. This unknown 
product 4.8 was characterized by 1H-NMR and mass spectroscopy. This reaction did not 
work since the tertiary butyldimethylsiloxy group got cleaved from the alcohol functional 
group during the acidic work up of the reaction. The protected alcohol 4.5 was stirred 
with a solution of aqueous HCl to confirm the acidic cleavage of the siloxy protecting 
group.  The acidic workup was avoided in later experiments. The reaction was then 
worked up by refluxing with methanol and ethanol to remove the hydrogen formed in the 
reaction. The reaction mixture was dissolved in methanol and passed through a silica 
column with ethyl acetate and hexane in 1:9 ratio. The pure white solid product carborane 
4.6 was formed in 60% yield. The reaction was repeated in a larger scale under same 
conditions to yield pure product in large amounts. 
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Scheme 4-1: Synthesis of compound 4.7 
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Scheme 4-2: Synthesis of unwanted compound 4.8 
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Carborane 4.6 was characterized by 1H-NMR and mass spectrometry. The 1H-NMR 
clearly shows the characteristic broad singlet proton of the CH on the ortho carborane at 
4.01 ppm, as seen in Figure 4-2. This is a shift from the proton on the terminal alkyne 4.5 
at 1.95 ppm (triplet). The methyl and butyl protons on the silyl group are at 0.06 and 0.9 
ppm respectively because of the low electro negativity of the silyl group. The methylene 
linkages appear as triplets at 2.44 and 3.72 ppm. 
 
 
 
 
Figure 4-2: 1H-NMR of the carborane 4.6 in CDCl3 at 300 MHz 
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The most acidic proton of carborane 4.6 is deprotonated with n-BuLi and a SN2 reaction 
of the 4-bromobenzylbromide resulted in a carborane-substituted bromobenzene 4.7.47 
The SN2 reaction between carborane 4.6 and the 4-bromobenzylbromide was successful 
after multiple trials with various solvents and different reaction conditions. Initially dry 
DME was used as a solvent and the reaction was stirred at room temperature. This did not 
yield any product even after various trials with the temperatures. DME probably was 
hampering the formation of anion on the carborane 4.6.  
 
 
Figure 4-3: 1H-NMR of carborane 4.7 in CDCl3 at 300 MHz 
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In a Dry THF the anion of carborane 4.6 was formed with n-BuLi and the SN2 reaction of 
this anion with 4-bromobenzylbromide gave the carborane-substituted bromo benzene 4.7 
in 75% yield. A catalytic amount of LiI was added to expedite the reaction by the 
substitution of the benzyl bromide with iodine which is a better leaving group. The 
impure product was purified on a silica gel column with DCM and petroleum ether 1:9. 
The pure product was characterized by 1H-NMR, in which the aromatic protons are 
downfield at 7.05 and 7.47 ppm, as seen in Figure 4-3. The protons of the methylene 
carbon linking the carborane to the bromobenzene are a singlet at 3.48 ppm. There is a 
slight shift in the methylene protons from 2.44 and 3.72 ppm (in carborane 4.6) to 2.56 
and 3.82 ppm in compound 4.7. The synthesis of the aldehyde 4.10 is the key step in the 
formation of the target porphyrin 4.1. The synthesis of aldehyde 4.10 was first attempted 
by reacting compound 4.7 with n-BuLi, which involves a Li-Br exchange, followed by 
reaction with DMF and acid hydrolysis with 2N HCl. 
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Scheme 4-3: Failed synthesis of aldehyde 4.10 
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This reaction did not work probably due to the non formation of the Li complex of 
compound 4.7 and the failure of the attack towards the DMF.48 The acid hydrolysis might 
have also cleaved the acid labile tertiary butyl dimethyl siloxy group. This was tried 
many times with similar results. 
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Scheme 4-4: Synthesis of aldehyde 4.10 
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Therefore a different route to aldehyde 4.10, as described in Scheme 4-4, was followed. 
In the first step 4-(bromomethyl)-benzonitrile 4.11 was reduced with 
diisobutylaluminium hydride followed by 10% H2SO4 to form pure white crystals of 4-
(bromomethyl)-benzaldehyde 4.12 in 90% yield.49 After the formation of aldehyde 4.12 
the formyl functional group was protected with 1, 2-ethane dithiol in the presence of 
BF3.Et2O.50 After stirring for 15 min at room temperature it was neutralized with 10% 
NaOH and then washed with brine and water to get the pure white product 4-
(bromomethyl)benzenedithiane 4.13 without further need for purification in 63% yield. 
The aldehyde functional group is protected to prevent a secondary reaction between the 
aldehyde and the anion of the carborane in the next step. The anion of carborane 4.6 
generated by addition of n-BuLi in dry THF undergoes an SN2 reaction with 4-
(bromomethyl)-benzyldithioethylene 4.13.  LiI in THF was added with dithiane 4.13 and 
the reaction mixture immediately changed to a red color from a colorless solution. After 
overnight stirring at room temperature the color changed to yellow and at this point it was 
quenched with water and worked up with ethyl ether. The impure product was passed 
through a silica gel column using DCM: Hexane 2:3 for elution to give the pure product 
carborane-substituted benzyldithiane 4.14 in 48% yield. The formation of the product 
carboranyl benzyldithiane 4.14 was confirmed by 1H-NMR which shows the 
disappearance of the broad singlet of the ortho proton on the carborane cage of 4.6. The 
two methylene linkage between the carborane and the silyl group shift from 2.44 and 3.72 
ppm in silylcarborane 4.6 to 2.57 ppm and 3.82 ppm in compound 4.14.  The aromatic 
doublet protons on the benzene ring appear at 7.12 and 7.50 ppm and a singlet benzyl 
proton at 5.63 ppm. The hydrogens on the dithiane form multiplets at 3.36 ppm and 3.49 
ppm. The methylene linkage between the carborane and the benzene appears at 3.52 ppm.  
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Deprotection of compound 4.1451 was done using two equivalents of mercury perchlorate 
in 5% aqueous THF. The reaction was completed in 15 min, the reaction mixture was 
filtered and the filtrate was washed with ethyl ether and then washed with an aqueous 
solution of Na2CO3 and water. The final product was purified with 1:9 ratio of DCM: 
hexane to recover some of the starting material 4.14.    
 
 
 
 
 
 
 
 
 
 
Figure 4-4: 1H-NMR of the carborane 4.10 in CDCl3 at 300 MHz 
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Scheme 4-5: Synthesis of porphyrin 4.1 
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In the 1H-NMR spectrum the characteristic aldehyde peak was seen at 10.03 ppm with 
the disappearance of the dithiane and benzyl protons, as seen in Figure 4-4. The 
methylene linkage between the carborane and the benzaldehyde shifted from 3.49 ppm to 
3.61 ppm. The aromatic protons shifted slightly downfield from 7.12 and 7.50 ppm in 
compound 4.14 to 7.36 ppm and 7.86 ppm in 4.10. Aldehyde 4.10 will then be condensed 
with pyrrole using Lindsey’s conditions to form the porphyrinogen which was oxidized 
with p-chloranil to form porphyrin 4.15.52 
The cleavage of the t-butyldimethylsiloxy groups to form the meso-tetra[4-(1-
hyrdoxyethyl-carboranyl)methylphenyl]porphyrin 4.1 will be accomplished using TFA.53 
4.3 Synthesis of Tetra[4-(1-triethylenegycol-carboranyl)methylphenyl]porphyrin 
 
The aim of this work was to develop a synthetic route to a poly(ethyleneglycol) 
containing carboranylporphyrin 4.2 which is thought to be more water-soluble than the 
meso-tetra[4-(1-hydroxyethyl-carboranyl)methylphenyl]porphyrin 4.1. Both these 
porphyrins will be synthesized and evaluated for biological importance. The 
amphiphilicity of porphyrins 4.1 and 4.2 will also be evaluated and compared.   
Tri(ethyleneglycol)monomethylethertosylate 4.17 was easily made from  
tri(ethyleneglycol)monomethylether 4.16 by substitution of the primary alcohol with the 
tosyl group using anhydrous pyridine as a solvent.  The product was formed in 90% yield 
and was used in the next step without further purification. This was followed by iodine 
substitution on tri(ethyleneglycol)monomethylethertosylate 4.17 to form the 
tri(ethyleneglycol)monomethylether iodide 4.18.54 The tosylate group was substituted 
with iodide by refluxing the tosylate 4.17 and NaI in butanone. The resulting crude 
product was purified with 10:1 ratio of DCM/ethyl acetate in silica gel. Both these steps 
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resulted in formation of the tri(ethyleneglycol)monomethylether iodide 4.18 in overall 
yield of 92%.  
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Scheme 4-6: Failed synthesis of dithianecarborane 4.22 
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The 1H-NMR confirmed the structure of the iodide 4.18 with methylene protons of the 
polyethylene gycol forming multiplets at 3.27, 3.57, 3.66 and 3.77 ppm, as seen in Figure 
4-5. The methyl protons formed a singlet at 3.40 ppm. 
 
 
 
 
 
Figure 4-5: 1H-NMR of the iodide 4.18 in CDCl3 at 300 MHz 
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This polyethylenegycol iodine 4.18 was then reacted with 4-(o-carboranyl)benzyl(1,3-
dithiane) 4.21. The 4-(o-carboranyl) benzyl (1, 3-dithiane) 4.21 was synthesized in three 
steps from commercially available 4-ethynylbenzaldehyde 4.19.34 Firstly the formyl 
functional group of the 4-ethynylbenzaldehyde 4.19 was protected using ethanedithiol 
and BF3.OEt2 to produce 4-ethynylbenzyl(1,3-dithiane) 4.20. The resulting residue was 
purified by column chromatography (dichloromethane-hexane, 1:4) to give 80% of p-
ethynylbenzyl(1,3–dithiane) 4.20. The 1H-NMR confirmed the structure of product 4.20 
with the disappearance of the aldehyde peak at 10.03 ppm in the starting material 4.19 
and the appearance of the methylene protons of the dithiane 4.20 at 3.38 and 3.52 ppm. 
The presence of the benzyl proton at 5.62 ppm also confirms the structure of the product.  
The proton on the terminal alkyne appears at 3.09 ppm and the aromatic protons at 7.42 
and 7.48 ppm. The terminal alkyne of the 4-ethynlbenzyl(1,3-dithiane) 4.20 is then 
attacked with ethyl sulfide complex of decaborane  in dry toluene to give the 4-(o-
carboranyl)benzyl(1,3-dithiane) 4.21. The three day reaction was followed by an acidic 
and basic workup to give a crude product which was purified by passing through a silica 
gel column with dichloromethane and hexane (1:4) used for elution. The yield of the 
reaction was 67%. The 1H-NMR of the product 4.21 dissolved in deuterated chloroform 
shows the ten boron protons of the carborane cage between 1.6 - 3.3 ppm. The 
characteristic ortho-carborane CH proton forms a broad singlet at 3.94 ppm, as seen in 
Figure 4-6. The idea of this route was to generate an anion on the ortho carborane 
position of the 4-(o-carboranyl)benzyl(1,3-dithiane) 4.21 with  one equivalence of n-BuLi 
and then do an SN2 reaction with the tri(ethyleneglycol)monomethylether iodide 4.18 to 
obtain the wanted product carborane 4.22. But this reaction did not work probably 
because of the deprotonation of the acidic proton on the benzylic position of the 4-(o-
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carboranyl) benzyl(1,3-dithiane) 4.21 rather than the proton on the ortho carborane 
position. 
 
 
 
 
Figure 4-6: 1H-NMR of the carborane 4.21 in CDCl3 at 300 MHz 
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The pKa values of both the acidic protons on carborane 4.21 are nearly similar and this 
might be reason for the competitive de-protonation within the same molecule. 
An alternate shorter route for the formation of porphyrin 4.2 where there is a methylene 
linkage between the carborane and the phenyl ring was tried. This route was inspired by 
the polyethylene glycol carborane 4.25 synthesized by Bregadze and coworkers.55  
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Scheme 4-7: Synthesis of polyethyleneglycol carborane 4.25 by Bregadze and coworkers 
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Bregadze and coworkers synthesized the polyethylene glycol carborane 4.25 in five steps 
from tri(ethyleneglycol)monomethylether 4.16. According to their route as shown in 
Scheme 4-7 compound 4.16 was converted to iodide 4.18 in two steps with a total yield 
of 92%. Compound 4.18 was then reacted with lithium trimethylsilylacetylenide to give 
trimethylsilylacetylenide 4.23. The compound 4.23 was then treated with 
tetrabutylammonium fluoride to remove the trimethylsilyl group and forms the acetylene 
4.24 in 86% yield.  The acetylene was then reacted with decaborane in acetonitrile to give 
the carborane 4.25.  
They also reacted o-carborane with the tri(ethyleneglycol)monomethyl iodide 4.18 and 
they obtained a disubstituted derivative and an unsubstituted o-carborane in a 2:1:1 ratio. 
Taking a cue from this failure of the reaction of o-carborane with 
tri(ethyleneglycol)monomethyl iodide 4.18  to give reasonable yields I decided to try the 
reaction between the tri(ethyleneglycol)monomethyl iodide 4.18 obtained from the 
previous reaction and commercially available o-carborane. o-carboranes always gives 
low yields due to disproportionation. In the first attempt o-carborane was dissolved in dry 
THF, the mixture was cooled to 00C and one equivalent of n-BuLi was added at this 
temperature. After stirring this mixture for 1.5 hours one equivalent of the 
tri(ethyleneglycol)monomethyl iodide 4.18 in dry THF was added. This was warmed to 
room temperature and after stirring overnight the reaction was worked up. This reaction 
did not result in any product. So a second trial was done wherein the reaction was carried 
out at -78 0C instead of 0 0C. The reaction resulted in the formation of polyethylene 
glycol carborane 4.25 after separation from the o-carborane with 1:3 ratio of ethyl 
acetate/hexane on a silica gel column.   Since the tosylate group is a better leaving group 
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than the iodide group the idea to react the tri(ethyleneglycol)monomethylether tosylate 
4.17 with the o-carborane was tried. 
 
TsCl
Dry Pyridine
NaI
Butanone
o-Carborane
n-BuLi
THF
o-Carborane
n-BuLi
THF
60%65%
= BH
= C
-78oC0 oC
92%
MeO
O
O
OH
MeO
O
O
OTs
MeO
O
O
I
H
4.25
O
O
OMe
4.16
4.17 4.18
 
 
 
Scheme 4-8: Synthesis of polyethyleneglycol carborane 4.25 
 
In this route tri(ethyleneglycol)monomethylether tosylate 4.17 was used to form the 
tri(ethyleneglycol)monomethylethercarborane 4.25 by the SN2 reaction of the anion of o-
carborane with the tosylate 4.17. Since tosylate group is a better leaving group than 
iodide, the compound 4.17 was used instead of the compound 4.18. Two hours after the 
addition of the n-BuLi at 0 0C the tri(ethyleneglycol)monomethylether tosylate 4.17 was 
added and the resulting mixture warmed to room temperature and stirred overnight. The 
crude mixture was separated using DCM for elution on a silica gel column. All the non 
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polar impurities eluted first and the product was eluted using 4:2 ratio of ethyl 
acetate/hexane. The yield of this reaction was 65% and this route also resulted in 
recovery of o-carborane in minor yields. This reaction has to have just equal equivalents 
of n-BuLi and the tri(ethyleneglycol)monomethylethertosylate 4.17 as there are two 
acidic hydrogens on the o-carborane and this might result in the formation of the 
unwanted disubstituted derivative.  
 
 
 
Figure 4-7: 1H-NMR of the carborane 4.25 in CDCl3 at 300 MHz 
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The 1H-NMR confirms the formation of the product carborane 4.25, as seen in Figure 4-
7. The hydrogens attached to the borons form a broad peak extending from 1.00 to 3.42 
ppm. The methylene attached directly to the carborane forms a triplet at 2.55 ppm and the 
remaining ten hydrogens on the polyethylene chain form a multiplet from 3.56 to 3.66 
ppm. The methyl on the terminal methoxy shows up as a singlet at 3.41 ppm and the 
characteristic hydrogen attached to the ortho position of the carborane forms a broad 
singlet at 4.25 ppm. The reaction to form the carborane 4.25 from the tosylate 4.17 was 
scaled up and good yields were obtained. The next step was to do an SN2 substitution on 
the 4-(bromomethyl)benzenedithiane 4.13 with the carborane 4.25. The idea was to 
generate the anion of the carborane 4.25 and attack at the bromide leaving group on 
compound 4.13. In the first attempt to form the target compound 4.27  the carborane in 
dry THF was cooled to 0 0C and the n-BuLi was added followed by the addition of the 
dithiane 4.13 and LiI  at -200C. After overnight stirring at room temperature the reaction 
mixture did not yield any product. The only isolated products were the starting materials. 
So the next trial was done wherein the n-BuLi was added to the carborane 4.25 in THF at 
-78 0C. This mixture was warmed to -20 0C and then the LiI and the dithiane 4.13 in dry 
THF were added. The resulting mixture was warmed to room temperature and stirred 
overnight. This method did not yield the wanted product but some substituted carboranes 
without the polyethyleneglycol were obtained. An alternate reaction was done using 
commercially available 4-bromobenzylbromide 4.26 instead of the 4-
(bromomethyl)benzenedithiane 4.13. 4-bromobenzylbromide 4.26 was used because of 
its easy availability compared with 4-(bromomethyl)benzenedithiane 4.13 which is 
obtained in a two step reaction. I also wanted to confirm the generation of the anion of 
the carborane 4.25 using various solvents and temperature conditions. 
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Scheme 4-9: Synthesis of carboranes 4.27 and 4.28 
 
In the first attempt to the mixture of the carborane 4.25 in dry THF at 0 0C and then after 
2 hours the temperature was reduced to -200C and the LiI and the 4-bromobenzylbromide 
were added and the reaction mixture stirred overnight at room temperature. This reaction 
failed to yield any product as tried before with the same conditions as dithiane 4.13. The 
reaction between the 4-bromobenzyl bromide and the carborane 4.25 was also tried at -78 
0C with the same results as before. So the reaction was tried at -30 to -40 0C.  
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Scheme 4-10: Synthesis of polyethyleneglycol porphyrin 4.2 
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The carborane 4.25 in dry THF was cooled to -40 0C and then n-BuLi was added 
followed by addition of the 4-bromobenzyl bromide 4.26 at -20 0C. The reaction mixture 
was warmed to room temperature and stirred overnight. This resulted in the formation of 
some wanted product 4.28. Further purification has to be done in order to characterize the 
compound 4.28. The same method will also be applied for the formation of the dithiane 
4.27. When either the dithiane 4.27 or compound 4.28 is formed they will be converted to 
the aldehyde 4.29. The dithiane 4.27 can be de-protected with mercury perchlorate to 
form aldehyde 4.29. The compound 4.28 can be reacted with dry DMF to form aldehyde 
4.29. The aldehyde 4.29 can than be condensed with distilled pyrrole in the presence of 
catalytic amount of TFA to form the porphyrinogen which can than be oxidized with p-
chloranil to form the tetra(1-triethyleneglycol-carboranyl)phenyl porphyrin 4.2 (Scheme 
4-10). The total synthesis and characterization of both the tetra(1-triethyleneglycol-
carboranyl)methylphenyl porphyrin 4.2 and the tetra(1-hydroxyethyl-
caboranyl)methylphenylporphyrin 4.1 will be done. The biological evaluation of both 
these porphyrins will also be done. 
4.4 Synthesis of Tetra[4-(1-aminomethyl-carboranyl)phenyl]porphyrin 
Porphyrin 4.37 was synthesized from commercially available 3-bromopropyne 4.31 as 
shown in Scheme 4-11. The propargyl bromide 4.31 was reacted with the potassium salt 
of phthlamide 4.30 to form the substituted product N-propargyl phthlamide 4.32. The 
solvent acetone was removed after 12 hours and the residue purified by column 
chromatography to give compound 4.32 in 80% yield. The 1H-NMR confirmed the 
formation of the product with the appearance of the aromatic doublet protons at 7.75 ppm 
and 7.87 ppm.  
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Scheme 4-11: Synthesis of dithianecarborane 4.35 
 
 135
 
Compound 4.32 was then coupled with 4-bromobenzaldehyde in the presence of 
Pd(OAc)2 and triphenyl-phosphine in anhydrous triethyl amine to form the 4-
(propynepthalamide)benzaldehyde 4.33.56 The final mixture obtained after 8 hours of 
reflux was purified with 1:4 ratios of DCM/hexanes on a silica gel column. The yield of 
this reaction was 78%.  The appearance of the aromatic protons of the benzylaldehyde at 
7.26 ppm and 7.58 ppm and also the characteristic aldehyde peak in the 1H-NMR at 9.98 
ppm confirms the formation of product 4.33. The aldehyde 4.33 was then protected with 
ethylene dithiol to form 4-(phthlamidopropnyl)-phenyl 1, 2-dithiane 4.34. The dark 
yellow mixture obtained was purified to obtain compound 4.34 in 83% yield. The 
disappearance of the aldehyde peak at 9.98 ppm and the appearance of the dithiane peaks 
in the 1H-NMR spectrum at 3.34 ppm and 3.47 ppm confirm the formation of compound 
4.34. The alkyne on the dithiane 4.34 was complexed with the Lewis base of the 
decaborane in dry toluene to form the carborane 4.35. After workup the crude product 
was purified on a silica gel column with 4:1 ratio of DCM/hexanes to form the 4-(1-
methylphthlamidocarborane)-phenyl 1, 2-dithiane 4.35 in 60% yield. The 1H-NMR 
confirmed the formation of product 4.35. The methylene linkage between the nitrogen 
and the alkyne in compound 4.34 appears at 4.68 ppm and it shifts upfield to 3.90 ppm in 
the carborane 4.35. All the aromatic and dithiane protons in the starting compound 4.34 
show similar 1H-NMR shifts in the carborane 4.35. The B-H protons on the carborane 
form a broad peak from 1.9 ppm to 3.4 ppm. The 4-(1-methylphthlamidocarborane)-
phenyl 1, 2-dithiane 4.35 was then deprotected with mercury (II) perchlorate to form 
aldehyde 4.36. The procedure used was similar to that of the previous methods of 
deprotection of the dithiane. The yield of this reaction was 75%.  
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Scheme 4-12: Synthesis of porphyrin 4.3 
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Figure 4-8: 1H-NMR of aldehyde 4.36 in CDCl3 at 300 MHz 
 
The disappearance of the dithiane peaks and the appearance of the aldehyde peak at 10.10 
ppm confirm the formation of compound 4.36, as seen in Figure 4-8. Condensation of 
aldehyde 4.36 with pyrrole in the presence of TFA under Lindsey conditions, as 
previously described, produced target porphyrin 4.37 in very low yields. After the 
disappearance of the aldehyde 4.36 in the reaction mixture p-chloranil was added to 
oxidize the porphyrinogen to the porphyrin 4.37.  
 138
 
 
Figure 4-9: UV-visible of the porphyrin 4.37 in DCM 
 
 
Figure 4-10: Fluorescence of porphyrin 4.37 
 139
The separation was also very difficult as multiple products were formed. The first 
separation was done using 7:3 of DCM/hexane on a silica gel column. This separation 
yielded three major fractions. The fastest running fraction was further purified with 3:7 of 
ethyl acetate and petroleum ether to get the product porphyrin 4.37 in the low yield of 
3%. The porphyrin 4.37 shows the characteristic UV-Visible spectrum of meso-
substituted porphyrins with an etio-type of spectrum (Figure 4-9).  Figure 4-10 shows the 
fluorescence emission spectrum of porphyrin 4.37 with emission peaks at 605 and 651 
nm when excited at 419 nm. Because of the low yields obtained further steps of 
deprotection of the pthalamide with hydrazine to form the amino porphyrin 4.3 were not 
performed. 57 
4.5 Conclusions and Future Work 
The aldehyde 4.10 required for the synthesis for the meso-tetra[4-(1-hydroxyethyl-
carboranyl)methylphenyl]porphyrin was formed in high yields and the further reaction 
for the formation of porphyrin 4.1 will be performed. The polyethyleneglycol carborane 
4.25 was formed in high yields and in fewer steps than the proposed route by Bregadze 
and coworkers. The further reaction to form the aldehyde 4.25 and the eventual reaction 
to form the meso-tetra[4-(1-triethyleneglycolcarboranyl)methylphenyl]porphyrin 4.2 will 
be done. The synthesis of the porphyrin 4.37 is completed and further characterization of 
porphyrin 4.37 will be done. The yield of the reaction in the formation of the porphyrin 
4.37 will also be increased and then the last step of deprotection to form the meso-tetra[4-
(1-aminomethyl-carboranyl)methylphenyl]porphyrin 4.3  will also be performed.  
The synthesis of all these novel porphyrins will be followed by biological evaluation of 
these porphyrins in tumor cells. The porphyrins will be tested for their toxicity towards 
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normal cells in culture and also in mice. The uptake concentration and the intracellular 
localization of these porphyrins in tumor cells will also be evaluated. 
4.6 Experimentals 
Chemistry: Commercially available starting materials were purchased from Sigma-
Aldrich and used without further purification. All solvents were purchased from Fisher 
Scientific (HPLC grade) and either directly used or dried and distilled according to 
literature procedures. Silica gel 60 (70-230 mesh, Merck) and alumina grade III (70-230 
mesh ASTM) were used for column chromatography. Analytical thin-layer 
chromatography (TLC) was performed on Merck 60 F254 silica gel (precoated sheets, 0.2 
mm thick). 1H-NMR spectra were obtained using a Bruker DPX 250 MHz or 300 MHz 
spectrometer; chemical shifts are expressed in ppm relative to TMS (0 ppm). Electronic 
absorption spectra were measured on a Perkin Elmer Lambda 35 UV-Vis 
spectrophotometer and fluorescence spectra on a Perkin Elmer LS55 instrument. Low 
resolution MS analyses were conducted at the LSU Mass Spectrometry Facility on a 
Bruker Prolix III MALDI-TOF mass spectrometer, and the HRMS were conducted at the 
Ohio State University Mass Spectrometry and Proteomics Facility. Melting points were 
measured on an Electrothermal MEL-TEMP instrument.  
4-(tert-butyldimethylsiloxy) 1-butyne (4.5): To a solution of 3-butyne-1-ol 4.4 (2 gm, 
28.5 mmol) and imidazole (5.8 gm, 85 mmol) in DMF (25 ml) was added TBDMSCl (6.5 
gms, 42.75 mmol) at room temperature. The reaction mixture was heated at 50 0C for 4.5 
hrs and quenched with aqueous NaHCO3 and then extracted with ethyl ether .The organic 
extracts were washed with water , brine  and then dried over Na2SO4 concentrated under 
vacuum to get a  oily liquid .It was separated using N-hexane to get a clear oily liquid in 
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60% yield (3 gm). MS m/e 184.8 1H-NMR (CDCl3) δ ppm: 0.08 (s, 6H, CH3) 0.9 (s, 9H, 
CH3), 1.95 (t, 1H, CH), 2.40 (m, 2H, CH2), 3.74 (t, 2H, CH2). 
4-(tert-butyldimethylsiloxy) 1, 2 o-carborane (4.6): Decarborane (1.328 gm, 10.86 
mmol), diethyl sulfide (2.236 gm, 24.8 mmol) and toluene (25 ml) were combined in a 
schlenk tube equipped with the stirbar. The solution was maintained at 40 0C for 3 hours 
and then at 60 0C for 2 hours and finally was cooled to room temperature. 4-(tert-
butyldimethylsiloxy) 1-butyne 4.5 (2 gm, 10.86 mmol) dissolved in the minimum amount 
of toluene was added to B10H12. 2S(CH2CH3) in the schlenk tube under argon 
atmosphere. The reaction was slowly warmed to 80 0C and stirred for 3  days .The 
solution was cooled and stripped of the solvent on a rotary evaporator to get an a oily 
compound. 250 ml of methanol was added to this oily compound and refluxed to destroy 
any unreacted boranes and then ethanol was added to remove the excess diethylsulfide by 
co-distillation. The residue was washed with water and organic extract was dried over 
Na2SO4.The crude material was purified on a silica column (EtOAc: hexane- 1:9) to get 
the product in 60% yield (2.0 gm). MS m/e 303.46; 1H-NMR (CDCl3) δ ppm: 0.06 (s, 
6H, CH3) 0.9 (s, 9H, CH3), 2.44 (t, 2H, CH2), 3.72 (t, 2H, CH2) 4.01 (s, 1H, CH). 
[4-(1-tert-butyldimethylsiloxyethylene)-o-carboranyl)methyl]bromobenzene (4.7) : 
n-BuLi (0.660 ml, 1.6 M in hexane) was added dropwise to a solution of 4-(tert-
butyldimethylsiloxy) 1, 2 o-carborane 4.6 (0.240g, 0.790 mmol) in dry THF (10 ml), at a 
temperature between -5o and 0o C, under Argon. The mixture was stirred at this 
temperature range for one and a half hours, then cooled to -15o to -20o C (ice/salt bath). A 
solution of LiI (0.034 g, 0.246 mmol) in dry THF (2 ml) and 4-bromomethyl 
bromobenzene (0.196 g, 0.781 mmol) in THF (1 ml) was added and the final reaction 
mixture allowed to warm up to room temperature and stirred for 16 hours. After 
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quenching the reaction with water the resulting mixture was extracted four times with 
diethyl ether. The organic extracts were washed once with water, once with brine, dried 
over anhydrous Na2SO4 and the solvent removed under vacuum. The crude product was 
purified by column chromatography using dichloromethane/hexane 6:4 for elution, and 
the main product collected to give 0.180 (56% yield) of the title compound,. MS m/e 
497.3; 1H-NMR (CDCl3) δ ppm: 0.08 (s, 6H, CH3) 0.90 (s, 9H, CH3), 2.56 (t, 2H, CH2), 
3.48 (s, 2H, CH2), 3.82 (t, 2H, CH2), 7.05(d, 2H, Ar-H), 7.47 (d, 2H, Ar-H). 
4-(bromomethyl)bezaldehyde(4.12): 4-(bromomethyl)cyanobenzene 4.11 (1.84 gm, 10 
mmol) was dissolved in 50 ml of  dry toluene and argon was bubbled through the solution 
for 30 minutes. DIBAL-H(10 ml, 10mmol) was then added at 0oC dropwise. After 
addition, the reaction mixture was heated at 55oC for 1 day .Then 10% H2SO4 was added 
until pH< 4. The resulting reaction mixture was stirred at room temperature overnight 
before being worked-up. The reaction mixture was separated and the aqueous phase was 
extracted with toluene. The combined organic phase was washed with water several 
times, before removing the solvent on a rotary evaporator. A yellowish solid was 
obtained. The title compound was recrystallized from CH2Cl2/hexane to give a white 
crystalline solid (1.8 gm, 90% yield).1H-NMR (CDCl3) δ ppm: 4.52 (s, 2H, CH2), 7.54 (d, 
2H, Ar-H), 7.85(d, 2H, Ar-H), 10.02(s, 1H, CHO). 
4-(bromomethyl)benzenedithiane (4.13):  Boron trifluoride di ethyl etherate (0.014 gm 
,0.1 mmol) was added to solution of  4-(bromomethyl)benzaldehyde  4.12 ( 0.199 gm ,1.0 
mmol) and ethane dithiol (0.103 gm, 1.1 mmol) at 0 0C under argon. After 10 min the 
reaction mixture was first washed with 10% NaOH and then with saturated NaCl .The 
organic extract was dried over Na2SO4. A white solid was obtained on evaporation of 
 143
solvent in 0.175gm (63% yield). 1H-NMR (CDCl3) δ ppm: 3.36(m, 4H, CH2), 3.52(s, 2H, 
CH2), 5.62(s, 1H, CH), 7.32(d, 2H, Ar-H), 7.48(d, 2H, Ar-H). 
[4-(1-tert-butyldimethylsiloxyethylene)-o-carboranyl)methyl]benzenedithiane (4.14):  
n-BuLi (0.445 ml, 1.6 M in hexane) was added dropwise to a solution of 4-(tert-
butyldimethylsiloxy) 1,2 o-carborane 4.6 (0.162 g, 0.533 mmol) in dry THF (5.0 ml), at a 
temperature between -5o and 0o C, under Argon. The mixture was stirred at this 
temperature range for one and a half hours, then cooled to -15o to -20o C (ice/salt bath). A 
solution of LiI (0.023 g, 0.165 mmol) in dry THF (2 ml) and compound 4.13 (0.145 g, 
0.527 mmol) in THF (1 ml) was added and the final reaction mixture allowed to warm up 
to room temperature and stirred for 16 hours. After quenching the reaction with water the 
resulting mixture was extracted four times with diethyl ether. The organic extracts were 
washed once with water, once with brine, dried over anhydrous Na2SO4 and the solvent 
removed under vacuum. The crude product was purified by column chromatography 
using dichloromethane/hexane 6:4 for elution, and the main product collected to give 
0.125 (48% yield) of the title compound. MS m/e 497.3; 1H-NMR (CDCl3) δ ppm: 0.08 
(s,6H, CH3) 0.91 (s, 9H, CH3),  2.57 (t, 2H, CH2), 3.36 (m, 2H, CH2), 3.49 (s, 2H, CH2), 
3.52 (m, 2H, CH2), 3.82 (t, 2H, CH2), 5.63 (s, 1H, CH), 7.12 (d, 2H, Ar-H), 7.50 (d, 2H, 
Ar-H). 
[4-(1-tert-butyldimethylsiloxyethylene)-o-carboranyl)methyl]benzaldehyde (4.10): 
compound 4.14 (0.050 gm,  0.1006 mmol) is dissolved in 5% aqueous THF(3 ml) in a 
RBF equipped with a stirrer under argon. To this reaction mixture a solution of mercury 
(II) perchlorate (0.080 gm, 0.200 mmol) was added drop-wise and the final reaction was 
stirred at room temperature for 15 min .The reaction mixture was filtered and the filtrate 
was extracted with diethyl ether. The organic phase  was washed with saturated solution 
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of Na2CO3,then with water and finally dried over Na2SO4.The crude product was 
concentrated and purified by column chromatography (silica gel, EtOAc/Hexane-1:9) to 
give a pure product in 65% yield (0.030 gm). Theoretical mass: 422.3; 1H-NMR (CDCl3) 
δ ppm: 0.10 (s, 6H, CH3) 0.91 (s, 9H, CH3), 2.59 (t, 2H, CH2), 3.61 (s, 2H, CH2), 3.84 (t, 
2H, CH2), 7.36 (d, 2H, Ar-H), 7.86 (d, 2H, Ar-H), 10.03 (s, 1H, CHO). 
Tri(ethyleneglycol)monomethylethertosylate(4.17): Tosylchloride (10.5 gm, 55mmol) 
was added in portions into a solution of tri(ethylenegycol)monomethylether (8.2 gm, 50 
mmol) in anhydrous pyridine ( 50 ml). This reaction mixture was cooled to 0oC and 
stirred overnight. The reaction mixture was then poured on crushed ice and extracted with 
ethyl ether. The organic phase was washed with 1mol/lit HCl and water and then dried 
over Na2SO4. It was then evaporated under vacuum to yield pale yellow liquid in 5.5 gm  
yield. This was proceeded to next step without purification. 
Tri(ethyleneglycol)monomethyl Iodide(4.18): A mixture of Tri(ethyleneglycol) 
monomethyltosylate 4.17 ( 5.5 gm, 17.3 mmol), sodiumiodide ( 5.19 gm, 34.6 mmol) and 
butanone ( 32 ml) were refluxed for 2 h. water was then added to the partially evaporated 
reaction mixture and then the mixture was extracted with ethyl ether. The organic phase 
was washed with NaHSO3 solution and water; it was dried over Na2SO4 and evaporated 
to give product as a pale yellow liquid. It was purified with 10:1(DCM: ethylacetate) to 
get 4.3 gm (92% yield). Mass: 274.01; 1H-NMR (CDCl3) δ ppm: 3.27 (m, 2H, CH2), 3.40 
(s, 3H, CH3), 3.57 (m, 2H, CH2), 3.66 (m, 6H, CH2), 3.77 (m, 2H, CH2). 
p-Ethynylbenzyl(1,3-dithiane) (4.20): To a solution of 4-ethynylbenzaldehyde 4.19 (6.0 
g, 46.15 mmol) and 1,2-ethanedithiol (5.0 g, 53.09 mmol) was added BF3·OEt2 (0.654 g, 
4.62 mmol) at 0 0C under argon. The mixture was stirred at 25 0C for 15 m then washed 
once with a 10% aqueous NaOH solution, and once with aqueous saturated solution of 
 145
NaCl. The organic layer was dried over anhydrous Na2SO4 and the solvent removed 
under vacuum. The resulting residue was purified by column chromatography 
(dichloromethane-hexane, 1:4) to give 7. 0 g (80%) of p-ethynylbenzyl(1,3–dithiane). 
M.p: 68-69 oC; MS (EI) m/z 206.0 (M+); 1H-NMR (CDCl3) δ ppm: 3.09 (s, 1H, CH), 
3.38 and 3.52 (m, 2H each, CH2CH2), 5.62 (s, 1H, SCH), 7.42 (d, 2H, Ar-H,), 7.48(d, 2H, 
Ar-H).   
p-(o-Carboranyl)benzyl(1,3-dithiane) (4.21): A solution of decacarborane (3.0 g, 24.59 
m mol) and ethyl sulfide (5.0 g, 55.44 mmol) in dry toluene (50 ml) were combined in a 
schlenk tube and was heated at 40 0C for 3 h and then at 60 0C for 2 h. The solution was 
allowed to cool to 25 oC and to this mixture p-ethynylbenzyl(1,3-dithiane) 4.20 (5.0g, 
24.26 mmol) in dry toluene (10 ml) was added and the final mixture was stirred at 80 0C 
for 3 days. After cooling to room temperature, the mixture was concentrated under 
vacuum and the oily residue was dissolved in methanol (250 ml) and heated to reflux for 
1 h (until no hydrogen was liberated). At room temperature, 2.5 ml of HCl (50% 
aqueous) was added dropwise and the mixture was again refluxed for another 30 m until 
the evolution of hydrogen was complete. After cooling to 25 0C, the mixture was diluted 
with ethanol and excess ethylsulfide was removed by ethanol-ethylsulfide co-distillation. 
The resulting residue was reduced in volume under vacuum and dissolved in 100 ml of 
benzene (CAUTION) at 5 0C. This was followed by addition of 100 ml of cold 10% 
aqueous NaOH solution, and the mixture was allowed to stir vigorously for 15 m. The 
organic layer was separated and washed twice with water and dried over anhydrous 
Na2SO4. After removing the solvent under vacuum, the residue was purified by column 
chromatography (eluting with dichloromethane-hexane, 1:4) to give 5.2 g (67%) of the 
title compound. M.p: 118-119 0C; MS (EI) m/z 324.1 (M+); 1H-NMR (CDCl3) δ ppm: 1.6 
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- 3.3 (br, 10H, BH), 3.36 and 3.47 (m, 2H each, CH2CH2), 3.94 (br s, 1H, o-carborane-
CH), 5.59 (s, 1H, SCH), 7.40 (d, 2H, Ar-H), 7.46 (d, 2H, Ar-H). 
1-[3’, 6’, 9’-Trioxadecyl)-1, 2-dicarba-closo-dodecaborane (4.25): A two necked 
round bottom flask with o-carborane (0.288 gm, 2 mmol) dissolved in dry THF ( 20 ml) 
under argon was stirred at -780C for 1h. To this mixture n-BuLi (1.3 ml, 1.6 M in hexane) 
was added dropwise and stirred for 1h at -780C. After which 
Tri(ethyleneglycol)monomethylIodide 4.18 (0.548 gm, 2 mmol) in dry THF was added 
drop wise and stirred for 2 h at -780C and then slowly warmed to room temperature and 
stirred overnight. The final reaction mixture was neutralized with H2O, separated with 
ethyl acetate and washed with water and brine. It was then dried over anhydrous Na2SO4 
and separated on silica gel column (1:3, EtoAc: hexane) to yield 0.300 gm (52 % yield). 
Mass: 290; 1H-NMR (CDCl3) δ ppm: 1.00-3.42 (m, 10H, B-H), 2.55 (t, 2H, CH2), 3.41 
(s, 3H, CH3), 3.56-3.66 (m, 10H, CH2), 4.25 (s, 1H, CH). 
1-[3’, 6’, 9’-Trioxadecyl)-1, 2-dicarba-closo-dodecaborane (4.25): A two necked 
round bottom flask with O-carborane (0.864 gm, 6 mmol) dissolved in dry THF ( 60 ml) 
under argon was stirred at 00C for 0.5 h. To this mixture n-BuLi (4 ml, 1.6 M in hexane) 
was added drop wise and stirred for 1.5 h at 00C. After which 
Tri(ethyleneglycol)monomethyltosylate 4.17 (1.90 gm, 6 mmol) in dry THF was added 
drop wise and then slowly warmed to room temperature and stirred overnight. The final 
reaction mixture was neutralized with H2O, separated with ethyl acetate and washed with 
NaHSO3, water and brine. It was then dried over anhydrous Na2SO4 and separated on 
silica gel column using DCM to yield 1.0 gm (60 % yield). Mass: 290; 1H-NMR (CDCl3) 
δ ppm: 2.55 (t, 2H, CH2), 3.41 (s, 3H, CH3), 3.56-3.66 (m, 10H, CH2), 4.25 (s, 1H, CH). 
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N-Propargyl phthlamide (4.32):  To a suspended solution of potassium phtlamide (5.00 
g, 26.993 mmol) in acetone (100 ml) was added propargyl bromide 4.31 (5 ml of 80% 
solution in toluene). The mixture was refluxed for 12 hrs and filtered. The acetone was 
removed and the residue was purified by column chromatography (silica gel, chloroform: 
petroleum ether-90:10) to give 4 gm of the product (80 % yield) MS m/e 185.19; 1H-
NMR (CDCl3) δ ppm: 2.23(s, 1H, CH), 4.46(s, 2H, CH2), 7.75(d, 2H, Ar-H), 7.87(d, 2H, 
Ar-H). 
4-(phthlamidopropnyl)-benzaldehyde (4.33): To a solution of 4-bromobenzaldehyde 
(5.00 g, 27.04 mmol) and triphenyl phosphine (0.350 g, 1.336 mmol) in anhydrous 
triethyl amine (50 ml) under argon, were added N-Propargylphthlamide 4.32 (6.26 gm, 
33.8 mmol) in toluene and palladium (II) acetate (75 mg, 0.334 mmol).The final mixture 
was heated to reflux for 8 hours and then cooled to room temperature and it was then 
filtered. The filtrate was concentrated and purified by column chromotography (silica gel, 
CH2Cl2: petroleum ether- 1:4) to give the resultant compound in 78% yield (6.12 gm). 
MS m/e 289.29; 1H-NMR (CDCl3) δ ppm: 4.71(s, 2H, CH2), 7.26(d, 2H, Ar-H), 7.58(d, 
2H, Ar-H), 7.77(d, 2H, Ar-H), 7.90(d, 2H, Ar-H), 9.98(s, 1H, CHO). 
4-(phthlamidopropnyl)-phenyl 1, 2-dithiane (4.34):  Boron trifluoride diethyl etherate 
(0.306 gm, 2.16 mmol) was added to solution of 4-(phthlamidopropnyl)-benzaldehyde 
4.33 (5 gm, 17.28 mmol) and ethanedithiol (2.03 gm, 21.60 mmol) at 0 0C under argon. 
After 10 min the reaction mixture was first washed with 10% NaOH and then with 
saturated NaCl. The organic extract was dried over Na2SO4. A dark yellow oil obtained 
on evaporation of solvent was purified by chromatography (silica, CH2Cl2: pet-ether- 1:4) 
yield a white solid in 5.30 gm (83% yield). MS m/e 365.46; 1H-NMR (CDCl3) δ ppm: 
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3.36(m, 4H, CH2), 4.68(s, 2H, CH2), 5.59(s, 1H, CH), 7.37(d, 2H, Ar-H), 7.45(d, 2H, Ar-
H), 7.77(m, 2H, Ar-H), 7.90(m, 2H, Ar-H). 
4-(1-methylphthlamidocarborane)-phenyl 1, 2-dithiane (4.35):  Decarborane (0.700 
mg, 5.7377 mmol), diethyl sulfide (1.046 gm, 11.6 mmol) and toluene (50 ml) were 
combined in a schlenk tube equipped with the stir bar. The solution was maintained at 40 
0C for 3 hours and then at 60 0C for 2 hours and finally was cooled to room temperature. 
4-(phthlamidopropnyl)-phenyl 1, 2-dithiane 4.34 (2 gm, 5.47 mmol) dissolved in the 
minimum amount of toluene was added to B10H12.2S (CH2CH3) in the schlenk tube under 
argon atmosphere. The reaction was slowly warmed to 80 0C and stirred for 3  days .The 
solution was cooled and stripped on a rotary evaporator to get an a oily compound. 250 
ml of methanol was added to this oily compound and refluxed to destroy any unreacted 
boranes and then ethanol was added to remove the excess diethylsulfide by co-
distillation. The residue was washed with water and organic extract was dried over 
Na2SO4.The crude material was purified on a silica column (CH2Cl2: hexane- 4:1) to get 
the product in 60% yield (400 mg). MS m/e 484.46; 1H-NMR (CDCl3) δ ppm: 1.9-3.3 
(br, 10H, B-H), 3.50(m, 4H, CH2), 3.90(s, 2H, CH2), 5.62(s, 1H, CH), 7.59(d, 2H, Ar-H), 
7.70(d, 2H, Ar-H), 7.77(m, 2H, Ar-H), 7.88(m, 2H, Ar-H). 
4-(1-methylphthlamidocarborane)-benzaldehyde (4.36): The compound 4.35 (400 mg, 
0.826 mmol) was dissolved in 5 ml of THF (5 % aqueous) in a 2-neck RBF under argon. 
To this a solution of mercury (II) perchlorate (660 mg, 1.652 mmol) in THF was added 
drop wise. The mixture was stirred for 15 min at room temperature. The reaction mixture 
was filtered and the filtrate was extracted with diethyl ether. The organic phase was 
washed with saturated solution of Na2CO3 and with water and finally dried over 
Na2SO4.The crude product was purified by column chromatogaphy to get pure product in 
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75% yield. MS m/e 484.46; 1H-NMR (CDCl3) δ ppm: 1.9-3.3 (br, 10H, B-H), 3.90(s, 2H, 
CH2), 7.59(d, 2H, Ar-H), 7.70(d, 2H, Ar-H), 7.77(m, 2H, Ar-H), 7.88(m, 2H, Ar-H), 
10.02 (s, 1H, CHO). 
Meso-tetra[4-(1-methylphthlamido-carborane)phenyl]porphyrin (4.37): A solution 
of the aldehyde 4.36 (0.420 g, 1.031 mmol) and freshly distilled pyrrole (0.078 ml,1.135 
mmol) in dry CH2Cl2 (100 ml) was purged with argon for 15 min. TFA (0.040 ml, 0.5155 
mmol) was added to the solution and the mixture was stirred at the room temperature 
under argon for 2.5 h (complete disappearance of starting  compound monitored by TLC 
). After addition of p-chloranil (0.190 g, 0.773 mmol) the reaction mixture was stirred at 
room temperature for 2 h. The solution was then washed once with aqueous saturated 
NaHCO3, and once with water before being dried over anhydrous Na2SO4. The residue 
obtained after removal of the solvent under vaccum was purified by the column 
chromatography on the silica gel (CH2Cl2/Hexane 7:3) 0.005 g of the title compound as 
purple crystals. Calculated weight 1822.32(M+). UV-Vis (CHCl3) λmax 421 nm, 515 nm, 
550 nm, 585 nm, 645 nm. 
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Chapter 5 
Synthesis of a Carboranylsapphyrin 
 
5.1 Introduction 
Sapphyrins are an important group of expanded porphyrins with an additional pyrrole 
subunit introduced into the porphyrin macrocycle. A sapphyrin macrocycle consists of 
five pyrrole rings linked by four methine bridges and one direct pyrrole-pyrrole bond. 
The sapphyrins are aromatic, like porphyrins and corroles, with an aromatic 22 electron π 
system which is confirmed by a Soret band at 450 nm in the UV-visible spectrum and 
diamagnetic ring current effects in the 1H NMR spectrum. The sapphyrins allow the study 
of aromaticity in large conjugated systems, and they also have the practical importance of 
the expanded core which can coordinate large metal ions.1 The sapphyrin shows more 
basicity than the porphyrin macrocycle and it can be easily obtained as the dication after 
chromatography on silica gel. The monocation and the freebase sapphyrins can be 
obtained by the controlled addition of bases to the dication.2   
Sapphyrins were the first expanded porphyrin to be obtained accidentally by R. B. 
Woodward and coworkers during their earlier attempts to synthesize the corrin core of 
vitamin B12.3 Woodward and coworkers implemented the most commonly used synthesis 
of sapphyrin 5.3 by a (3+2) approach (Scheme 5-1) where a bipyrrole aldehyde 5.1 was 
condensed with tripyrrane 5.2.4, 5 Woodward and coworkers also developed a less 
efficient synthetic route involving a (4+1) condensation (Scheme 5-2) of 
bipyrryldipyrromethane 5.4 and pyrrole dialdehyde 5.5.3 The one pot synthesis of 
sapphyrins was found by Woodward and Sessler groups.6, 7 Latos-Grazynski and 
coworkers developed an easy one-pot synthesis of sapphyrin by condensation of 
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benzaldehyde and pyrrole in a 1:3 molar ratio under conditions of oxidative acid 
catalysis.8  
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Scheme 5-1: Synthesis of sapphyrin 5.3 using a (3+2) approach by Woodward and 
coworkers4 
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Scheme 5-2: Synthesis of sapphyrin 5.6 using a (4+1) approach by Woodward and 
coworkers3 
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They reported very low yields of 1%. Dolphin and coworkers reported reasonable yields 
for the efficient synthesis of sapphyrins using tripyrrane precursors.9 Tavarekere and 
coworkers developed a one-pot synthesis of sapphyrins from a dipyrromethane with 
yields of 7%.10 A high yield (20% yield) method for the synthesis of the sapphyrin was 
developed by Paolesse, Smith and coworkers.11 This method involves the formation of 
sapphyrin 5.9 (Scheme 5-3) from biladiene 5.7 and formylpyrrole 5.8.  
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Scheme 5-3: Synthesis of sapphyrin 5.9 from biladiene 5.7 and formylpyrrole 5.8 by 
Paolesse, Smith and coworkers11 
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The method also enables preparation of sapphyrins with substituents arranged in a less 
symmetrical fashion than those obtained using the other methods. 
The UV-Visible spectra of sapphyrins show an intense Soret band at around 456 nm 
indicating a polypyrrolic aromatic macrocycle and this is accompanied by weak Q type 
absorption bands between 616 and 790 nm.12, 13, 14 The sapphyrin also exhibits 
flourescence properties upon excitation within the Soret band. The 1H-NMR of the 
unsymmetrical sapphyrins is strongly dependent upon the pattern of the peripheral 
substituents and the nature of the counter ion.4 The 1H-NMR of the sapphyrins are similar 
to that of the porphyrins with the external meso-type protons reasonating around 10 ppm 
and the internal NH protons located around -2 ppm. Sapphyrins have a larger core size 
than the porphyrin (an internal N-N distance of about 5.5 A0 compared to 4.0 A0). 
Because of this and the presence of an additional nitrogen donor site, the sapphyrins 
might stabilize large metal complexes.15 Woodward and coworkers reported the 
formation of the Zn and Co complexes and the Sessler group reported the Rh and Ir 
complexes with the metal ion located outside the plane of the macrocycle.16 In 1990, the 
first X-ray crystallographic analysis of a sapphyrin derivative, showing a planar 
diprotonated sapphyrin with five hydrogen bonds to a central fluoride anion, led to the 
suggestion that sapphyrins may act as anion receptors. 17-20 A great deal of work has been 
done in the area of anion binding and transport properties of sapphyrin.21, 22, 23 
Diprotonated sapphyrins have potential as receptors of biologically important anions, 
such as phosphates, including nucleotide monophosphate.12, 13, 14 A single oxygen of the 
phosphate is displaced from the five nitrogen plane and forms the hydrogen bonds with 
some of the NH protons of the diprotonated sapphyrin. These numbers of hydrogen bonds 
to the oxygen distinguishes the phosphate unit.24, 25 The binding of halide ions, 26, 27, 28 
 158
azide29, 30 and carboxylate31, 32 was also explored. Sapphyrins are also known to be 
solution-phase carriers for nucleotides,33 nucleotide analogues21 and amino acids.34 
Sapphyrins have potential application in PDT because of their absorbance in the 680-710 
range of the spectral region.4, 26, 27, 35 This property is an important prerequisite for a new 
generation of photosensitizers which can achieve a greater depth of light penetration.  
In this chapter I report the first synthesis of a carboranylsapphyrin. The 
carboranylsapphyrin was synthesized in very low yield and consequently its 
characterization was not complete. The goal of this project was to make a novel 
tetracarboranylsapphyrin followed by insertion of gadolinium into the sapphyrin core. 
This would make it an ideal NCT agent as both the 10B and the 157Gd would capture the 
neutrons and result in NCT. 157Gd has a higher cross section of neutron capture than the 
boron.36 
5.2 Synthesis of a Carboranylsapphyrin 
The synthesis of a carboranylsapphyrin happened by accident during the synthesis of 
meso-tetra(3-carboranylphenyl)porphyrin. The meso-tetra(3-carboranylphenyl)porphyrin 
was being synthesized in order to study its biological properties in comparison with the 
isomeric meso-tetra(4-carboranylphenyl)porphyrin which has the carborane groups on the 
para- rather than the meta-positions. The synthesis of meso-tetra(3 
carboranylphenyl)porphyrin started with 3-carboranylbenzaldehyde 5.10, as seen in 
Scheme 5-4. The benzaldehyde 5.10 was condensed with freshly distilled pyrrole in the 
presence of TFA.37 After the formation of the porphyrinogen it was oxidized with p-
chloranil to form the meso-tetra(3-carboranylphenyl)porphyrin 5.11. But when the 
separation was performed using 2:3 ratio of CH2Cl2 and hexane on a silica gel column, 
three different products were obtained.  
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Scheme 5-4: Synthesis of sapphyrin 5.12, corrole 5.13 and porphyrin 5.11 
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The fastest running fraction contained both sapphyrin 5.12 and the porphyrin 5.11 and 
this was followed by a fraction with the corrole 5.13. The fast running fraction with the 
sapphyrin 5.12 and the porphyrin 5.11 was further separated using 4.5:5.5 ratio of DCM 
and hexane on a silica gel column.  Sapphyrin 5.12, corrole 5.13 and porphyrin 5.11 were 
all characterized by MALDI-MS, UV-Vis, 1H-NMR. This unexpected formation of 
sapphyrin sparked the idea to make the carboranylsapphyrin in larger amount, followed 
by gadolinium ion insertion in its inner core which would make it an ideal gadolinium 
and boron NCT agent. Gadolinium has the highest neutron capture cross section value 
which is 66 times more than that of 10B and with the presence of boron will make it a 
perfect BNCT delivery agent if it can selectively localize in the tumor cells. Following a 
similar synthetic scheme as for the synthesis of the meso-tetra(3- 
carboranylphenyl)sapphyrin 5.12, the synthesis of a meso-tetra(4-
carboranylphenyl)sapphyrin 5.16 was tried using as the starting material 4-carboranyl 
benzaldehyde 5.14 because of its easy availability of compared with the 3-carboranyl 
benzaldehyde 5.10. 
The synthesis of meso-tetra(4-carboranylphenyl)sapphyrin 5.16 was initially attempted 
using the method devised by Tavarekere and coworkers10 and then the one-pot synthesis 
by the Latos-Grazynski was also tried.8 
A one-step synthesis of sapphyrin 5.16 was attempted using a condensation of meso(4-
carboranylphenyl)dipyrromethane 5.15 with the benzaldehyde 5.14, as seen in Scheme 5-
5. The meso-carboranyldipyrromethane 5.15 was synthesized from 4-
carboranylbenzadehyde 5.14 and freshly distilled pyrrole. The 4-carboranylbenzaldehyde 
5.14 was dissolved in 34 equivalents of pyrrole and a drop of TFA was added. The final 
mixture was stirred at room temperature for 20 min. The excess pyrrole was distilled to 
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give the dipyrromethane product 5.15 in 90% yield. Dipyrromethane 5.15 was 
characterized with 1H-NMR as seen in Figure 5-1. Dipyrromethane 5.15 was used for the 
one-pot synthesis of sapphyrin 5.16 by a route suggested by Tavarekere and coworkers.10   
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Scheme 5-5: Synthesis of the sapphyrin 5.16 from dipyrromethane 5.15 
 
The dipyrromethane 5.15 was dissolved in dry DCM and to this solution one equivalent 
of TFA was added. After stirring for one hour p-chloranil was added. A black 
polymerized mixture was obtained which was very hard to separate. 
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Figure 5-1: 1H-NMR of the dipyrromethane 5.15 in CDCl3 at 300 MHz 
 
None of the fractions could be separated in pure form for characterization. This route was 
not repeated anymore because of the uncertainty in the conversion of the dipyrromethane 
into a sapphyrin. The 4-carboranylbenzaldehyde 5.14 used is also difficult to synthesize 
and with the addition of the uncertain results this method was abandoned.  
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Another one pot methodology suggested by Latos-Grazynski and coworkers was 
attempted. In this synthesis of sapphyrin was prepared from benzaldehyde 5.17 instead of 
4-carboranylbenzaldehyde 5.14 in order to test the conditions for this route. The reaction 
of benzaldehyde 5.17 with the excess pyrrole 5.18 (1:3 molar ratio) in dichloromethane 
was done using BF3.Et2O as a catalyst (Scheme 5-6). The BF3.Et2O was used under 
modified conditions as compared to those used in the synthesis of the porphyrins.  
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Scheme 5-6: Synthesis of sapphyrin 5.19 from benzaldehyde 5.17 and pyrrole 5.18 
 
This reaction yielded a very low yield (1%) of the tetraphenylsapphyrin 5.19 which was 
obtained after complicated separations. The majority of the product was the 
tetraphenylporphyrin obtained in 25% yield. 3% of corrole was also isolated. The 
sapphyrin was characterized by MALDI-MS as seen in Figure 5-2. The sapphyrin had a 
complicated NMR.  In the next experiment TFA was used instead of the BF3.Et2O and 
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after overnight stirring, p-chloranil was added to yield a mixture of products. The mixture 
was separated by passing through basic alumina with DCM as the eluent. This separation 
was followed by another separation of the fast running products with 10:1 of DCM/CCl4 
which resulted in the minor yields (1%) of the tetraphenylsapphyrin 5.19. The sapphyrin 
was characterized by MALDI-MS, which showed the molecular ion (Figure 5-2) with a 
peak at 677. 
 
 
 
 
Figure 5-2: MALDI-MS of the tetraphenylsapphyrin 5.19 
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Using the mechanism of Rothemund synthesis designed for the sapphyrins by Latos-
Grazynski and coworkers the 4-carboranylbenzaldehyde 5.14 was condensed with three 
equivalents of pyrrole 5.18 in very dry DCM (Scheme 5-7). The BF3.Et2O was used as a 
catalyst and after the disappearance of the 4-carboranylbenzaldehyde 5.14 by TLC in the 
reaction mixture, p-chloranil was added and the mixture was purified using 2:3 
DCM/CCl4 solvent mixture. Several fractions obtained were analysed by MALDI mass 
spectrometry. The fast running fraction showed the meso-tetra(4-
carboranylphenyl)sapphyrin 5.16 peak at 1249, as seen in Figure 5-3. This was the only 
characterization that was possible for this sapphyrin 5.16 as the amount of sapphyrin 5.16 
obtained was very small.  
 
NH
N
H
N
N
N
H
H
CHO
+
N
H
H
H
H
H
1 : 3
DCM
p-chloranil
BF3.OEt2
5.165.14 5.18  
 
Scheme 5-7: Synthesis of the sapphyrin 5.16 from benzaldehyde 5.14 and pyrrole 5.18 
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Figure 5-3: MALDI-MS of the tetracarboranylsapphyrin 5.16 
 
The mechanism for the formation of the tetraphenylsapphyrin from the benzaldehyde and 
pyrrole was proposed by Latos-Grazynski and coworkers.8 According to this mechanism 
excess pyrrole molecules attack the tetrapyrromethane in its preferred helical 
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conformation to create a helical pentapyrrolic structure. A significant distortion from the 
planarity allows the extension of the structure by avoiding the overlap of the terminal 
ligand substituents. The helical geometry of the pentapyrrole provides the required 
orientation for the ring closure by the acidic α-α pyrrole coupling. This ring closing 
results in a sapphyrinogen related molecule which can then be oxidized to sapphyrin.  
All the methods utilized resulted in very low yields of the target sapphyrins, less than 1%. 
The most plausible route which can deliver high yields of sapphyrins for further 
metalation with gadolinium is yet to be done. This synthesis of the sapphyrin can be 
followed by the evaluation of its in vitro and the in vivo characteristics. The most 
promising route for the synthesis of the meso substituted tetracarboranylsapphyrin 5.16 
might be the one proposed by Dolphin and co-workers.9 This route follows a 3+2 
condensation of tripyrrane 5.21 and bipyrrole 5.20 to form the tetracarboranylsapphyrin 
5.16. Dolphin and coworkers formed a tripyrrane as a side product in a single step 
reaction by condensation of excess pyrrole with benzaldehyde in presence of the acid. 
The tripyrrane was obtained as a red-orange glass after the sublimation of the crude 
products. Tripyrranes have been previously synthesized by multi-step procedures by Lee 
and coworkers.38 5, 10-Di(4-carboranyl)phenyltripyrrane 5.21 could be obtained using a  
similar procedure to that of Dolphin and coworkers, as it would minimize the number of 
steps. Tripyrrane 5.21, dipyrrole 5.20 and the 4-carboranylbezaldehyde 5.14 can be 
dissolved in dry DCM (Scheme 5-8). This can be followed by the condensation with 
BF3.Et2O to form the macrocycle which can then be aromatized with p-chloranil. The 
target tetracarboranylsapphyrin 5.16 once obtained can be metalated with gadolinium to 
form the metalated tetracarboranylsapphyrin 5.22.  
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Scheme 5-8: Proposed synthesis of the metalated sapphyrin 5.22 
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5.3 Conclusions 
The synthesis of the tetraphenylsapphyrin 5.19 and the tetracarboranylsapphyrin 5.16 was 
achieved in very low yields. Many different routes for the synthesis of the 
tetracarboranylsapphyrin 5.16 were tried with little success. Characterization of the 
tetraphenylsapphyrin 5.19 and the tetracarboranylsapphyrin 5.16 was done by MALDI-
MS and UV-Vis. The synthesis of the target tetracarboranylsapphyrin 5.16 using the 
synthetic route developed by Dolphin and coworkers will be tried. This route may result 
in higher yields and further characterization of the tetracarboranylsapphyrin 5.16. This 
sapphyrin would then be metalated with gadolinium and evaluated in vitro and in vivo for 
application in gadolinium and boron neutron capture therapy. 
5.4 Experimentals 
Chemistry: Commercially available starting materials were purchased from Sigma-
Aldrich and used without further purification. All solvents were purchased from Fisher 
Scientific (HPLC grade) and either directly used or dried and distilled according to 
literature procedures. Silica gel 60 (70-230 mesh, Merck) and alumina grade III (70-230 
mesh ASTM) were used for column chromatography. Analytical thin-layer 
chromatography (TLC) was performed on Merck 60 F254 silica gel (precoated sheets, 0.2 
mm thick). 1H-NMR spectra were obtained using a Bruker DPX 250 MHz or 300 MHz 
spectrometer; chemical shifts are expressed in ppm relative to TMS (0 ppm). Electronic 
absorption spectra were measured on a Perkin Elmer Lambda 35 UV-Vis 
spectrophotometer and fluorescence spectra on a Perkin Elmer LS55 instrument. Low 
resolution MS analyses were conducted at the LSU Mass Spectrometry Facility on a 
Bruker Prolix III MALDI-TOF mass spectrometer, and the HRMS were conducted at the 
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Ohio State University Mass Spectrometry and Proteomics Facility. Melting points were 
measured on an Electrothermal MEL-TEMP instrument.  
Meso-tetra(3-carboranylphenyl)sapphyrin (5.12): A solution of the 3-
carboranylbenzaldehyde 5.10 (0.124 g, 0.5 mmol) and freshly distilled pyrrole (0.035 
mL, 0.505 mmol) in dry CH2Cl2 (50 ml) was purged with argon for 15 min. TFA (0.020 
ml, 0.25 mmol) was added to the solution and the mixture was stirred at the room 
temperature under argon for 20 h (complete disappearance of starting  compound 
monitored by TLC ). After addition of p-chloranil (0.093 g, 0.375 mmol) the reaction 
mixture was stirred at room temperature for 2 h. The solution was then washed once with 
aqueous saturated NaHCO3, and once with water before being dried over anhydrous 
Na2SO4. The residue obtained after removal of the solvent under vaccum was purified by 
the column chromatography on the silica gel (CH2Cl2/hexane .45:.55) and the fastest 
running fraction was collected and recrystallized from CH2Cl2/methanol, yielding the title 
compound, mp >300 0C . MS (MALDI) m/e 1249.365 (M+). 
Meso(4-carboranylphenyl)dipyrromethane (5.15): 4-carboranylbenzaldehyde 5.14 ( 
0.124 gm, 0.5 mmol) was dissolved in the pyrrole ( 1.18 ml, 17 mmol) and was bubbled 
with argon for 5 min. To this mixture a drop of TFA was added and stirred under argon 
for 15-20 min. The final reaction mixture was quenched with water after the complete 
consumption of the aldehyde and it was extracted with DCM. The organic fractions were 
washed with water and dried over Na2SO4. Vacuum distillation was done to remove the 
pyrrole and then it was purified by passing it through a silica gel column (3:7, 
ethylacetate: hexane) to yield the pure compound in 90% yield. Mass: 364.  1H-NMR 
(CDCl3) δ ppm: 1.8 - 3.5 (br, 10H, BH), 3.96 (br s, 1H, o-carborane-CH), 5.34 (s, 1H, 
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CH), 5.91 (s, 2H, CH), 6.20 (q, 2H, CH), 6.76 (q, 2H, CH) 7.20 (d, 2H, Ar-H), 7.44 (d, 
2H, Ar-H), 7.97 (s, 2H, NH). 
Meso-tetra(4-carboranylphenyl)sapphyrin (5.16): 4-carboranylbenzaldehyde 5.14 
(0.124 gm, 0.5 mmol) was dissolved in dry DCM (65 ml) and bubbled with argon for 15 
min. first a freshly distilled pyrrole ( 0.104 mL, 1.5 mmol) was added to this mixture and 
then BF3.OEt2 (0.024 mL, 0.1875 mmol) was also added. The reaction mixture was 
stirred at room temperature overnight and then p-chloranil (0.125 gm, 0.187 mmol) was 
added and stirred again for 3h. The solution was then washed once with aqueous 
saturated NaHCO3, and once with water before being dried over anhydrous Na2SO4. The 
residue obtained after removal of the solvent under vaccum was purified by the column 
chromatography on the silica gel (CH2Cl2/CCl4, 2:3). A very small fraction of product 
was obtained and was characterized with MALDI and UV-visible. It had a complicated 
NMR. MS (MALDI) m/e 1249.755 (M+). 
5, 10, 15, 20-tetraphenylsapphyrin (5.19): Benzaldehyde (0.807 mL, 8 mmol) was 
added to a 1 L of DCM and bubbled with argon for 0.5 h and then pyrrole ( 1.662 mL, 24 
mmol) and BF3.OEt2 (0.376 mL, 3 mmol) were added and stirred at room temperature 
under argon for 2h. This was followed by oxidation with p-chloranil (2g) and stirred for 
2h at the room temperature. The solution was evaporated to dryness and then passed 
through basic alumina with DCM as solvent for elution. The fractions were collected and 
then the solvent was stripped and passed through another column with 10:1 DCM: CCl4 
to get a very small fraction of sapphyrin. MALDI confirmed the product 677.441 
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